adenosine has been researched along with Cardiovascular Stroke in 732 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (3.42) | 18.7374 |
| 1990's | 150 (20.49) | 18.2507 |
| 2000's | 185 (25.27) | 29.6817 |
| 2010's | 348 (47.54) | 24.3611 |
| 2020's | 24 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Börner, MS; Castro, JJ; López, F; Pellegrini, A; Salzberg, S | 1 |
| Jalbani, J; Karim, M; Khan, KA; Kumar, D; Kumar, R; Qamar, N; Qayyum, D; Saghir, T; Sial, JA; Yasin, U | 1 |
| Cao, Q; Ma, J; Ma, Q; Sun, X; Wang, L; Zhang, L; Zhang, Z | 1 |
| Ahmed, S; Carsons, SE; De Leon, J; Kasselman, L; Reiss, AB; Teboul, I | 1 |
| Aboalhasan, E; Abu-Dogosh, A; Abu-Salman, A; Alnsasra, H; Arbel, R; Azuri, J; Barrett, O; El Nasasra, A; Golan, YB; Hammerman, A; Tsaban, G; Weissberg, I; Westreich, R | 1 |
| Devaux, Y; Dong, X; Jäger, C; Leszek, P; Linster, CL; Lumley, AI; Mączewski, M; Niedolistek, M; Oknińska, M; Paterek, A; Vausort, M | 1 |
| Gao, C; Guo, R; Wang, X; Wu, Y; Yan, J; Zhao, L | 1 |
| Fischbach, K; Reinartz, S | 1 |
| Bansilal, S; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dellborg, M; Im, K; Johanson, P; Magnani, G; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Aurigemma, C; Bianchini, E; Burzotta, F; Ciliberti, G; Crea, F; D'Amario, D; Galli, M; Laborante, R; Leone, AM; Montone, RA; Princi, G; Restivo, A; Rodolico, D; Romagnoli, E; Trani, C; Vergallo, R; Zito, A | 1 |
| Kheifets, M; Kornowski, R; Leshem Lev, D; Perl, L; Schamroth Pravda, N; Spectre, G; Wiessman, M; Ziv, E | 1 |
| Alter, C; Bahr, J; Ding, Z; Hayat, S; Henseler, AS; Hesse, J; Kostenis, E; Kramann, R; Lautwein, T; Owenier, C; Scheller, J; Schrader, J | 1 |
| Erlinge, D; Gan, LM; Omerovic, E; Rylance, R; Svedlund, S; Torngren, K | 1 |
| Libby, P; Nakao, T | 1 |
| Chen, J; Gao, X; He, H; Hong, Y; Hu, B; Huang, X; Li, W; Li, X; Liang, X; Liu, B; Shen, Y; Zhang, Y | 1 |
| Alcedo, KP; Battaglia, RA; Minor, M; Snider, NT | 1 |
| Albertsson, P; Angerås, O; Erlinge, D; Gan, LM; Haraldsson, I; Lagerström-Fermér, M; Odenstedt, J; Omerovic, E; Petursson, P; Råmunddal, T; Redfors, B; Svedlund, S; Torngren, K; Westergren, HU | 1 |
| Saxena, R; Tang, Y; Weintraub, NL | 1 |
| Abola, MT; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Corbalan, R; Furtado, RHM; Im, K; Jensen, EC; Johanson, P; Kiss, RG; Kontny, F; Magnani, G; Nicolau, JC; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF | 1 |
| Bollati, M; Dall'Ara, G; Di Mario, C; Gasparini, GL; Grotti, S; Mattesini, A; Oreglia, JA; Tarantino, F; Testa, L; Tumscitz, C | 1 |
| Chan, K; Ip, TP; Lee, CH; Ng, MY; Vardhanabhuti, V; Wan, EYF; Wintersperger, BJ; Yan, AT; Yiu, KH; Yu, EYT; Zhou, W | 1 |
| Cui, SX; Doviak, H; Epstein, FH; French, BA; Leor, J; Sano, S; Shah, SA; Walsh, K; Wang, Y; Waters, CD | 1 |
| Kaolawanich, Y; Krittayaphong, R; Tanapibunpon, P; Yimcharoen, S; Zhang, S | 1 |
| Boland, P; Chong, AY; Di Santo, P; Froeschl, M; Gaudet, C; Hibbert, B; Joseph, J; Jung, RG; Labinaz, A; Le May, M; Marbach, J; Moreland, R; Motazedian, P; Parlow, S; Promislow, S; Ramirez, FD; Russo, JJ; Simard, T; So, D | 1 |
| Anwar, M; Beazley-Long, N; Benest, AV; Besnier, M; Chamorro-Jorganes, A; Chandrasekera, D; Emanueli, C; Katare, R; Ritchie, AA; Ruiz-Polo, I; Sala-Newby, G; Sweaad, WK | 1 |
| Bamba, D; Cai, B; Dong, C; Gao, X; Gong, R; Han, Z; Jiang, Z; Li, H; Li, S; Li, X; Liu, S; Liu, Y; Ma, W; Wang, N; Wang, X; Xu, B; Yang, F; Yu, Y; Zhang, W; Zhao, Y | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Boden, E; Deussen, A; Dieterich, P; Ding, Z; Floss, DM; Friebe, D; Hesse, J; Leberling, S; Roderigo, C; Rose, CR; Scheller, J; Schmidt, T; Schrader, J | 1 |
| Eeckhout, E; Gaxherri, M; Hugelshofer, S; Iglesias, JF; Lorenzoni, V; Masci, PG; Monney, P; Muller, O; Pellaton, C; Rutz, T; Schwitter, J; Sierro, C; Vincenti, G | 1 |
| Hua, YH; Li, JN; Liu, C; Liu, J; Song, L; Tan, Y; Wu, Y; Yan, HB; Yang, YM; Zhao, HJ; Zhou, P | 1 |
| Adamski, P; Buszko, K; Koziński, M; Krintus, M; Kubica, J; Marszałł, MP; Obońska, K; Ostrowska, M; Sikora, J; Sypniewska, G | 1 |
| Kalkinis, A; Katsikis, A; Kolovou, G; Konstantinou, K; Koutelou, M; Papaioannou, S; Theodorakos, A | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bax, JJ; Kajander, S; Knuuti, J; Maaniitty, T; Mäki, M; Saraste, A; Stenström, I; Ukkonen, H; Uusitalo, V | 1 |
| Choi, KN; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Park, YA; Seo, JS; Shin, HC; Yang, TH | 1 |
| Han, X; Jing, Q; Li, R; Tang, X; Wang, Q; Yang, M; Yu, X; Zhao, J | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, DJ; Cohen, M; Li, H; Magnuson, EA; Sabatine, MS; Shafiq, A; Steg, PG; Storey, RF; Vilain, K; Wang, K | 1 |
| Bernhardt, P; Buckert, D; Cieslik, M; Rottbauer, W; Tibi, R; Witzel, S | 1 |
| Aravot, D; Barac, YD; Kornowski, R; Lev, EI; Orvin, K; Perl, L; Rubchevsky, V; Sharony, R; Snir, E; Wasserstrum, Y | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Kaandorp, TAM; Kuijpers, D; Oudkerk, M; van der Harst, P; van Dijk, R; van Dijkman, PRM; Vliegenthart, R | 1 |
| Grove, EL; Hvas, AM; Kristensen, SD; Larsen, ML; Pedersen, OH | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, MC; Goudev, A; Im, K; Isaza, D; Jensen, EC; Johanson, P; Kamensky, G; Magnani, G; Montalescot, G; Murphy, SA; Ophuis, TO; Parkhomenko, A; Rudah, M; Sabatine, MS; Steg, PG; Storey, RF; Theroux, P | 1 |
| Baldus, S; Reuter, H | 1 |
| Al-Salama, ZT; Keam, SJ; Keating, GM | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Jia, P; Wang, XF; Ye, M; Zeng, YJ | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Deppen, J; García, AJ; Levit, RD; Shin, EY; Strobel, F; Tirouvanziam, R; Wang, L; Xu, K; Zemskova, M | 1 |
| Burton, M; Colas, RA; Curtis, AM; Dalli, J; Marques, RM; Souza, PR; Walker, ME; Zasłona, Z | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG | 1 |
| Baracioli, LM; Giugliano, RP; Nicolau, JC | 1 |
| Bonello, L; Cautella, J; Colomb, B; Cordier, C; Fenouillet, E; Gaubert, M; Guieu, R; Kerbaul, F; Kipson, N; Laine, M; Marlinge, M; Mottola, G; Paganelli, F; Resseguier, N; Ruf, J; Thuny, F | 1 |
| Li, W; Yu, D; Yu, J | 1 |
| Cayla, G; Collet, JP; Diallo, A; Ecollan, P; Hamm, CW; Kerneis, M; Lapostolle, F; Lattuca, B; Montalescot, G; Silvain, J; Van 't Hof, AW; Vicaut, E; Yan, Y | 1 |
| Adamiak, M; Agarwal, N; Bouchareb, R; Chen, J; Chepurko, E; Fish, K; Hajjar, RJ; Ishikawa, K; Jha, D; Kohlbrenner, E; Lebeche, D; Liang, Y; Mathiyalagan, P; Mayourian, J; Sahoo, S; Sassi, Y; Singh, R; Trivieri, MG; Zhang, S | 1 |
| Bai, J; Fu, Q; Gao, CZ; Liu, R; Ma, QQ; Wang, F; Wei, P; Wu, J; Yang, XJ | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| Cui, JJ; Dai, QF; Gao, JH; Liu, Q; Lu, FY; Wang, YY; Wu, SY; Xin, JJ; Yu, XC; Zhao, YX; Zhou, C | 1 |
| Brown, JM; Lust, RM; Sheehan, NL; Thompson, LC; Walters, DM; Wingard, CJ | 1 |
| Jaggi, AS; Kumar, M; Singh, H; Singh, N | 1 |
| Bittl, JA | 1 |
| Andre, F; Backes, M; Buss, SJ; Chatzitofi, M; Greulich, S; Kaesemann, P; Katus, HA; Mahrholdt, H; Seitz, A; Steubing, H | 1 |
| Alvarez, DF; Audia, JP; Cohen, MV; Downey, JM; Gadde, S; Yang, XM | 1 |
| Igarashi, J; Nishikido, T; Node, K; Oyama, JI; Shiraki, A; Tsukamoto, I | 1 |
| Esaka, Y; Hatasa, M; Kanamori, H; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Tanaka, T; Uno, B; Yamada, Y | 1 |
| Cerrato, E; Del Trigo, M; Escaned, J; Fernández-Ortiz, A; Gonzalo, N; Jiménez-Quevedo, P; Knaapen, P; Koo, BK; Lee, JM; Macaya, C; Mejía-Rentería, H; Nombela-Franco, L; Núñez-Gil, IJ; Salinas, P; van der Hoeven, NW; van Royen, N | 1 |
| Kuijpers, D; Oudkerk, M; van Assen, M; van Dijk, R; Vliegenthart, R | 1 |
| Gan, LM; Glover, DK; Hauser, A; Salerno, M; Van Houten, M; Yang, Y; Yeager, M | 1 |
| Alexopoulos, D; Davlouros, P; Siapika, A; Stavrou, K; Theodoropoulos, KC; Tsoni, E; Xanthopoulou, I | 1 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Santini, A; Valenti, R | 1 |
| Cantor, WJ; Goodman, SG; Hamm, CW; Lapostolle, F; Lassen, JF; Licour, M; Montalescot, G; Silvain, J; ten Berg, JM; Tsatsaris, A; van't Hof, AW | 1 |
| Araszkiewicz, A; Grajek, S; Grygier, M; Lesiak, M | 2 |
| Brekke, M | 1 |
| Grove, EL; Kristensen, SD | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Kassimis, G; Koutsogiannis, N; Makris, G; Theodoropoulos, K; Tsigkas, G; Xanthopoulou, I | 1 |
| Burzotta, F; Corvo, P; Cosentino, N; Crea, F; D'Amario, D; De Caterina, AR; De Vita, MR; Fabbiocchi, F; Ferrari, R; La Torre, G; Leone, AM; Lo Schiavo, P; Niccoli, G; Olivares, P; Porto, I; Rigattieri, S; Romagnoli, E; Tarantino, F; Tomai, F; Trani, C; Valgimigli, M | 1 |
| Albuquerque, A; Costa, G; Cunha, MJ; Ferreira, MJ; Lima, J; Moreira, AP; Pego, M; Ramos, D | 1 |
| Aung Naing, K; Li, L; Su, Q; Wu, T | 1 |
| Alexopoulos, D; Angelidis, C; Anthopoulos, P; Chiladakis, J; Davlouros, P; Deftereos, S; Gkizas, V; Hahalis, G; Karanikas, S; Koutsogiannis, N; Makris, G; Patsilinakos, S; Perperis, A; Xanthopoulou, I | 1 |
| Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Alhammouri, A; Cohen, MV; Cui, L; Downey, JM; Yang, XM | 1 |
| Cabiati, M; Caselli, C; Del Ry, S; Lionetti, V; Martino, A; Mattii, L; Morales, MA; Prescimone, T | 1 |
| Alexopoulos, D; Goudevenos, J; Kalantzi, K; Ntalas, I; Pipilis, A; Xanthopoulou, I | 1 |
| Auffray, JP; Bessereau, J; Bonello, L; Brun, PM; Champenois, A; Fournier, N; Luigi, S; Mazille, A; Meyran, D; Michelet, P; Paganelli, F; Toesca, R; Yvorra, S | 1 |
| Siasos, G; Stefanadis, C; Tousoulis, D | 1 |
| Abbate, R; Antoniucci, D; Parodi, G | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Aylward, P; Brandrup-Wognsen, G; Brilakis, ES; Claeys, MJ; Cools, F; Cornel, JH; Held, C; Himmelmann, A; James, SK; Lewis, BS; Meier, B; Stevens, SR; Wallentin, L; Weaver, D | 1 |
| Caldarone, CA; Callahan, J; Fu, YY; Kato, H; Leung, CH; Nielsen, JM; Redington, AN; Tropak, MB; Wang, L | 1 |
| Chiang, SC; Huang, CH; Lai, CC; Tsai, SK; Weng, ZC | 1 |
| Altamura, L; Aurigemma, C; Crea, F; De Persio, G; Lanza, GA; Scalone, G; Stazi, A; Tomai, F | 1 |
| Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
| Fell, G; Keegan, T; Lee, D; Lindsay, S; Reynolds, B | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q | 1 |
| Gharanei, AM; Hussain, A; Maddock, HL; Nagra, AS | 1 |
| Crea, F; Niccoli, G; Spaziani, C | 1 |
| Kapoor, N; Leesar, MA; Raza, S; Siddiqui, T; Yalamanchili, V | 1 |
| Hartmark-Hill, JR; Tsang, K | 1 |
| Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B | 1 |
| Chen, M; Li, FO; Li, Q; Miao, GB; Tong, ZC; Wei, Y; Zhang, JJ; Zhao, H | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Ardissino, D; Becker, RC; Budaj, A; Cannon, CP; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Khurmi, NS; Mahaffey, KW; Montgomery, D; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Yu, CM | 1 |
| Baloch, E; Bamberg, F; Ebersberger, U; Hetterich, H; Hildebrandt, K; Hinkel, R; Hoffmann, U; Kupatt, C; Marcus, RP; Nikolaou, K; Reiser, MF; Sandner, TA; Schlett, CL; Schwarz, F; Theisen, D | 1 |
| Camici, PG; Colombo, A; Durante, A; Latib, A; Pizzetti, G | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Arif Yalcin, A; Biyik, I; Celik, O; Erturk, M; Faruk Akturk, I; Murat Caglar, I; Oner, E; Sarikamis, C; Turhan Caglar, N; Uzun, F | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Taylor, J | 1 |
| Burzotta, F; Cosentino, N; Crea, F; Davies, J; Fabretti, A; Falcioni, E; Fracassi, F; Leone, AM; Niccoli, G; Panebianco, M; Roberto, M; Scalone, G; Trani, C | 1 |
| Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Cigarroa, JE; Hundal, H | 1 |
| Lev, EI; Musallam, A; Roguin, A | 1 |
| Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Echavarria-Pinto, M; van de Hoef, TP | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Kornowski, R; Lerman-Shivek, H; Lev, EI; Orvin, K; Perl, L; Rechavia, E; Vaduganathan, M; Weissler-Snir, A; Zemer-Wassercug, N | 1 |
| Banovic, M; Beleslin, B; Djordjevic-Dikic, A; Djukanovic, N; Marinkovic, J; Nedeljkovic, I; Orlic, D; Ostojic, M; Petrovic, M; Petrovic, O; Sobic-Saranovic, D; Stankovic, S; Stepanovic, J; Tesic, M; Trifunovic, D; Vujisic-Tesic, B | 1 |
| Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Andreadou, I; Dagres, N; Iliodromitis, EK; Iliodromitis, K | 1 |
| Abrams, KR; Adgey, AA; Been, M; Blackman, DJ; Gershlick, AH; Greenwood, JP; Khan, JN; Kunadian, V; Mahmoud, IZ; McCann, GP; Nazir, SA; Wilcox, R | 1 |
| Vengoechea, F | 1 |
| Bessereau, J; Bonello, L; Bultez, B; Champenois, A; Chelini, V; Dignat-George, F; Frère, C; Gaubert, M; Laine, M; Luigi, S; Mokrani, Z; Paganelli, F; Peyrol, M; Thuny, F; Toesca, R; Yvorra, S | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Bousquenaud, M; Devaux, Y; Ernens, I; Lenoir, B; Wagner, DR | 1 |
| Chang, NC; Chen, WT; Lee, TM; Lin, SZ; Yang, CC | 1 |
| Anselmi, CV; Bacci, M; Mendolicchio, GL; Quagliuolo, V; Rota, LL; Roveda, M; Ruggeri, ZM; Zavalloni, D | 1 |
| Elizaga, J; Evangelista, A; Fernandez-Avilés, F; Ferreira-González, I; García-del-Blanco, B; Garcia-Dorado, D; Gimeno, F; Otaegui, I; Pineda, V; Rodríguez-Palomares, J; Ruiz-Salmerón, R; San-Román, A | 1 |
| Codner, P; Dadush, O; Eisen, A; Kazum, S; Kornowski, R; Lerman-Shivek, H; Leshem-Lev, D; Lev, EI; Perl, L; Rechavia, E; Zemer-Wassercug, N | 1 |
| Montalescot, G; van 't Hof, AW | 1 |
| Alexopoulos, D; Parodi, G | 1 |
| Cuculi, F; Sabti, Z; Toggweiler, S | 1 |
| Hoole, SP; Montone, RA; West, NE | 1 |
| Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY | 1 |
| Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
| De Luca, L; Ferlini, M; Visconti, LO | 1 |
| Radke, PW | 1 |
| Alexopoulos, D; Antoniucci, D; Bellandi, B; Capodanno, D; Capranzano, P; Migliorini, A; Parodi, G; Stavrou, K; Tamburino, C; Valenti, R; Xanthopoulou, I | 1 |
| Chausskaia, E; Gorbunov, AS; Khaliulin, IG; Krylatov, AV; Maslov, LN; Mrochek, AG; Naryzhnaia, NV; Portnichenko, AG; Tsibulnikov, SIu | 1 |
| Szabo, C | 1 |
| Abbate, R; Alexopoulos, D; Angelidis, C; Antoniucci, D; Baldereschi, GJ; Bellandi, B; Gensini, GF; Gkizas, V; Karanikas, S; Marcucci, R; Migliorini, A; Parodi, G; Patsilinakos, S; Valenti, R; Xanthopoulou, I | 1 |
| Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A | 1 |
| French, BA; Linden, J; Marshall, M; Tian, Y; Yang, Z | 1 |
| Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD | 1 |
| Bergmark, BA; Bhatt, DL; Galper, BZ; Shah, AM | 1 |
| Mearns, BM | 1 |
| Kanorskiĭ, SG | 1 |
| Angerås, O; Omerovic, E; Petursson, P; Råmunddal, T; Redfors, B | 1 |
| Adamski, P; Grześk, G; Koziński, M; Kubica, J; Laskowska, E; Obońska, E; Obońska, K; Ostrowska, M; Paciorek, P; Winiarski, P | 1 |
| Montalescot, G; van't Hof, AW | 1 |
| Aradi, D; Sibbing, D | 1 |
| Cherepanov, V; Dukhanin, A; Serebruany, V | 1 |
| Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH | 1 |
| Li, G; Liu, T; Xu, Y; Yang, Y; Zhang, N; Zhang, Z | 1 |
| Li, L; Nyi, TS; Su, Q | 1 |
| Biasco, L; Clemmensen, P; De Backer, O; Engstrøm, T; Helqvist, S; Holmvang, L; Jørgensen, E; Kelbaek, H; Olivecrona, G; Pedersen, F; Ratcovich, H; Saunamäki, K; Tilsted, HH | 1 |
| Alexopoulos, D; Kanakakis, I; Moulias, A; Xanthopoulou, I | 1 |
| Overbeck, P | 1 |
| Bonello, L; Cluzel, M; Dignat-George, F; Frere, C; Gaubert, M; Guieu, R; Hasan, A; Kerbaul, F; Laine, M; Mancini, J; Michelet, P; Paganelli, F; Thuny, F | 1 |
| Berry, C; Corcoran, D; Hennigan, B; Layland, J; Oldroyd, KG; Watkins, S | 1 |
| Cherepanov, V; Kim, MH; Serebruany, VL; Tomek, A | 1 |
| Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y | 1 |
| Bonhomme, F; Cartier Faessler, V; Fontana, P; Maillard, J | 1 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Alexopoulos, D | 1 |
| Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW | 1 |
| Abtan, J; Barthélémy, O; Brugier, D; Collet, JP; Galier, S; Hauguel, M; Kerneis, M; Montalescot, G; Payot, L; Silvain, J | 1 |
| Alexopoulos, D; Banning, AP; Davlouros, P; De Maria, G; Kallistratos, MS; Kassimis, G; Kharbanda, RK; Manolis, AJ; Patel, N | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Lüscher, TF | 1 |
| Chong, AY; Qutub, MA; So, DY | 1 |
| Decking, U; Truse, R; Wolff, G | 1 |
| Gao, Q; Guo, Y; Yang, B; Zheng, F | 1 |
| Ahmed, Z; Bajwa, A; Bhardwaj, B; Laster, SB; Magalski, A | 1 |
| Bagatini, MD; Bonfanti, G; Brucker, N; De Oliveira, LZ; Lavall, MC; Moretto, MB; Morsch, VM; Schetinger, MR; Thomé, GR | 1 |
| Buccheri, S; Capodanno, D; Capranzano, P; Tamburino, C | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wong, LK | 1 |
| Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Koutsogiannis, N; Nylander, S; Parodi, G; Tsigkas, G; Vogiatzi, C; Xanthopoulou, I | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Collet, JP; Costa, F; Kereiakes, DJ; Lee, CW; Lincoff, AM; Mauri, L; Montalescot, G; Park, SJ; Sabatine, MS; Udell, JA; Valgimigli, M | 1 |
| Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P | 1 |
| Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Bonaca, MP; Braunwald, E; Sabatine, MS | 1 |
| Kaur, N; Sharma, R; Sharma, S | 1 |
| Costa, F; Valgimigli, M | 1 |
| Marciniak, TA | 1 |
| Gurbel, PA; Jeong, YH; Smith, SC | 1 |
| Bakhai, A; Flather, M; Perez de Arenaza, D | 1 |
| Bulluck, H; Garcia-Dorado, D; Hausenloy, DJ; Loke, YK; Sirker, A | 1 |
| Angiolillo, DJ; Bass, TA; Bhatti, M; Carraway, E; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Nanavati, A; Rollini, F; Suryadevara, S; Zenni, MM | 1 |
| Ahmed, N; Berry, C; Carberry, J; Carrick, D; Curzen, N; Davie, A; Eteiba, H; Hood, S; Layland, J; Lindsay, M; Mahrous, A; McConnachie, A; McEntegart, M; Oldroyd, KG; Petrie, MC; Teng, V; Watkins, S | 1 |
| Ardissino, D; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalan, R; Dellborg, M; Goudev, AR; Held, P; Im, K; Isaza, D; Jensen, EC; Kontny, F; Kuder, J; Magnani, G; Medina, F; Parkhomenko, A; Sabatine, MS; Steg, G; Storey, RF | 1 |
| Borghesi, M; D'Amico, G; Musumeci, G; Parodi, G; Tarantini, G | 1 |
| Ardissino, D; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dalby, A; Diaz, R; Goto, S; Held, P; Im, K; Jensen, EC; López-Sendón, J; Magnani, G; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Steg, PG; Storey, RF; Van de Werf, F | 1 |
| Adamski, P; Buszko, K; Jilma, B; Koziński, M; Kubica, J; Kubica, JM; Marszałł, MP; Navarese, EP; Ostrowska, M; Rość, D; Sikora, J; Siller-Matula, JM; Sroka, WD; Stankowska, K | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Jacquemyn, Y; Mannaerts, D; Muys, J; Verbruggen, M | 1 |
| Millar, CG; Noman, A; Parasuraman, SK; Teo, AI | 1 |
| De Rosa, S; Indolfi, C; Polimeni, A; Sabatino, J; Sorrentino, S | 1 |
| Frantz, S; Hofmann, U | 1 |
| Ferreira, VM; Francis, JM; Liu, A; Neubauer, S; Piechnik, SK; Robson, MD; Wijesurendra, RS | 1 |
| Amico, F; Mazzoni, J; Schlesinger, A | 1 |
| Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K | 1 |
| Duncker, DJ; Falotico, R; Krabbendam-Peters, I; Manintveld, OC; Merkus, D; Serruys, PW; Te Lintel Hekkert, M; Uitterdijk, A; van Beusekom, HMM; van Geuns, RM; Yetgin, T; Zijlstra, F | 1 |
| Ragosta, M | 1 |
| Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY | 1 |
| Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Karanikas, S; Karvounis, H; Kontoprias, K; Koutsogiannis, N; Patsilinakos, S; Tsigkas, G; Xanthopoulou, I; Ziakas, A | 1 |
| Jung, J; Lee, YC; Park, SJ | 1 |
| Kawaji, K; Kramer, CM; Lang, RM; Mor-Avi, V; Nathan, S; Patel, AR; Patel, MB | 1 |
| Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L | 1 |
| Parker, WA; Storey, RF | 1 |
| Li, Y; Li, Z; Miao, W; Su, G; Zhang, T | 1 |
| Cherian, T; Devlin, G; Green, SA; Lee, M | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Bravo, CA; Pachon, R; Vatner, DE; Vatner, SF; Zhang, J | 1 |
| Ahsan, AJ; Angiolillo, DJ; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Franchi, F; Judge, HM; Kuder, JF; Muthusamy, R; Rollini, F; Sabatine, MS; Steg, PG; Storey, RF; Thomas, MR | 1 |
| Brar, SS | 1 |
| Lozano, I; Rondan, J; Segovia, E; Vegas, JM | 2 |
| Coetzee, WA; Foster, MN; Ho, J; Jana, K; Rindler, MJ; Yang, HQ | 1 |
| Angiolillo, DJ; Bansilal, S; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Im, K; Murphy, SA; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF | 1 |
| Ruiz-Nodar, JM | 1 |
| Dégano, IR; Elosua, R; Grau, M; Marrugat, J; Sayols-Baixeras, S | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Adamski, P; Dąbrowska, A; Fabiszak, T; Gurbel, PA; Hobl, EL; Jilma, B; Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
| Serebruany, V; Tomek, A | 1 |
| Ditmarsch, M; Held, P; Himmelmann, A | 1 |
| Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C | 1 |
| Cotton, JM; Cox, AR; Khan, N | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY | 1 |
| Chung, SC; Denaxas, S; Emmas, C; Hemingway, H; Moayyeri, A; Pasea, L; Pujades-Rodriguez, M; Rapsomaniki, E; Shah, AD; Stogiannis, D; Timmis, A | 1 |
| Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Aylward, PE; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dalby, AJ; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Kontny, F; Kuder, J; Magnani, G; Medina, FA; Oude Ophuis, T; Sabatine, MS; Špinar, J; Steg, PG; Storey, R; Theroux, P | 1 |
| Axel, L; Hochman, JS; Mauricio, R; Reynolds, HR; Srichai, MB | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Åkesson, J; Albertsson, PA; Alfredsson, J; Bodegard, J; Brorsson, H; Jerström, S; Johnston, N; Karlsson, JE; Varenhorst, C | 1 |
| Wise, J | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF | 1 |
| Branny, M; Cervinka, P; Dusek, J; Hlinomaz, O; Hromadka, M; Jarkovsky, J; Kala, P; Knot, J; Kramarikova, P; Majtan, B; Miklik, R; Motovska, Z; Mrozek, J; Ostransky, J; Rokyta, R; Simek, S; Tousek, F; Varvarovsky, I; Widimsky, P | 1 |
| Attmann, T; Beyersdorf, F; Boening, A; Cremer, J; Danner, BC; de Waha, A; Fischlein, T; Goerlach, G; Hambrecht, R; Hamm, C; Hammel, D; Joost, A; Kastrati, A; Knosalla, C; Koch-Buettner, K; Lange, R; Laufer, G; Misfeld, M; Mohr, FW; Oberhoffer, M; Putman, LM; Radke, PW; Sandner, S; Schmoeckel, M; Schöndube, FA; Schönrath, F; Schulz, R; Schunkert, H; Siepe, M; Sievers, HH; von Scheidt, M; Walther, T; Zeymer, U; Ziegelhöffer, T | 1 |
| Emdin, M; Giannoni, A; Passino, C | 1 |
| Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I | 1 |
| Barillà, F; Borzi, M; Camici, P; Cas, LD; Di Biase, M; Filardi, PP; Indolfi, C; Mercuro, G; Montemurro, V; Padeletti, L; Pelliccia, F; Romeo, F; Vizza, CD | 1 |
| Badimon, L; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Pons-Lladó, G; Varela, L; Vilahur, G | 1 |
| Blank, M; Lawrence, J; McDowell, TY; Stockbridge, N | 1 |
| Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE | 1 |
| Andersson, T; Hamrén, B; Nyberg, J; Röshammar, D; Stanski, D; Storey, RF | 1 |
| Bagai, A; Brass, N; Cheema, AN; Dehghani, P; Dery, JP; Ducas, J; Fisher, HN; Fung, A; Goodman, SG; Kassam, SA; Kim, HH; Mehta, SR; Quraishi, AU; Schampaert, E; Wang, TY; Welsh, RC; Zhang, X; Zhu, YE | 1 |
| Andell, P; Erlinge, D; Götberg, M; James, S; Koul, S; Mohammad, MA; Scherstén, F | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Fang, L; Li, Y; Liu, B; Meng, S; Shen, C; Sun, Y; Xu, Q; Zhang, Y | 1 |
| Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC | 1 |
| Ariotti, S; Gargiulo, G; Valgimigli, M | 1 |
| Andersson, T; Bergstrand, M; Hamrén, B; Röshammar, D; Storey, RF | 1 |
| Andersson, HB; Dridi, NP; Frydland, M; Holmvang, L; Kjaergaard, J; Ratcovich, H; Sadjadieh, G; Wiberg, S | 1 |
| Ahsan, AJ; Ajjan, RA; Angiolillo, DJ; Bhatt, DL; Bonaca, MP; Cohen, M; Franchi, F; Judge, HM; Kuder, JF; Muthusamy, R; Rollini, F; Sabatine, MS; Steg, PG; Storey, RF; Thomas, MR | 1 |
| Devaux, Y; Ernens, I; Haas, B; Léonard, F; Longrois, D; Rolland-Turner, M; Schwartz, C; Velot, E; Wagner, DR | 1 |
| Chen, JL; Go, RL; Pei, WD; Sun, YH; Yang, YJ; Zhao, JL | 1 |
| Kennedy, DP; Lankford, AR; Linden, J; Marshall, MA; Rork, TH; Wallace, KL | 1 |
| Bonan, CD; Morsch, VM; Schetinger, MR; Wyse, AT | 1 |
| Ball, SG; Greenwood, JP; Plein, S; Ridgway, JP; Sparrow, P; Younger, JF | 1 |
| Monassier, JP | 1 |
| Anagnostopoulos, C; Donovan, J; Harbinson, M; Loong, CY; Reyes, E; Underwood, SR | 1 |
| Asai, T; Asakura, M; Asanuma, H; Fujita, M; Hashimoto, K; Kikuchi, H; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Oku, N; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M | 1 |
| Davidson, SM; Gonçalves, L; Hausenloy, DJ; Mocanu, MM; Monteiro, P; Paiva, M; Providência, L; Riksen, NP; Rongen, GA; Smits, P; Yellon, DM | 1 |
| Barrett, EJ; Chyun, DA; Davey, JA; Filipchuk, N; Heller, GV; Inzucchi, SE; Iskandrian, AE; Ratner, RE; Taillefer, R; Wackers, FJ; Wittlin, SD; Young, LH | 1 |
| Bartorelli, A; Cosentino, N; Crea, F; D'amario, D; De Vita, MR; Fabbiocchi, F; Ferrari, R; Imola, F; Marino, M; Niccoli, G; Prati, F; Rigattieri, S; Schiavo, PL; Spaziani, C; Tarantino, F; Valgimigli, M | 1 |
| Makarov, LM; Serebruany, VL | 1 |
| Sadat, U | 1 |
| Anand-Srivastava, MB; Balakumar, P; Reddy, K; Singh, H | 1 |
| Dreysse, S; Fleck, E; Gebker, R; Graf, K; Kelle, S; Klein, C; Nagel, E; Schnackenburg, B | 1 |
| Dubois, C | 1 |
| Honbo, N; Karliner, JS; Li, L; Vessey, DA | 1 |
| Tan, KT | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Alexopoulos, N; Anadiotis, AV; Janik, M; Lerakis, S; McLean, DS; Oshinski, JN; Stillman, AE; Veledar, E; Zaragoza-Macias, E | 1 |
| Chen, W; Fang, LG; Fang, Q; Li, J; Zhu, WL | 1 |
| Gao, HQ; Hou, BW; Liu, XQ; Xing, YQ; Zhang, Y | 1 |
| Bøtker, HE; Christophersen, TB; Egstrup, K; Høfsten, DE; Løgstrup, BB; Møller, JE; Pellikka, PA | 1 |
| Atar, D; Serebruany, VL | 2 |
| Anthonio, RL; de Smet, BJ; Fokkema, ML; Gu, YL; Jessurun, GA; Kampinga, MA; Tan, ES; van den Heuvel, AF; Vlaar, PJ; Vogelzang, M; Zijlstra, F | 1 |
| Fath-ordoubadi, F; Fraser, D; Venetucci, L | 1 |
| Cattaneo, M | 2 |
| Auchampach, JA; Ge, ZD; Maas, JE; van der Hoeven, D; Wan, TC | 1 |
| Hale, SL; Kloner, RA | 1 |
| Khan, NU; Movahed, A; Mustafa, JS; Raza, JA | 1 |
| Bhavsar, J; Rosenson, RS | 1 |
| Guo, KW; Tan, JW | 1 |
| Ke, JJ; Rao, Y; Wang, YL; Yu, FX | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 1 |
| Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X | 1 |
| Crea, F; Marino, M; Niccoli, G; Spaziani, C | 1 |
| Cohen, MV; Downey, JM; Krieg, T; Methner, C; Schmidt, K | 1 |
| Dai, X; Kharbanda, RK; Li, J; Manlhiot, C; Redington, A; Steensrud, T; Tropak, M | 1 |
| Brown, JM; Cathey, BL; Hilderbrand, SC; Katwa, P; Ke, PC; Lin, S; Lust, RM; Podila, R; Rao, A; Walters, DM; Wingard, CJ | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Serebruany, VL | 2 |
| Adriaenssens, T; Belmans, A; Bogaert, J; Desmet, W; Dubois, C; Dymarkowski, S; Ganame, J; Janssens, S; Pappas, C; Sinnaeve, P; Van de Werf, F | 1 |
| Fang, LL; Feng, XH; Ma, XW; Shi, HW; Wang, C; Wang, LM; Zhang, PY | 1 |
| Buechel, RR; Gaemperli, O; Ghadri, JR; Herzog, BA; Husmann, L; Kaufmann, PA; Küest, SM; Nkoulou, RN; Pazhenkottil, AP; Wolfrum, M | 1 |
| Kerkhof, M; Kuijpers, D; Lubbers, DD; Oudkerk, M; Rijlaarsdam-Hermsen, D; Sijens, PE; van Dijkman, PR | 1 |
| Araszkiewicz, A; Grajek, S; Grygier, M; Janus, M; Kowal, J; Lesiak, M; Mitkowski, P; Pyda, M; Skorupski, W | 1 |
| Bingham, SE; Hachamovitch, R | 1 |
| Devaux, Y; Ernens, I; Leonard, F; Rolland-Turner, M; Vausort, M; Wagner, DR | 1 |
| Berger, PB; Good, CW | 1 |
| Enmi, J; Fukuda, H; Hirano, Y; Iida, H; Knuuti, J; Koshino, K; Miyagawa, S; Sawa, Y; Teramoto, N; Yokoyama, I; Zeniya, T | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Devaux, Y; Ernens, I; Haas, B; Leonard, F; Rodius, S; Rolland-Turner, M; Vausort, M; Wagner, DR | 1 |
| Anadiotis, A; Hartlage, G; Janik, M; Kremastinos, D; Lerakis, S; Oshinski, J; Stillman, A; Veledar, E | 1 |
| Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Reis, F | 1 |
| Buros, JL; Ciaglo, LN; Gibson, CM; Kunadian, V; Morrow, DA; Pride, YB | 1 |
| Berdeaux, A; Chenoune, M; Cohen, MV; Darbera, L; Downey, JM; Ghaleh, B; Lidouren, F; Tissier, R | 1 |
| Frick, M; Furundzija, V; Gebker, R; Jahnke, C; Manka, R; Marx, N; Paetsch, I; Schnackenburg, B | 1 |
| Lasley, RD; McIntosh, VJ; Zhan, E | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Choo, K; Chun, KJ; Faranesh, AZ; Han, D; Kim, J; Kim, JH; Kim, JS; Lederman, RJ; Park, JH; Park, YH; Song, SK | 1 |
| Chauhan, A; More, RS; Morgan, KP | 1 |
| Chan, W; Duffy, SJ; Ellims, AH; Kaye, DM; Taylor, AJ | 1 |
| De Luca, G; Iorio, S; Marino, P; Venegoni, L | 1 |
| Barchetta, S; Bonomo, L; Crea, F; De Caterina, AR; Fedele, E; Galiuto, L; Leone, AM; Locorotondo, G; Natale, L; Paraggio, L; Porto, I; Rebuzzi, AG | 1 |
| Das, R; Dundon, BK; Leung, MC; Liew, GY; Meredith, IT; Molaee, P; Teo, KS; Williams, K; Wong, DT; Worthley, MI; Worthley, SG | 1 |
| Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Andreotti, F; Buffon, A; Castriota, F; Cremonesi, A; Gurbel, PA; Kozinski, M; Kubica, A; Kubica, J; Musumeci, G; Navarese, EP; Tavazzi, L | 1 |
| Kramer, CM; Narula, J | 1 |
| Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
| Braunwald, E | 1 |
| Chen, L; Chen, YD; Liu, HB; Tian, F; Wang, J; Xu, Y; Zhi, G; Zhou, X | 1 |
| Forconi, S; Gori, T; Liuni, A; Luca, MC; Münzel, T; Muxel, S; Parker, JD | 1 |
| Gewirtz, H | 1 |
| Calvi, V; Capodanno, D; Tamburino, C | 1 |
| Brasolin, B; Calcagno, S; Canali, E; De Carlo, C; Fedele, F; Lucisano, L; Mancone, M; Sardella, G; Stio, RE | 1 |
| Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bertaso, AG; Leung, MC; Meredith, IT; Puri, R; Richardson, JD; Teo, KS; Williams, K; Wong, DT; Worthley, MI; Worthley, SG | 1 |
| Niccoli, G; Sgueglia, GA; Tarantini, G | 1 |
| Gerczuk, PZ; Kloner, RA | 1 |
| Boersma, HH; Dierckx, RA; Glauche, J; Glaudemans, AW; Golestani, R; Jansen, JW; Oudkerk, M; Slart, RH; Tio, RA; Willems, TP; Zeebregts, CJ | 1 |
| Grajek, S | 1 |
| Grześk, G; Koziński, M; Kubica, J | 1 |
| Biaggioni, I; Blackburn, MR; Feoktistov, I; Goldstein, AE; Novitskiy, SV; Ryzhov, S | 1 |
| Fang, LL; Feng, WF; Ma, XW; Ran, H; Wu, WF; Zhang, PY | 1 |
| Bönner, F; Borg, N; Burghoff, S; Schrader, J | 1 |
| Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y | 1 |
| Arora, R; Khosla, K; Khosla, S; Molnar, J; Shah, T; Singh, M; Singh, P | 1 |
| Held, C | 1 |
| Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
| Galagudza, M; Grigorova, Y; Korolev, D; Naumisheva, E; Postnov, V; Shlyakhto, E; Uskov, I | 1 |
| Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
| Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
| Anderson, RD; Azarbal, B; Handberg, E; Johnson, BD; Kar, S; Kelsey, SF; Kothawade, K; Lerman, A; Mehta, PK; Merz, CN; Pepine, CJ; Petersen, J; Samuels, B; Sharaf, B; Shaw, L; Shufelt, C; Sopko, G; Wei, J | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Budaj, A; Gurbel, PA; Tantry, US | 1 |
| Guan, L; Mu, Y; Quaglia, LA; Shih, MC; Tang, Q; Wang, C; Yang, L | 1 |
| Lochner, A; Moolman, JA; Salie, R | 1 |
| Chen, L; Chen, SL; Hu, ZY; Tian, NL; Wang, F; Zhang, H; Zhang, YJ | 1 |
| Fukuda, H; Furuhashi, T; Hase, H; Joki, N; Kunimasa, T; Masai, H; Moroi, M; Sugi, K | 1 |
| Granfeldt, A | 1 |
| Johnston-Cox, H; Koupenova, M; Ravid, K | 1 |
| Dechant, LM | 2 |
| Huber, K | 1 |
| Fort, JG; Plachetka, JR | 1 |
| Ahmed, A; Dean, PJ; Hage, FG; Heo, J; Iqbal, FM; Iskandrian, AE; Raslan, S | 1 |
| Wenger, NK | 1 |
| Atalay, M; Isilak, Z; Kardesoglu, E; Uz, O; Yalcin, M | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Kassimis, G; Koutsogiannis, N; Makris, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Bevilacqua, M; Cirillo, P; D'Anna, C; De Rosa, R; Di Gioia, G; Galasso, G; Niglio, T; Piccolo, R; Piscione, F; Strisciuglio, T | 1 |
| Mamedova, SI; Petrenko, IV; Petrenko, OA; Popova, MA; Urvantseva, IA | 1 |
| Andersen, KF; Madsen, C; Zerahn, B | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
| Agrawal, K; Bhatt, DL | 1 |
| Bousquenaud, M; Devaux, Y; Goretti, E; Léonard, F; Marie, PY; Maskali, F; Nicolas, C; Rolland-Turner, M; Wagner, D; Zhang, L | 1 |
| Bernhardt, P; Buckert, D; Dewes, P; Rottbauer, W; Walcher, T | 1 |
| Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M | 1 |
| Cabarrus, BR; Ershadi, RE; Kulhanek, J; Movahed, A; Short, DB; Sorrell, VL | 1 |
| Auchampach, JA; Black, RG; Bolli, R; Ge, ZD; Guo, Y; Jones, WK; Murphree, SS; Prabhu, SD | 1 |
| McCarthy, J; Sack, MN; Smith, RM; Suleman, N | 1 |
| Backx, PH; Batthish, M; Diaz, RJ; Wilson, GJ; Zeng, HP | 1 |
| Berdeaux, A; Ghaleh, B; Giudicelli, JF; Lellouche, N; Souktani, R; Tissier, R | 1 |
| Maddock, HL; Mocanu, MM; Yellon, DM | 1 |
| Cohen, MV; Downey, JM; Qin, Q | 1 |
| Ibuki, M; Katayama, M; Mizoguchi, S; Morioka, S; Nagai, K; Ono, M; Shiratori, K; Takagi, T; Tamita, K; Tanabe, K; Tani, T; Yagi, T; Yamabe, K; Yamamuro, A | 1 |
| Knowles, S | 1 |
| Ostrovskiĭ, IuP; Sidorenko, GI | 1 |
| Fisher, NG; Goodman, NC; Kaul, S; Leong-Poi, H; Sakuma, T | 1 |
| Kato, T; Yoshimoto, N | 1 |
| Chan, KY; Chiu, CW; Lam, WW; Sanderson, JE; So, NM | 1 |
| Budde, JM; Corvera, JS; Guyton, RA; Morris, CD; Thourani, VH; Vinten-Johansen, J; Zhao, ZQ | 1 |
| Gross, GJ; Peart, JN | 1 |
| Auchampach, JA; Ge, ZD; Gross, GJ; Moore, J; Wan, TC | 1 |
| Edner, M; Hjemdahl, P; Kahan, T; Kjerr, AC; Näsman, P; Quintana, M; Rehnqvist, N; Sollevi, A; Swahn, E | 1 |
| Kukreja, RC; Zhao, TC | 1 |
| Headrick, JP; Peart, J | 1 |
| Beleslin, B; Djordjevic-Dikic, A; Giga, V; Nedeljkovic, I; Nedeljkovic, M; Ostojic, M; Petrasinovic, Z; Saponjski, J; Stepanovic, J; Stojkovic, S | 1 |
| Genda, S; Ichikawa, Y; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Sakamoto, J; Shimamoto, K; Tanno, M | 1 |
| Aviles, RJ; Bell, MR; Frommell, G; Gibbons, RJ; Holland, AE; Jain, A; Kellett, M; Kopecky, SL; Lobl, JK; Midei, M; Ramsey, K; Tipping, D | 1 |
| Gibson, CM | 1 |
| Flynn, DM; Hill, RJ; Knight, DR; Magee, WP; Oleynek, JJ; Smith, AH; Tracey, WR | 1 |
| STADLER, H | 1 |
| Bullough, DA; Erion, MD; Ito, BR; Makhsudova, L; Montag, AC; Villarreal, F; Zimmermann, S | 1 |
| Berglund, M; Eriksson, BE; Sadigh-Lindell, B; Sylvén, C | 1 |
| Budde, JM; Guyton, RA; Morris, CD; Muraki, S; Velez, DA; Wang, NP; Zhao, ZQ | 1 |
| Dong, JH; He, RR; Ji, ES; Liu, YX | 1 |
| de Cock, CC; Elkelini, M; Hanrath, P; Heussen, N; Hoffmann, R; Kamp, O; Lepper, W; Sieswerda, GT; Visser, CA; Voci, P | 1 |
| Boucher, M; Cardinal, R; de Montigny, C; Falcao, S; Pesant, S; Rousseau, G; Schampaert, E | 1 |
| Asakura, M; Asanuma, H; Hori, M; Kitakaze, M; Minamino, T; Mori, H; Node, K; Ogai, A; Ogita, H; Sanada, S; Shinozaki, Y; Takashima, S; Tomoike, H | 1 |
| Imamura, H; Nakao, S; Otani, H; Shingu, K; Uchiyama, Y; Wakeno-Takahashi, M | 1 |
| Hjemdahl, P; Kahan, T; Quintana, M | 1 |
| Fleischmann, S; Jenni, R; Kaufmann, PA; Koepfli, P; Namdar, M; Wyss, CA | 1 |
| Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Mori, H; Node, K; Ogai, A; Ogita, H; Sanada, S; Shinozaki, Y; Shintani, Y; Takashima, S; Tomoike, H | 1 |
| Heldman, AW; St John, M | 1 |
| Beunis, A; Bosmans, J; Claeys, MJ; De Ceuninck, M; Vergauwen, W; Vorlat, A; Vrints, CJ | 1 |
| Erbel, R; Gres, P; Haude, M; Heusch, G; Konietzka, I; Martin, C; Schulz, R; Skyschally, A | 1 |
| Kloner, RA; Rezkalla, SH | 2 |
| Anderson, TJ; Bonan, R; Chugh, SK; Curtis, MJ; DiMario, C; Goodhart, D; Koppel, J; Meredith, IT; Scott, M; Shewchuk, L; Tardif, JC; Worthley, SG | 1 |
| Edner, M; Hjemdahl, P; Kahan, T; Quintana, M; Rehnqvist, N; Sollevi, A | 1 |
| Canyon, SJ; Dobson, GP | 1 |
| Ahn, YK; Bae, EH; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DG; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, SY; Park, HW; Park, JC; Yoon, KH | 1 |
| Boomsma, F; Duncker, DJ; Liem, DA; Manintveld, OC; te Lintel Hekkert, M; Verdouw, PD | 1 |
| Ivan, E; Jasti, V; Leesar, MA; Wongpraparut, N; Yalamanchili, V | 1 |
| Pizzuto, F; Romeo, F; Voci, P | 1 |
| Duncker, DJ; Houweling, B; Merkus, D; van Vliet, M | 1 |
| Ball, SG; Cranny, G; Greenwood, JP; Plein, S; Ridgway, JP; Sivananthan, MU | 1 |
| Riksen, NP; Rongen, GA; Smits, P | 1 |
| Karliner, JS | 1 |
| Berman, DS; Cohen, I; Friedman, JD; Hachamovitch, R; Hayes, SW | 1 |
| Selker, HP; Udelson, JE | 1 |
| Baba, K; Fujiwara, H; Kariya, T; Kawai, T; Minatoguchi, S; Takahashi, M; Takemura, G; Uno, Y; Zhang, C | 1 |
| Boucher, M; Cardinal, R; Kaloustian, S; Massé, R; Rousseau, G; Schampaert, E; Wann, BP | 1 |
| Keith, BJ; Kristo, G; Lasley, RD; Mentzer, RM; Yoshimura, Y | 1 |
| Lasley, RD | 1 |
| Przyklenk, K; Whittaker, P | 2 |
| Duncker, DJ; Keijzer, E; Manintveld, OC; te Lintel Hekkert, M; Verdouw, PD | 1 |
| Berges, A; Timmermans, JP; Van Nassauw, L; Vrints, C | 1 |
| Chen, JL; Chen, ZJ; Gao, RL; Jing, ZC; Meng, L; Tian, Y; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Alexander, RW; Gibbons, RJ; Kloner, RA; Ross, AM; Stone, GW | 1 |
| Amerson, BS; Guyton, RA; Halkos, ME; Headrick, JP; Kerendi, F; Kin, H; Lofye, MT; Vinten-Johansen, J; Zatta, AJ; Zhao, ZQ | 1 |
| Gams, E; Klein, KK; Korbmacher, B; Schipke, JD; Sunderdiek, U | 1 |
| Alfayoumi, F; Geller, M; Gradman, A; Srinivasan, V | 1 |
| Bolli, R; Guo, Y; Li, Q; Stein, AB; Tan, W; Wu, WJ; Zhu, X | 1 |
| Barbagelata, A; Birnbaum, Y; Califf, RM; Di Carli, MF; Garg, J; Gibbons, RJ; Goodman, SG; Granger, CB; Grinfeld, L; Mahaffey, KW; Wagner, GS | 1 |
| Balcells, EA; Belcik, TA; Kaul, S; Lindner, JR; Micari, A; Powers, E; Wei, K | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G | 1 |
| Yang, YJ; Zhao, JL | 1 |
| Duong, HT; Gao, ZG; Jacobson, KA; Joshi, BV; Liang, BT; Sonin, D; Tchilibon, S | 1 |
| Aronovich, A; Blatt, A; Czuriga, I; Gurevich, Y; Hendler, A; Kaluski, E; Krakover, R; Leitman, M; Reicher, M; Vered, Z; Zyssman, I | 1 |
| Al-Housni, MB; Cheetham, AM; Ghiotto, F; Kelion, AD; McGhie, J; Naylor, V | 1 |
| de Belder, MA; Graham, J; Hall, JA; Kunadian, B; Sutton, A; Vijayalakshmi, K; Whittaker, VJ; Wright, RA | 1 |
| Aiello, VD; Chagas, AC; Dourado, PM; Luz, PL; Mathias, W; Ramires, JA; Sbano, JC; Tsutsui, JM | 1 |
| Cohen, MV; Cui, L; Davis, AM; Downey, JM; Philipp, S; Yang, XM | 1 |
| Forman, MB; Jackson, EK | 4 |
| Cohen, MV; Downey, JM | 1 |
| Kennedy, TP; Vinten-Johansen, J | 1 |
| Harding, SA | 1 |
| Goto, M; Haruna, Y; Hiramatsu, O; Kajiya, F; Kashihara, N; Mori, H; Morita, Y; Ogasawara, Y; Shimokawa, H; Shinozaki, Y; Yada, T | 1 |
| Aihara, K; Kogi, K; Sasamori, J; Sato, I; Takeo, S; Yoneyama, F | 1 |
| Chen, JL; Chen, ZJ; Gao, RL; Jing, ZC; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Cui, CJ; Gao, RL; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Alexander, RW; Forman, MB; Gibbons, RJ; Kloner, RA; Ross, AM; Stone, GW | 1 |
| Dietzel, C; Mangano, DT; Miao, Y; Tudor, IC | 1 |
| Kloner, RA | 2 |
| Boucher, M; Cardinal, R; Godbout, R; Kaloustian, S; Rousseau, G; Wann, BP | 1 |
| Ito, H | 1 |
| Edenbrandt, L; Gjertsson, P; Lomsky, M; Ohlsson, M; Richter, J; Tout, D; Underwood, R; van Aswegen, A | 1 |
| Forman, MB; Jackson, EK; Stone, GW | 1 |
| Cappello, S; Losano, G; Mancardi, D; Pagliaro, P; Penna, C; Rastaldo, R | 1 |
| Auchampach, JA; Ge, ZD; Gross, GJ; Jacobson, MA; Kreckler, LM; Peart, JN; Wan, TC | 1 |
| Maurer, G | 1 |
| Ferrari, M; Figulla, HR; Fritzenwanger, M; Surber, R; Werner, GS | 1 |
| Gams, E; Kerendi, F; Schipke, JD; Vinten-Johansen, J | 1 |
| Chan, F; Hellinger, J; Herfkens, R; McConnell, MV; Narayan, G; Nguyen, P; Pauly, JM; Tsukiji, M; Yang, PC | 1 |
| Allam, A; Dakik, HA; Filipchuk, NG; Henzlova, MJ; Iskander, SS; Keng, F; Mahmarian, JJ; Moyé, LA; Pratt, CM; Ruddy, TD; Shaw, LJ | 2 |
| Ackerstaff, RG; Bogers, AJ; Hartman, JM; Kelder, HC; Swieten, HA; Vermeulen, FE | 1 |
| Ball, SG; Greenwood, JP; Plein, S; Ridgway, JP; Sivananthan, MU; Younger, JF | 1 |
| Eckle, T; Eltzschig, HK; Grenz, A; Jacobson, MA; Köhler, D; Krahn, T; Ledent, C; Mittelbronn, M; Osswald, H; Thompson, LF; Unertl, K | 1 |
| Fleck, E; Gebker, R; Jahnke, C; Kelle, S; Kokocinski, T; Manka, R; Nagel, E; Paetsch, I | 1 |
| Cacciabaudo, JM; Donaldson, D; Green, SJ; Heller, GV; Katz, S; Maddahi, J; Makaryus, AN; Mieres, JH; Ong, L; Rampersaud, T; Rosen, SE; Shaw, LJ | 1 |
| Rich, JD; Wiviott, SD | 1 |
| Banning, AP; van Gaal, WJ | 1 |
| Bluemke, DA; Fishman, EK; Vogel-Claussen, J | 1 |
| Roe, MT; Steinhubl, S | 1 |
| Dorfman, TA; Iskandrian, AE | 1 |
| de Lemos, JA; Wiviott, SD | 1 |
| Chen, HL; Liang, J; Lin, G; Xie, M; Xu, LM; Zhou, Y | 1 |
| Hussain, F | 1 |
| Eckle, T; Eltzschig, HK; Faigle, M; Grenz, A; Hart, ML; Köhler, D; Laucher, S; Mittelbronn, M; Müller, CE; Robson, SC | 1 |
| Bronzwaer, JG; de Cock, CC; Marques, KM; Stoel, MG; von Birgelen, C; Zijlstra, F | 1 |
| Bosch-Marce, M; Cai, Z; Fox-Talbot, K; Semenza, GL; Trush, MA; Wang, L; Wei, C; Zhong, H | 1 |
| Scholte, AJ; Stokkel, MP; van der Hiel, B | 1 |
| Satler, LF | 1 |
| Chen, YD; Fang, F; Li, ZA; Lü, SZ; Song, XT; Tian, F; Yuan, F | 1 |
| Niveditha, T; Sadasivudu, B; Saleem, Y | 1 |
| McCarty, MF | 1 |
| Kukes, VG; Kuz'min, AI; Saprygina, TV; Syrkin, AL; Vakhliaev, VD | 1 |
| Chin, WP; Hashimoto, K; Hashimoto, T; Imai, S; Katano, Y; Nakagawa, Y; Satoh, H; Tsukada, T | 1 |
| Hegge, JO; Konyn, PJ; Lasley, RD; Mentzer, RM | 1 |
| Armstrong, S; Ganote, CE | 1 |
| Bullough, D; Mullane, K | 1 |
| Forman, S; Heyrich, GP; Keen, WD; Marshall, ES; Raichlen, JS; Weitz, HH | 1 |
| Dillon, D; Silva, PH; Van Wylen, DG | 1 |
| Burckhartt, B; Cohen, MV; Downey, JM; Mullane, KM; Tsuchida, A; Yang, XM | 2 |
| Gross, GJ; Mizumura, T; Nithipatikom, K | 3 |
| Belardinelli, L; Bertolet, BD; Hill, JA; McMurtrie, EB | 1 |
| Applegate, RJ; Braden, GA; Kerensky, RA; Kutcher, MA; Little, WC; Solis, GA | 1 |
| Mahmarian, AC; Mahmarian, JJ; Marks, GF; Pratt, CM; Verani, MS | 1 |
| Maripu, E; Nilsson, S; Ronquist, G; Waldenström, A; Wikström, G | 1 |
| Hudspeth, DA; McGee, DS; Sato, H; Van Wylen, DG; Vinten-Johansen, J; Williams, MW; Zhao, ZQ | 1 |
| Alonso, L; Arganda, L; Castillo, JA; Peral, V; Rollán, MJ; San Román, JA; Sánchez-Harguindey, L; Vilacosta, I | 1 |
| Neild, GH; Patel, VC; Woolfson, RG; Yellon, DM | 1 |
| Gross, GJ; Yao, Z | 2 |
| Downey, JM; Liu, GS; Mullane, K; Olsson, RA; Richards, SC; Walsh, RS | 1 |
| Chujo, M; Hori, M; Kitakaze, M; Minamino, T; Mori, H; Morioka, T; Node, K; Sato, H; Shinozaki, Y; Takashima, S | 1 |
| Berman, DS; Friedman, J; Germano, G; Kiat, H; Matzer, L; Van Train, K; Wang, FP | 1 |
| Baxter, GF; Marber, MS; Patel, VC; Yellon, DM | 1 |
| Downey, JM; Olsson, RA; Thompson, R; Tsuchida, A | 1 |
| Cohen, MV; Downey, JM; Liu, Y; Ytrehus, K | 1 |
| Jennings, RB; Reimer, KA; Vander Heide, RS | 2 |
| Lopez, JA; Lufschanowski, R; Massumi, A | 1 |
| Cohn, JN; Francis, GS; McDonald, KM; Ugurbil, K; Yoshiyama, M; Zhang, J | 1 |
| Chujo, M; Hori, M; Inoue, M; Kitakaze, M; Minamino, T; Mori, H; Morioka, T; Sato, H; Shinozaki, Y; Takashima, S | 2 |
| Chien, GL; Davis, RF; Kuzume, K; Soifer, BE; Van Winkle, DM; Wolff, RA | 1 |
| McGee, DS; Nakanishi, K; Tan, P; Vinten-Johansen, J; Zhao, ZQ | 1 |
| Brooks, R; Collis, MG; Conant, AR; Pleeth, RM; Poucher, SM | 1 |
| Verani, MS | 2 |
| Cave, V; Heo, J; Iskandrian, AS; Mallavarapu, C; Pancholy, S; Wasserleben, V | 1 |
| Asimakis, GK; Conti, VR; Inners-McBride, K | 1 |
| Aguirre, FV; Bach, RG; Caracciolo, EA; Donohue, TJ; Flynn, MS; Kern, MJ; Wolford, T | 1 |
| Gupta, VK; Johnston, DL; Mahmarian, JJ; Verani, MS; Wendt, RE | 1 |
| Banerjee, A; Harken, AH; Meldrum, DR; Mitchell, MB | 1 |
| Kroeker, TS; Pride, HP; Rubart, M; Warner, MR; Zipes, DP | 1 |
| Das, DK | 1 |
| Marber, M; Walker, D; Yellon, D | 1 |
| Bellows, SD; Hale, SL; Hammerman, H; Kloner, RA | 1 |
| Downey, JM; Liu, Y | 2 |
| Johnston, WE; McGee, DS; Toombs, CF; Vinten-Johansen, J | 1 |
| Downey, JM; Liu, GS; Tsuchida, A; Wilborn, WH | 1 |
| Ashar, MS; Johnston, WE; McGee, S; Nakanishi, K; Toombs, CF; Vinten-Johansen, J; Zhao, ZQ | 1 |
| Aguirre, FV; Bach, RG; Caracciolo, EA; Donohue, TJ; Flynn, MS; Kern, MJ | 1 |
| Brodin, LA; Ehrenberg, J; Juhlin-Dannfelt, A; Owall, A; Sollevi, A | 1 |
| Dagianti, A; Di Pierro, D; Fedele, F; Giardina, B; Lazzarino, G; Penco, M; Romano, S; Tavazzi, B | 1 |
| Downey, JM; Liu, GS; Mullane, K; Tsuchida, A | 1 |
| Forman, MB; Inagami, T; Jackson, EK; Morrow, JA; Velasco, CE; Vitola, JV | 1 |
| Downey, JM; Liu, GS; Thornton, JD | 1 |
| Iimura, O; Miura, T | 1 |
| Abreu, A; Mahmarian, JJ; Nishimura, S; Pratt, CM; Verani, MS | 1 |
| Crake, T; Crea, F; Davies, G; Galassi, A; Gaspardone, A; Kaski, JC; Maseri, A | 1 |
| Auchampach, JA; Gross, GJ | 1 |
| Cohen, MV; Downey, JM; Goto, M; Walsh, RS | 1 |
| Flameng, W | 1 |
| Cheirif, J; Feinstein, SB; Winkelmann, JW | 1 |
| Blockx, PP; Bosmans, JM; Bossaert, LL; Claeys, MJ; Krug, B; Snoeck, JP; Vrints, CJ | 1 |
| Kloner, RA; Przyklenk, K; Whittaker, P | 1 |
| Dickinson, CZ; Dworkin, HJ; Juni, JE; O'Neill, WW; Weissman, IA | 1 |
| Andreotti, F; Pasceri, V | 1 |
| Reimer, KA; Vander Heide, RS | 1 |
| Abraham, SA; Alpert, NM; Fischman, AJ; Gewirtz, H; Mukerjee, AK; Picard, MH; Skopicki, HA; Weissman, NJ | 1 |
| Camarano, G; Goodman, NC; Ismail, S; Kaul, S; Sklenar, J; Villanueva, FS | 1 |
| Iimura, O; Miki, T; Miura, T; Tsuchihashi, K | 1 |
| Patel, VC; Woolfson, RG; Yellon, DM | 1 |
| Elliott, GT; Kloner, RA; Przyklenk, K; Zhao, L | 1 |
| Chien, GL; Davis, RF; Haessler, R; Kuzume, K; Van Winkle, DM; Wolff, RA | 1 |
| Kalkman, EA; Saxena, PR; Schoemaker, RG | 1 |
| Sato, H; Todd, J; Van Wylen, DG; Vinten-Johansen, J; Williams, MW; Zhao, ZQ | 1 |
| Bache, RJ; Duncker, DJ; Herrlinger, SH; Ishibashi, Y; Klassen, CL; Pavek, TJ | 1 |
| Firschke, C; Goodman, NC; Kaul, S; Lindner, JR; Skyba, DM; Wei, K | 1 |
| Gross, GJ; Mei, DA; Mizumura, T; Yao, Z | 1 |
| Anthopoulos, L; Anthopoulos, P; Antonellis, J; Bonou, M; Bouki, T; Kappos, K; Kesse, M; Kostopoulos, K; Kranidis, A; Ralli, D; Sideris, A; Tavernarakis, A | 1 |
| Bradamante, S; de Jong, JW; de Jonge, R; Janssen, M; Marchesani, A | 1 |
| Marsh, JD; Vander Heide, RS | 1 |
| Funaya, H; Hori, M; Kitakaze, M; Minamino, T; Mori, H; Node, K; Shinozaki, Y | 1 |
| Lasley, RD; Martin, BJ; Mentzer, RM | 1 |
| Casati, C; Forlani, A; Lozza, G; Monopoli, A | 1 |
| Auchampach, JA; Bolli, R; Maldonado, C; Qiu, Y; Rizvi, A; Tang, XL; Teschner, S | 1 |
| Baxter, GF; Yellon, DM | 1 |
| Granger, CB | 1 |
| Cohen, MV; Downey, JM; Miki, T; Sato, H; Thornton, CS; Thornton, JD | 1 |
| Blockx, PP; Claeys, MJ; Rademakers, FE; Snoeck, JP; Vrints, CJ | 1 |
| Belardinelli, L; Bertolet, BD; Hill, JA; Kerensky, RA | 1 |
| Gallagher, KP; Martin, BJ; McClanahan, TB; Van Wylen, DG | 1 |
| Ma, XL; Sato, H; Todd, JC; Vinten-Johansen, J; Zhao, ZQ | 1 |
| Baxter, GF | 1 |
| Sun, J; Xu, J; Yuan, F | 1 |
| Bagheri, B; Heo, J; Iskandrian, AE; Johnson, JH; Nallamothu, N | 1 |
| Bel, A; Duriez, M; Faris, B; Menasché, P; Mouas, C; Peynet, J; Wassef, M | 1 |
| Miki, T; Miura, T; Shimamoto, K; Suzuki, K; Tsuchida, A | 1 |
| Claeys, MJ; Dabrowska-Kugacka, A; Rademakers, FE | 1 |
| Berman, DS; Cabico, JA; Cohen, I; Diamond, GA; Friedman, J; Hachamovitch, R; Kiat, H; Shaw, LJ | 1 |
| Dhalla, N; Domenech, RJ; Liu, X; Macho, P; Sánchez, G; Vélez, D | 1 |
| Dubey, RK; Gillespie, DG; Jackson, EK | 1 |
| Bouchard, JF; Lamontagne, D | 1 |
| Bouvier, F; Höjer, J; Hulting, J; Jensen-Urstad, M; Ruiz, H; Samad, B | 1 |
| Levitsky, S; McCully, JD; Parker, RA; Uematsu, M | 1 |
| Barbieri, JT; Gross, GJ; Hsu, AK; Li, PL; Schultz, JE | 1 |
| Gross, GJ; Lasley, RD; Mei, DA; Nithipatikom, K | 1 |
| Bailey, KR; Garratt, KN; Gibbons, RJ; Hodge, DO; Holmes, DR; Laudon, DA; Lobl, JK; Molina-Viamonte, V; Reeder, GS | 1 |
| Brown, MD; Deveci, D; Hudlicka, O; Thomas, DP | 1 |
| Gaudette, GR; Laurikka, JO; Levitsky, S; McCully, JD; Uematsu, M | 1 |
| Kapelko, VI; Kuzmin, AI; Lakomkin, VL; Vassort, G | 1 |
| Heusch, G; Post, H; Schulz, R; Vahlhaus, C | 1 |
| Cohen, MV; Downey, JM; Hashimi, MW; Thornton, JD | 1 |
| de Geest, H; Dubiel, J; Dudek, D; Flameng, W; Grodecki, J; Kocurek, A; Pieniazek, P; Trebacz, J; Zmudka, K | 1 |
| Bouvier, F; Höjer, J; Hulting, J; Jensen-Urstad, K; Jensen-Urstad, M; Ruiz, H; Samad, BA | 1 |
| Andreotti, F; De Marco, E; Maseri, A; Sciahbasi, A | 1 |
| Drew, GM; Hunt, AA; Louttit, JB; Maxwell, MP | 1 |
| Levitsky, S; McCully, JD; Uematsu, M | 1 |
| Crea, F; Gaspardone, A | 1 |
| Elson, SH | 1 |
| Bernardo, NL; Kukreja, RC; Maaieh, MM; Okubo, S; Wood, MA | 1 |
| Imai, K; Imai, S; Ito, Y; Kamiyama, H; Matsui, K; Nagai, R; Naganuma, F; Nakano, M; Ohashi, N; Ui, G | 1 |
| Hori, M; Kitakaze, M | 1 |
| Drew, GM; Gray, KM; Louttit, JB; Sheldrick, A | 1 |
| Nasa, Y; Takeo, S | 1 |
| Barbagelata, NA; Blevins, R; Bolli, R; Browne, KF; Califf, RM; Casas, AC; DiCarli, MF; Eisenberg, PR; Gibbons, RJ; Granger, CB; Leesar, MA; Mahaffey, KW; Molina-Viamonte, V; Orlandi, C; Puma, JA | 1 |
| Dickson, EW; Fenton, RA; Gysembergh, A; Lorbar, M; Porcaro, WA; Przyklenk, K; Reinhardt, CP | 1 |
| Ala-Kokko, TI; Alahuhta, S; Kiviluoma, K; Ruskoaho, H; Spalding, MB | 1 |
| Breall, JA; Diver, DJ; Marshall, RJ; Rashid, H | 1 |
| Fisher, JD; Kaplan, AV; Kaplan, IV | 1 |
| Akahoshi, M; Hirai, M; Hirayama, H; Inden, Y; Ito, T; Kondo, T; Murakami, Y; Okamoto, M; Saito, H; Toyama, J; Tsuboi, N; Tsuda, M; Tsuji, Y; Yamada, T; Yoshida, Y | 1 |
| Barbagelata, A; Califf, RM; Casabe, H; Clemmensen, P; Criger, DA; Di Carli, MF; Gates, KB; Gibbons, RJ; Granger, CB; Mahaffey, KW; Sgarbossa, EB; Wagner, GS | 1 |
| Maehara, K; Maruyama, Y; Ogawa, K; Yaoita, H | 1 |
| Marraccini, P; Marzilli, M; Orsini, E; Testa, R | 1 |
| Edvinsson, L; Erlinge, D; Hedner, T; Sun, XY; Zhao, XH | 1 |
| Dana, A; Jonassen, AK; Yamashita, N; Yellon, DM | 1 |
| Edwards, RJ; Marber, MS; Rakhit, RD; Saurin, AT | 1 |
| Barenghi, L; Beemster, P; Bertelli, AA; Bradamante, S; De Jong, JW; De Jonge, R; Piccinini, F | 1 |
| Chelliah, J; Kukreja, RC; Levasseur, JE; Xi, L; Zhao, T | 1 |
| Anderson, HV; Assali, AR; Denkats, AE; Fujise, K; Ghani, M; Hanna, GP; Rosales, OR; Schroth, G; Sdringola, S; Smalling, RW; Yepes, A | 1 |
| Futterman, LG; Lemberg, L | 1 |
| Di Gregorio, V; Levitsky, S; McCully, JD; Parker, RA; Toyoda, Y | 1 |
| Budde, JM; Guyton, RA; Morris, C; Muraki, S; Velez, DA; Vinten-Johansen, J; Wang, NP; Zhao, ZQ | 1 |
| Levitsky, S; McCully, JD; Stewart, RD; Toyoda, Y; Uematsu, M | 1 |
| Hines, DS; Kukreja, RC; Zhao, TC | 1 |
| Domenech, R; Macho, P; Sánchez, G; Schwarze, H; Solis, E | 1 |
| Dubey, RK; Gillespie, DG; Jackson, EK; Mi, Z; Zacharia, LC | 1 |
| Jahania, MS; Lasley, RD; Mentzer, RM | 1 |
| Auchampach, JA; Bhattacharya, S; Black, RG; Bolli, R; Kodani, E; Takano, H; Tang, XL; Yang, Z | 1 |
| Baxter, GF; Cohen, MV; Downey, JM; Hale, SL; Kloner, RA; Miki, T; Yellon, DM | 1 |
| Bjerner, T; Henze, A; Ronquist, G; Thelin, S; Waldenström, A; Wikström, G; Zemgulis, V | 1 |
| Agafitei, RD; Berman, DS; Cohen, I; Friedman, JD; Germano, G; Kang, X; Lewin, HC; Miranda, R; Sharir, T | 1 |
| Gattullo, D; Losano, G; Pagliaro, P; Rastaldo, R | 1 |
| Cohen, MV; Downey, JM; Heusch, G; Liu, GS; Yang, XM | 1 |
| de Zeeuw, S; Duncker, DJ; Liem, DA; van den Doel, MA; Verdouw, PD | 1 |
| Latchman, DS; Schulman, D; Yellon, DM | 1 |
| Cerniway, RJ; Jacobson, MA; Linden, J; Matherne, GP; Yang, Z | 1 |
| Behrends, M; Cohen, MV; Downey, JM; Heusch, G; Schulz, R | 1 |
| Berdeaux, A; Ghaleh, B; Giudicelli, JF; Henry, P; Lellouche, N; Parent de Curzon, O; Souktani, R; Tissier, R | 1 |
| Polad, JE; Wilson, LM | 1 |
| Hasebe, N; Jin, YT; Kawabe, J; Kikuchi, K; Matsusaka, T | 1 |
| Cemri, M; Cengel, A; Ciftci, H; Dortlemez, O; Ozdemir, M; Timurkaynak, T | 1 |
| Duncker, DJ; Kazim, S; Liem, DA; Ploeg, H; Verdouw, PD | 1 |
| Berdeaux, A; Bruneval, P; Ghaleh, B; Giudicelli, JF; Souktani, R; Tissier, R | 1 |
| Fetisova, TV; Sokolova, GG | 1 |
| Fetisova, TV; Khomaziuk, AI; Neshcheret, AP; Razumnaia, NM; Vorob'eva, TM | 1 |
| Cobb, FR; McHale, PA; Rembert, JC | 1 |
| Hoak, JC; Wu, KK | 1 |
| Cohen, MV; Kirk, ES; Sonnenblick, EH | 1 |
| Jones, CE; Parker, JC; Thomas, JX | 1 |
| Wagner, J | 1 |
| Allman, KC; Berry, J; Petry, NA; Schwaiger, M; Stafford, KA; Sucharski, LA; Wysor, W | 1 |
| Johnston, WE; McGee, S; Toombs, CF; Vinten-Johansen, J | 1 |
| Berne, RM; Ely, SW | 1 |
| Ito, M; Nagashima, M; Namekawa, A; Odakura, H; Onodera, S; Sato, T; Shinoda, S; Suzuki, H; Yagi, T | 1 |
| Cook, SA; Go, RT; MacIntyre, WJ; Neumann, DR | 1 |
| Downey, JM; Liu, GS; Olsson, RA; Thornton, JD | 1 |
| Almazov, VA; Eliseev, VV; Gurevich, VS; Krylova, IB; Poltavchenko, GM; Skholl'-Engberts, AD | 1 |
| Goto, M; Iimura, O; Iliodoromitis, EK; Ishimoto, R; Miura, T; O'Leary, EL; Yellon, DM | 1 |
| Belkina, LM; Evsev'eva, ME; Meerson, FZ; Obol'nikova, EA; Pozdniakov, OM; Samokhvalov, GI; Slobodianik, VV; Vovk, VI | 1 |
| Albertsson, P; Caidahl, K; Edlund, A; Emanuelsson, H; Wallentin, I | 1 |
| Granrud, GA; Vatterott, PJ | 1 |
| Cobb, MA; Forman, MB; Turner, M; Velasco, CE; Virmani, R | 1 |
| Forman, MB; Jackson, EK; Pitarys, CJ; Vildibill, HD; Virmani, R | 1 |
| Downey, JM; Liu, GS; Olsson, RA; Stanley, AW; Thornton, J; Van Winkle, DM | 1 |
| Esterbrooks, D; Frick, MP; Gupta, NC; Hilleman, D; Mohiuddin, S; Shiue, CY; Sunderland, J | 1 |
| Downey, HF; Kim, SJ; Lee, SC; Murakami, H; Strete, D | 1 |
| Babbitt, DG; Forman, MB; Norton, ED; Vildibill, HD; Virmani, R | 1 |
| Borgers, M; De Geest, H; Flameng, W; Jang, IK; Van de Werf, F; Vanhaecke, J | 1 |
| Kapel'ko, VI; Kuz'min, AI; Medvedev, OS; Saprygina, TV; Selivanov, VN; Shul'zhenko, VS | 1 |
| Fletcher, DD; Hoff, PT; Homeister, JW; Lucchesi, BR | 1 |
| Grover, GJ; Schumacher, WA | 1 |
| Brown, MD; Hudlická, O | 1 |
| Edlund, A; Jonzon, B; Sylvén, C | 1 |
| Eliseev, VV; Evdokimova, NR; Krylova, IB; Ovchinnikova, AG; Prokopenko, VM | 1 |
| Eliseev, VV; Evdokimova, NR; Krylova, IB | 1 |
| Garg, D; Garg, KN; Lal, H; Singh, J | 1 |
| Grover, GJ; Parham, CS; Sleph, PG | 1 |
| Eliseev, VV; Evdokimov, NR; Ovchinnikova, AG | 1 |
| Belardinelli, L; Berne, RM; DiMarco, JP; Lerman, BB; Wesley, RC | 1 |
| Smith, ER | 1 |
| Vaisrub, S | 1 |
| Weiss, HJ | 1 |
| Schaper, W | 1 |
117 review(s) available for adenosine and Cardiovascular Stroke
| Article | Year |
|---|---|
[Ischemic heart disease : More than just chronic CAD].
Topics: Adenosine; Contrast Media; Coronary Artery Disease; Gadolinium; Humans; Myocardial Infarction; Myocardial Ischemia | 2022 |
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Atrioventricular Block; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Vasodilator Agents | 2023 |
Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Animals; Arteries; Calcinosis; Central Nervous System; Gene Expression Regulation; GPI-Linked Proteins; Heart Failure; Homeostasis; Humans; Mutation, Missense; Myocardial Infarction; Organ Specificity; Reperfusion Injury; Respiratory System | 2019 |
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.
Topics: Adenosine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor | 2017 |
Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease.
Topics: Acute Coronary Syndrome; Adenosine; Government Regulation; Half-Life; Hemorrhage; Humans; Myocardial Infarction; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data.
Topics: Adenosine; Chemotherapy, Adjuvant; Humans; Myocardial Infarction; Myocardial Reperfusion; No-Reflow Phenomenon; Vasodilator Agents | 2013 |
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
Topics: Adenosine; Cause of Death; Humans; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Vasodilator Agents; Verapamil | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Drug Administration Schedule; Drug Costs; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; United States | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticagrelor | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Perspective of use of agonists of adenosine and opioid receptors for prevention of reperfusion damages of heart. Analysis of experimental and clinical data].
Topics: Adenosine; Analgesics, Opioid; Drug Discovery; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Receptors, Opioid; Receptors, Purinergic P1 | 2014 |
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
Topics: Adenosine; Cause of Death; Humans; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Vasodilator Agents; Verapamil | 2015 |
Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Pressure Determination; Cardiac Imaging Techniques; Central Venous Pressure; Coronary Disease; Coronary Stenosis; Forecasting; Fractional Flow Reserve, Myocardial; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sex Factors; Vascular Resistance; Vasodilator Agents | 2015 |
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.
Topics: Adenosine; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Survival Analysis; Ticagrelor; Ticlopidine | 2015 |
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?
Topics: Adenosine; Cardiotonic Agents; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Myocardial Infarction; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Efficacy of Adenosine in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A PRISMA-Compliant Meta-Analysis.
Topics: Adenosine; Cardiotonic Agents; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Stroke Volume; Vasodilator Agents | 2015 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazoles; Carvedilol; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Echocardiography; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Propanolamines; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2015 |
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
Topics: Adenosine; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials.
Topics: Adenosine; Electrocardiography; Humans; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Vasodilator Agents | 2016 |
Impact of intracoronary adenosine administration during primary PCI: A meta-analysis.
Topics: Adenosine; Coronary Vessels; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Vasodilator Agents | 2016 |
Role of T-cells in myocardial infarction.
Topics: Acute Coronary Syndrome; Adaptive Immunity; Adenosine; Animals; Cell Movement; Disease Models, Animal; Humans; Immunity, Innate; Lymphocyte Activation; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Signal Transduction; T-Lymphocytes | 2016 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.
Topics: Adenosine; Drug Interactions; Humans; Morphine; Myocardial Infarction; Observational Studies as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
Topics: Acute Coronary Syndrome; Adenosine; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
Topics: Adenosine; Administration, Oral; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors | 2016 |
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.
Topics: Adenosine; Blood Platelets; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Treatment Outcome | 2017 |
NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Atherosclerosis; Blood Coagulation; Blood Platelets; Cell Communication; Demyelinating Diseases; Epilepsy; Humans; Metabolism, Inborn Errors; Myocardial Infarction; Neoplasms; Platelet Activation; Platelet Aggregation; Seizures; Signal Transduction; Tamoxifen; Thrombosis | 2007 |
Reperfusion injury in acute myocardial infarction: from bench to cath lab. Part II: Clinical issues and therapeutic options.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Animals; Coronary Circulation; Electrocardiography; Heart Conduction System; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Nicorandil; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombectomy; Treatment Outcome; Vasodilator Agents | 2008 |
Signaling pathways of cardioprotective ischemic preconditioning.
Topics: Acetylcholine; Adenosine; Angioplasty, Balloon, Coronary; Animals; Bradykinin; Coronary Circulation; Disease Models, Animal; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Primary Prevention; Prognosis; Prospective Studies; Protein Kinases; Radiography; Reactive Oxygen Species; Risk Assessment; Signal Transduction | 2009 |
Cardiac protection during acute myocardial infarction.
Topics: Adenosine; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Combined Modality Therapy; Heart Failure; Hospital Mortality; Humans; Myocardial Infarction; Purinergic P1 Receptor Agonists; Stents; Survival Rate; Thrombolytic Therapy | 2007 |
Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy.
Topics: Adenosine; Blood Viscosity; Dipyridamole; Erythrocyte Deformability; Erythrocytes; Humans; Myocardial Infarction; Myocardial Reperfusion Injury | 2010 |
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Prevention and treatment of no-reflow.
Topics: Abciximab; Adenosine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Reperfusion; No-Reflow Phenomenon; Thrombectomy; Treatment Outcome; Verapamil | 2010 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Principles, current status and clinical implications of ischaemic heart disease assessment by cardiac magnetic resonance imaging.
Topics: Acute Coronary Syndrome; Adenosine; Contrast Media; Coronary Circulation; Defibrillators, Implantable; Edema, Cardiac; Gadolinium; Heart Function Tests; Humans; Magnetic Resonance Imaging; Microcirculation; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Organ Size; Preoperative Care; Reproducibility of Results; Vasodilator Agents | 2012 |
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Treatment Outcome | 2012 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Chronic pharmacological preconditioning against ischemia.
Topics: Adenosine; Animals; Cardiotonic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning, Myocardial; Mice; Morphine; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitroglycerin; Rats; Swine | 2011 |
PET measurement of adenosine stimulated absolute myocardial blood flow for physiological assessment of the coronary circulation.
Topics: Adenosine; Blood Flow Velocity; Coronary Circulation; Humans; Myocardial Infarction; Myocardial Perfusion Imaging; Positron-Emission Tomography; Vasodilator Agents | 2012 |
Ticagrelor in ST-elevation myocardial infarction.
Topics: Adenosine; Animals; Arrhythmias, Cardiac; Evidence-Based Medicine; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2012 |
CME instructions: PET measurement of adenosine stimulated absolute myocardial blood flow for physiological assessment of the coronary circulation.
Topics: Adenosine; Blood Flow Velocity; Coronary Circulation; Humans; Myocardial Infarction; Myocardial Perfusion Imaging; Positron-Emission Tomography; Vasodilator Agents | 2012 |
An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials.
Topics: Adenosine; Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Cardiotonic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Coronary Vessels; Humans; Ischemic Postconditioning; Myocardial Infarction; Reperfusion Injury | 2012 |
Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatine Kinase, MB Form; Electrocardiography; Heart Failure; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Randomized Controlled Trials as Topic; Stents; Stroke Volume; Vasodilator Agents | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet therapy beyond 2012: role of personalized medicine.
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Organ dysfunction following regional and global ischemia/reperfusion. Intervention with postconditioning and adenocaine.
Topics: Adenosine; Animals; Anti-Arrhythmia Agents; Drug Combinations; Heart Arrest; Humans; Ischemia; Ischemic Postconditioning; Lidocaine; Myocardial Infarction; Reperfusion Injury; Shock, Hemorrhagic; Vasodilator Agents | 2012 |
Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors.
Topics: Adenosine; Animals; Atherosclerosis; Foam Cells; Humans; Myocardial Infarction; Receptors, Purinergic P1; Risk Factors | 2012 |
UA/NSTEMI: Are you following the latest guidelines?
Topics: Adenosine; Angina, Unstable; Anticoagulants; Blood Glucose; Guideline Adherence; Humans; Kidney Failure, Chronic; Myocardial Infarction; Patient Education as Topic; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guide
Topics: Adenosine; Administration, Oral; Angina, Unstable; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome; Warfarin | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticagrelor | 2014 |
[The no-reflow phenomenon and its clinical significance].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Atherectomy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Heart Failure; Hospital Mortality; Humans; Microvascular Angina; Myocardial Infarction; Nicorandil; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Stents; Vasodilator Agents; Verapamil | 2002 |
Ischaemic preconditioning and outcomes after angioplasty: effects of drug therapy.
Topics: Adenosine; Angina Pectoris; Angioplasty, Balloon, Coronary; Bradykinin; Death, Sudden, Cardiac; Humans; Ischemic Preconditioning, Myocardial; Models, Biological; Myocardial Infarction; Nicorandil; Nitroglycerin; Potassium Channels; Randomized Controlled Trials as Topic; Receptors, Purinergic P1 | 2003 |
Adenosine in myocardial protection in on-pump and off-pump cardiac surgery.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Heart Arrest, Induced; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Potassium Channels; Receptors, Purinergic P1; Thrombolytic Therapy; Vasodilator Agents | 2003 |
Has my patient achieved adequate myocardial reperfusion?
Topics: Adenosine; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Chest Pain; Coronary Angiography; Coronary Circulation; Electrocardiography; Humans; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Vasodilator Agents | 2003 |
Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects.
Topics: Adenosine; Animals; Cardiovascular System; Humans; In Vitro Techniques; Models, Biological; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Receptors, Purinergic P1; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2003 |
Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.
Topics: Adenosine; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Primary Prevention; Receptors, Adenosine A2; Vasodilator Agents; Ventricular Dysfunction, Left | 2004 |
Cardiac protection during acute myocardial infarction: where do we stand in 2004?
Topics: Adenosine; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Animals; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Glucose; Humans; Insulin; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; Potassium; Potassium Channels; Sodium-Hydrogen Exchangers | 2004 |
Coronary flow: a new asset for the echo lab?
Topics: Adenosine; Blood Flow Velocity; Coronary Artery Bypass; Coronary Artery Disease; Coronary Stenosis; Coronary Thrombosis; Echocardiography; Echocardiography, Doppler; Humans; Intra-Aortic Balloon Pumping; Microcirculation; Myocardial Infarction; Stents; Vasodilator Agents | 2004 |
Ischaemic preconditioning: from molecular characterisation to clinical application--part I.
Topics: Adenosine; Bradykinin; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Norepinephrine; Potassium Channels; Reactive Oxygen Species; Signal Transduction; Time Factors | 2004 |
The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach.
Topics: Adenosine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Echocardiography; Humans; Microcirculation; Myocardial Infarction; Myocardial Reperfusion Injury; Nicorandil; Single-Chain Antibodies; Thrombolytic Therapy; Vascular Patency; Vasodilator Agents; Verapamil | 2005 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine; Time Factors; Vasodilator Agents | 2005 |
Preconditioning, postconditioning and their application to clinical cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Nicorandil; Randomized Controlled Trials as Topic; Stents; Vasodilator Agents | 2006 |
A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: where do we go from here?
Topics: Adenosine; Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Stroke; Vasodilator Agents | 2006 |
No-reflow phenomenon and prognosis in patients with acute myocardial infarction.
Topics: Adenosine; Clinical Trials as Topic; Coronary Angiography; Coronary Circulation; Echocardiography, Doppler; Electrocardiography; Humans; Microcirculation; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prognosis; Thrombectomy; Vasodilator Agents | 2006 |
Role of adenosine as adjunctive therapy in acute myocardial infarction.
Topics: Adenosine; Animals; Cardiotonic Agents; Humans; Infusions, Intravenous; Models, Biological; Myocardial Infarction; Myocardial Reperfusion Injury | 2006 |
[Ischemic postconditioning: an effective strategy of myocardial protection?].
Topics: Adenosine; Animals; Antioxidants; Coronary Circulation; Drug Synergism; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Donors; Phosphotransferases; Rats; Time Factors | 2006 |
[Postconditioning: a brief review].
Topics: Adenosine; Anesthetics; Animals; Collateral Circulation; Disease Models, Animal; Dogs; Humans; Ischemic Preconditioning, Myocardial; Mice; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Stunning; Myocytes, Cardiac; Rabbits; Rats; Reactive Oxygen Species; Reperfusion Injury; Thoracic Surgery; Time Factors | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
New antiplatelet therapies for acute coronary syndromes.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2007 |
Percutaneous coronary intervention and the no-reflow phenomenon.
Topics: Adenosine; Animals; Atherectomy, Coronary; Collateral Circulation; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardial Revascularization; Prostheses and Implants; Regional Blood Flow; Saphenous Vein; Thrombectomy; Ultrasonography, Interventional; Vasodilator Agents | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2007 |
Adenosine single photon emission computed tomography for assessing risk after myocardial infarction: recent developments.
Topics: Adenosine; Clinical Trials as Topic; Disease-Free Survival; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Risk Assessment; Survival Analysis; Tomography, Emission-Computed, Single-Photon | 2007 |
Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Carrier Proteins; Dogs; Endothelium, Vascular; Energy Metabolism; Guinea Pigs; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rabbits; Rats; Receptors, Purinergic P1; Reperfusion Injury; Ribonucleosides; Signal Transduction | 1995 |
Ischemic preconditioning slows ischemic metabolism and limits myocardial infarct size.
Topics: Adenine Nucleotides; Adenosine; Animals; Dogs; Energy Metabolism; Gene Expression; Ion Channel Gating; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Oxidative Phosphorylation; Potassium Channels; Receptors, Adrenergic, alpha; Time Factors | 1994 |
Pharmacologic stress myocardial perfusion imaging.
Topics: Adenosine; Contraindications; Coronary Circulation; Coronary Disease; Dipyridamole; Dobutamine; Exercise Test; Hemodynamics; Humans; Myocardial Infarction; Myocardial Ischemia; Radionuclide Imaging; Vasodilation | 1993 |
Cardiac preconditioning. Induction of endogenous tolerance to ischemia-reperfusion injury.
Topics: Adenosine; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Energy Metabolism; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Phenylephrine; Protein Kinase C; Rats; Receptors, Adrenergic, alpha; Receptors, Purinergic P1; Signal Transduction | 1993 |
Adenosine and the anti-infarct effects of preconditioning.
Topics: Adenosine; Animals; Dogs; Myocardial Infarction; Myocardial Ischemia; Rabbits; Receptors, Purinergic | 1993 |
Infarct size limitation by preconditioning: its phenomenological features and the key role of adenosine.
Topics: Adenosine; Animals; Dogs; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rabbits; Receptors, Purinergic; Time Factors | 1993 |
New strategies for intraoperative myocardial protection.
Topics: Adenosine; Animals; Cardiac Surgical Procedures; Heart; Heart Arrest, Induced; Humans; Intraoperative Care; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Sodium-Hydrogen Exchangers; Tissue Survival; Ventricular Dysfunction, Left | 1995 |
Perfusion imaging with contract echocardiography: assessment of the no-reflow phenomenon.
Topics: Adenosine; Calcium Channel Blockers; Echocardiography; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Vasodilator Agents | 1995 |
Ischemic preconditioning against infarction: its mechanism and clinical implications.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Angina Pectoris; Animals; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Myocardium; Potassium Channels; Protein Kinase C; Rabbits; Receptors, Purinergic P1 | 1996 |
Controversies in preconditioning.
Topics: Adenosine; Angina Pectoris; Animals; Catecholamines; Glycolysis; Humans; Hydrolases; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Species Specificity | 1997 |
Adenosine for myocardial protection in acute myocardial infarction.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Vasodilator Agents | 1997 |
Ischaemic preconditioning of myocardium.
Topics: Adaptation, Physiological; Adenosine; Angioplasty, Balloon, Coronary; Animals; Coronary Artery Bypass; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Protein Kinases; Time Factors | 1997 |
[Pre-infarction angina and post-thrombolysis recanalization].
Topics: Adenosine; Angina, Unstable; Animals; Bradykinin; Dogs; Epoprostenol; Female; Humans; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Nitric Oxide; Prognosis; Prospective Studies; Rabbits; Thrombolytic Therapy; Time Factors | 1998 |
Mechanisms and significance of anginal pain.
Topics: Adenosine; Angina Pectoris; Angina, Unstable; Animals; Bradykinin; Dogs; Humans; Microvascular Angina; Myocardial Infarction; Myocardial Ischemia; Receptors, Purinergic P1; Syndrome | 1999 |
It is time to ask what adenosine can do for cardioprotection.
Topics: 5'-Nucleotidase; Adenosine; Cardiovascular Agents; Collateral Circulation; Heart Failure; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Protein Kinase C | 1998 |
Role of energy metabolism in the preconditioned heart--a possible contribution of mitochondria.
Topics: Adenosine; Adenosine Triphosphate; Animals; Energy Metabolism; Glycolysis; Ischemic Preconditioning, Myocardial; Mitochondria, Heart; Myocardial Infarction; Myocardium; Potassium Channels; Rats; Reactive Oxygen Species | 1999 |
Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction.
Topics: Adenosine; Animals; Apoptosis; Caspases; Cell Death; Enzyme Inhibitors; Heart; Humans; In Situ Nick-End Labeling; Insulin-Like Growth Factor I; Myocardial Infarction; Myocardial Ischemia; Protein Kinase Inhibitors | 2000 |
Therapeutic potential of ischaemic preconditioning.
Topics: Adenosine; Adenosine Triphosphate; Angina, Unstable; Animals; Anti-Arrhythmia Agents; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Protein Kinase C; Receptors, Purinergic P1 | 2000 |
Ischemic preconditioning: from the first to the second window of protection.
Topics: Adenosine; Animals; Coronary Disease; Free Radicals; Heart; Heat-Shock Proteins; Humans; Ischemic Preconditioning, Myocardial; Mitochondria, Heart; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Potassium Channels; Protein Kinase C | 2001 |
Signal transduction of ischemic preconditioning.
Topics: Adenosine; Animals; Animals, Genetically Modified; Bradykinin; Free Radicals; Humans; Ischemic Preconditioning; Models, Animal; Myocardial Infarction; Myocardial Ischemia; Narcotics; Neurotransmitter Agents; Prostaglandins; Protein Kinases; Signal Transduction; Species Specificity; Time Factors | 2001 |
Preinfarct angina and exercise: yet another reason to stay physically active.
Topics: Adenosine; Age Factors; Aged; Angina Pectoris; Arrhythmias, Cardiac; Collateral Circulation; Coronary Circulation; Exercise; Hospital Mortality; Humans; Ischemic Preconditioning, Myocardial; Middle Aged; Myocardial Infarction; Prognosis; Shock, Cardiogenic; Treatment Outcome | 2001 |
Protective effects of adenosine in myocardial ischemia.
Topics: Adenosine; Animals; Cardioplegic Solutions; Collateral Circulation; Coronary Disease; Energy Metabolism; Heart Transplantation; Humans; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Organ Preservation; Receptors, Purinergic | 1992 |
Myocardial perfusion imaging in the diagnosis of coronary artery disease.
Topics: Adenosine; Coronary Circulation; Coronary Disease; Dipyridamole; Heart; Humans; Myocardial Infarction; Myocardium; Tomography, Emission-Computed | 1992 |
Arrhythmias and acute myocardial infarction.
Topics: Adenosine; Arrhythmias, Cardiac; Electrocardiography; Humans; Myocardial Infarction; Pacemaker, Artificial; Risk Factors | 1991 |
Adenosine in myocardial perfusion imaging using positron emission tomography.
Topics: Adenosine; Adult; Aged; Coronary Disease; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Tomography, Emission-Computed | 1991 |
Acute myocardial infarction and muscle salvage: a potential role for pharmacological agents.
Topics: Adenosine; Adrenergic alpha-Agonists; Animals; Assisted Circulation; Collateral Circulation; Coronary Artery Bypass; Coronary Circulation; Digitalis Glycosides; Diuretics; Electric Stimulation; Glucocorticoids; Glucose; Humans; Hyaluronoglucosaminidase; Insulin; Ischemia; Myocardial Infarction; Myocardium; Necrosis; Nitroglycerin; Oxygen; Oxygen Consumption; Potassium; Propranolol; Ventricular Fibrillation | 1974 |
Pathophysiology of coronary circulation.
Topics: Adaptation, Physiological; Adenosine; Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Heart; Homeostasis; Humans; Hypoxia; Ischemia; Male; Middle Aged; Myocardial Infarction; Myocardium; Vasodilator Agents | 1971 |
131 trial(s) available for adenosine and Cardiovascular Stroke
| Article | Year |
|---|---|
Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial).
Topics: Acute Coronary Syndrome; Adenosine; Coronary Angiography; Coronary Circulation; Epinephrine; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Treatment Outcome | 2022 |
Clinical Efficacy of Ulinastatin Combined with Meglumine Adenosine Cyclophosphate in the Treatment of Acute Myocardial Infarction.
Topics: Adenosine; Glycoproteins; Humans; Meglumine; Myocardial Infarction; Quality of Life; Treatment Outcome | 2022 |
Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Gene Expression; Humans; Inflammation; Leukocytes, Mononuclear; Methotrexate; Monocytes; Myocardial Infarction; Receptors, Purinergic P1 | 2022 |
Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor.
Topics: Adenosine; Endothelial Progenitor Cells; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Thrombin; Ticagrelor; Treatment Outcome | 2023 |
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
Topics: Adenosine; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Treatment Outcome | 2020 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
Topics: Adenosine; Aged; Area Under Curve; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac Output; China; Creatine Kinase; Creatine Kinase, MB Form; Creatinine; Diabetes Mellitus, Type 2; Echocardiography; Female; Glycated Hemoglobin; Heart Atria; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Treatment Outcome; Trimetazidine; Troponin I; Urea; Vasodilator Agents | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
Topics: Adenosine; Aged; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2017 |
Magnetic resonance Adenosine perfusion imaging as Gatekeeper of invasive coronary intervention (MAGnet): study protocol for a randomized controlled trial.
Topics: Adenosine; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Germany; Humans; Magnetic Resonance Imaging; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Predictive Value of Tests; Prospective Studies; Research Design; Time Factors; Treatment Outcome; Vasodilator Agents | 2017 |
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
Topics: Adenosine; Aged; Cause of Death; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Survival Rate; Thrombolytic Therapy; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Neointima; Prospective Studies; Prostheses and Implants; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis
Topics: Adenosine; Aged; Double-Blind Method; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Treatment Outcome | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients.
Topics: Adenosine; Blood Platelets; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Topics: Adenosine; Aged; Aged, 80 and over; Comparative Effectiveness Research; Drug Monitoring; Electrocardiography; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
Effect of new method of intracoronary adenosine injection during primary percutaneous coronary intervention on microvascular reperfusion injury - clinical outcome and 1-year follow-up.
Topics: Adenosine; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; Humans; Injections, Intralesional; Male; Microvessels; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Secondary Prevention; Treatment Outcome; Vasodilator Agents | 2013 |
Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: t
Topics: Adenosine; Aged; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Italy; Male; Microcirculation; Middle Aged; Myocardial Infarction; Nitroprusside; Percutaneous Coronary Intervention; Recurrence; Suction; Thrombectomy; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2013 |
Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis.
Topics: Adenosine; Adult; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thrombolytic Therapy; Ticagrelor | 2014 |
Ticagrelor or prasugrel for pre-hospital protocols in STEMI?
Topics: Adenosine; Aged; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Survival Analysis; Ticagrelor; Treatment Outcome | 2013 |
Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Injections, Intralesional; Italy; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Reperfusion; Nitroprusside; Pulse Therapy, Drug; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Remodeling | 2014 |
Cardioprotective effect of high-dose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention.
Topics: Adenosine; Aged; Coronary Angiography; Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Graft Occlusion, Vascular; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Regional Blood Flow; Saphenous Vein; Stents; Vasodilator Agents | 2014 |
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2014 |
[Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction].
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2013 |
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Treatment Outcome | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction.
Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Prognosis; Prospective Studies; Survival Rate; Tirofiban; Tyrosine; Vasodilator Agents; Verapamil | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time-to-Treatment | 2014 |
The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised control
Topics: Adenosine; Clinical Protocols; Coronary Angiography; Coronary Circulation; Coronary Vessels; Humans; Magnetic Resonance Imaging; Microcirculation; Myocardial Infarction; Myocardial Perfusion Imaging; Nitroprusside; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Prospective Studies; Reperfusion Injury; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vasodilator Agents | 2014 |
Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial.
Topics: Adenosine; Aged; Double-Blind Method; Female; Humans; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Vasodilator Agents | 2014 |
Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study.
Topics: Adenosine; Chemistry, Pharmaceutical; Humans; Internationality; Intubation, Gastrointestinal; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor | 2015 |
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Prospective Studies; Ticagrelor; Ticlopidine | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Ticagrelor | 2015 |
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
Topics: Adenosine; Aged; Analgesics, Opioid; Biotransformation; Blood Platelets; Chromatography, Liquid; Clinical Protocols; Double-Blind Method; Drug Interactions; Drug Monitoring; Female; Humans; Male; Mass Spectrometry; Morphine; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Poland; Purinergic P2Y Receptor Antagonists; Research Design; Ticagrelor; Treatment Outcome | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Sample Size; Thrombophilia; Thrombosis; Ticagrelor | 2015 |
Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult | 2015 |
[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
Topics: Adenosine; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internationality; Ischemic Attack, Transient; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Research Design; Ticagrelor; Treatment Outcome | 2015 |
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.
Topics: Adenosine; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Posture; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Tablets; Ticagrelor | 2016 |
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Agonists; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigati
Topics: Adenosine; Aged; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Female; Humans; Intestinal Absorption; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2015 |
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Factors; Ticagrelor; Treatment Outcome | 2016 |
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
Topics: Adenosine; Aged; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Purinergic P2Y Receptor Antagonists; Risk Factors; Secondary Prevention; Ticagrelor; Treatment Outcome | 2016 |
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
Topics: Adenosine; Administration, Oral; Analgesics, Opioid; Area Under Curve; Double-Blind Method; Drug Interactions; Female; Humans; Injections, Intravenous; Male; Middle Aged; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
Topics: Adenosine; Biomarkers; Blood Platelets; Clopidogrel; Electrocardiography; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for
Topics: Adenosine; Biomarkers; C-Reactive Protein; CD40 Ligand; Clinical Protocols; Clopidogrel; Endothelium, Vascular; Humans; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sample Size; Ticagrelor; Ticlopidine | 2016 |
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Topics: Adenosine; Blood Platelets; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome | 2016 |
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Topics: Adenosine; Aged; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor; Vascular Grafting | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
Topics: Adenosine; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Quality of Life; Secondary Prevention; Stroke; Ticagrelor | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
Topics: Adenosine; Aged; Body Mass Index; Exercise; Female; Health Behavior; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Mobile Applications; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Secondary Prevention; Smartphone; Smoking Cessation; Ticagrelor | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Stroke; Ticagrelor | 2016 |
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
Topics: Adenosine; Adult; Aged; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2016 |
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.
Topics: Adenosine; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2017 |
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
Topics: Activation, Metabolic; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Gastrointestinal Absorption; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Topics: Adenosine; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Diabetes Mellitus; Drug Administration Schedule; England; Female; Florida; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.
Topics: Adenosine; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Vasodilator Agents | 2009 |
Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Protocols; Combined Modality Therapy; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Italy; Myocardial Infarction; Nitroprusside; No-Reflow Phenomenon; Research Design; Suction; Thrombectomy; Treatment Outcome; Vasodilator Agents | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Influence of abnormal glucose metabolism on coronary microvascular function after a recent myocardial infarction.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Blood Glucose; Coronary Angiography; Coronary Circulation; Diabetes Mellitus; Echocardiography, Doppler, Color; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperemia; Infusions, Intravenous; Logistic Models; Male; Microcirculation; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Female; Humans; Injections; Male; Microcirculation; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Thrombectomy; Time Factors; Treatment Outcome; Vasodilator Agents | 2009 |
High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Double-Blind Method; Electrocardiography; Female; Humans; Injections, Intralesional; Magnetic Resonance Angiography; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Prospective Studies; Salvage Therapy; Stroke Volume; Treatment Outcome; Vasodilator Agents | 2011 |
New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Vessels; Electrocardiography; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Prospective Studies; Treatment Outcome; Vasodilator Agents | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis.
Topics: Adenosine; Aged; Cardiac Catheterization; Coronary Circulation; Coronary Vessels; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perfusion; Regional Blood Flow; Thrombolytic Therapy | 2011 |
Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial).
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Vessels; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Treatment Outcome; Vasodilator Agents | 2012 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I | 2012 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction.
Topics: Adenosine; Adult; Aged; Angioplasty, Balloon, Coronary; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Treatment Outcome | 2012 |
Effect of adenosine intracoronary bolus on myonecrosis occurrence in elective PCI (RACE trial).
Topics: Adenosine; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Coronary Vessels; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Injections, Intra-Arterial; Intraoperative Period; Italy; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Treatment Outcome; Troponin T; Vasodilator Agents | 2012 |
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Clinic value of two-dimensional speckle tracking combined with adenosine stress echocardiography for assessment of myocardial viability.
Topics: Adenosine; Echocardiography; Echocardiography, Stress; Elasticity Imaging Techniques; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Stunning; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tissue Survival; Vasodilator Agents | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Ventricular Function, Left | 2012 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Topics: Adenosine; Aged; Blood Platelets; Drug Administration Schedule; Female; Greece; Humans; Least-Squares Analysis; Linear Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Single-Blind Method; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2012 |
Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study.
Topics: Adenosine; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Streptokinase; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Low-dose adenosine stress echocardiography: detection of myocardial viability.
Topics: Adenosine; Dose-Response Relationship, Drug; Echocardiography; Exercise Test; Feasibility Studies; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Middle Aged; Myocardial Infarction; Reproducibility of Results; Sensitivity and Specificity; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myoc
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Myocardial Infarction; Pyridines; Radionuclide Imaging; Technetium Tc 99m Sestamibi | 2003 |
Role of adenosine and opioid-receptor mechanisms for pain in patients with silent myocardial ischemia or angina pectoris: a double-blind, placebo-controlled study.
Topics: Adenosine; Angina Pectoris; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Time Factors | 2003 |
Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Cohort Studies; Echocardiography; Female; Humans; Injections, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Prospective Studies; Treatment Outcome; Vasodilator Agents | 2004 |
Is left ventricular diastolic function an independent marker of prognosis after acute myocardial infarction?
Topics: Adenosine; Aged; Biomarkers; Diastole; Double-Blind Method; Echocardiography, Doppler; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Probability; Prognosis; Prospective Studies; Regression Analysis; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).
Topics: Adenosine; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Thrombolytic Therapy; Vasodilator Agents | 2005 |
Does adenosine pharmacologically precondition human myocardium during coronary bypass surgery?
Topics: Adenosine; Aged; Biomarkers; Coronary Artery Bypass; Coronary Disease; Creatine Kinase, MB Form; Electrocardiography; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Intraoperative Period; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Treatment Outcome; Troponin I; Vasodilator Agents | 2005 |
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.
Topics: Adenosine; Electrocardiography; Humans; Myocardial Infarction; Prospective Studies; Thrombolytic Therapy | 2005 |
Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting.
Topics: Adenosine; Blood Vessel Prosthesis Implantation; Blood Volume; Coronary Angiography; Coronary Circulation; Coronary Disease; Echocardiography; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Stents; Stroke Volume; Systole; Treatment Outcome; Vascular Patency; Vasodilator Agents; Ventricular Function, Left | 2005 |
Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Echocardiography; Electrocardiography; Female; Humans; Injections; Male; Middle Aged; Myocardial Infarction; Nitroprusside; Pilot Projects; Single-Blind Method; Stroke Volume; Time Factors; Vasodilator Agents; Verapamil | 2006 |
Is stress-only imaging practical when a 1-day stress-rest 99mTc-tetrofosmin protocol is used?
Topics: Adenosine; Allied Health Personnel; Exercise Test; Female; Humans; Male; Myocardial Infarction; Observer Variation; Organophosphorus Compounds; Organotechnetium Compounds; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; United Kingdom | 2006 |
Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Angiography; Coronary Circulation; Echocardiography; Feasibility Studies; Female; Humans; Injections, Intralesional; Male; Middle Aged; Myocardial Infarction; Syndrome; Treatment Outcome; Vasodilator Agents; Verapamil | 2006 |
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Recurrence; Thrombolytic Therapy; Time Factors; Treatment Outcome; Vasodilator Agents | 2006 |
Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.
Topics: Adenosine; Aged; Aminoimidazole Carboxamide; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Preoperative Care; Ribonucleosides; Risk Factors; Survival Rate | 2006 |
A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction.
Topics: Adenosine; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Prospective Studies; Radiopharmaceuticals; Risk Assessment; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2006 |
An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction.
Topics: Adenosine; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Treatment Outcome | 2006 |
Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Comorbidity; Coronary Circulation; Coronary Disease; Disease-Free Survival; Dobutamine; Echocardiography, Stress; Female; Follow-Up Studies; Heart Rate; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Motion; Myocardial Infarction; Observer Variation; Prognosis; Risk Factors; Single-Blind Method | 2007 |
High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study.
Topics: Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Vessels; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Infusions, Intralesional; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2008 |
Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction.
Topics: Adenosine; Coronary Angiography; Coronary Circulation; Echocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Ventricular Function, Left | 2008 |
Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
Topics: Adenosine; Aged; Aminoimidazole Carboxamide; Coronary Artery Bypass; Double-Blind Method; Female; Hemodynamics; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Ribonucleosides; Ventricular Function, Left | 1995 |
The effects of intracoronary adenosine on preconditioning during coronary angioplasty.
Topics: Adenosine; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Vessels; Double-Blind Method; Electrocardiography; Humans; Infusions, Intra-Arterial; Myocardial Infarction | 1995 |
Pharmacologic stress dual-isotope myocardial perfusion single-photon emission computed tomography.
Topics: Adenosine; Aged; Coronary Angiography; Coronary Disease; Dipyridamole; Feasibility Studies; Female; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Sensitivity and Specificity; Stress, Physiological; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 1994 |
Effects of low-dose adenosine on myocardial performance after coronary artery bypass surgery.
Topics: Adenosine; Aged; Cardiac Output; Coronary Artery Bypass; Double-Blind Method; Female; Heart Rate; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Oxygen; Placebos; Pulmonary Wedge Pressure; Stroke Volume; Vascular Resistance; Ventricular Function, Left | 1993 |
Delayed recovery of myocardial perfusion in acute myocardial infarction: a scintigraphic study after early thrombolytic treatment.
Topics: Adenosine; Coronary Circulation; Female; Fibrinolytic Agents; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Stunning; Prospective Studies; Radiopharmaceuticals; Streptokinase; Technetium Tc 99m Sestamibi; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 1998 |
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.
Topics: Adenosine; Adult; Aged; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Radiography; Thrombolytic Therapy; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents | 1999 |
Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias : evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Cyclic AMP; Dipyridamole; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Prospective Studies; Treatment Outcome; Vasodilator Agents | 2000 |
The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine.
Topics: Adenosine; Combined Modality Therapy; Coronary Circulation; Electrocardiography; Humans; Myocardial Infarction; Signal Processing, Computer-Assisted; Technetium Tc 99m Sestamibi; Thrombolytic Therapy; Tomography, Emission-Computed, Single-Photon | 1999 |
Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Vessels; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Vasodilator Agents | 2000 |
Angina pectoris-like pain provoked by i.v. bolus of adenosine: relationship to coronary sinus blood flow, heart rate and blood pressure in healthy volunteers.
Topics: Adenosine; Adult; Blood Pressure; Chest Pain; Coronary Circulation; Female; Heart Rate; Humans; Injections, Intravenous; Male; Myocardial Infarction | 1989 |
484 other study(ies) available for adenosine and Cardiovascular Stroke
| Article | Year |
|---|---|
[Systemic inflammatory response syndrome associated with use of ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Systemic Inflammatory Response Syndrome; Ticagrelor | 2021 |
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Secondary Prevention; Ticagrelor; Treatment Outcome | 2022 |
Regulation of N6-Methyladenosine after Myocardial Infarction.
Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Female; Heart Failure; Humans; Myocardial Infarction; RNA, Messenger; Ventricular Function, Left | 2022 |
Comprehensive Analysis of N6-Methyladenosine RNA Methylation Regulators in the Diagnosis and Subtype Classification of Acute Myocardial Infarction.
Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Fragile X Mental Retardation Protein; Humans; Methylation; Methyltransferases; Myocardial Infarction; RNA | 2022 |
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54.
Topics: Adenosine; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Secondary Prevention; Ticagrelor; Treatment Outcome | 2022 |
IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling.
Topics: Adenosine; Animals; Fibroblasts; Humans; Interleukin-6; Mice; Mice, Inbred C57BL; Myocardial Infarction; T-Lymphocytes | 2023 |
Ticagrelor Treatment is Associated With Increased Coronary Flow Reserve in Survivors of Myocardial Infarction.
Topics: Adenosine; Coronary Circulation; Cross-Sectional Studies; Female; Humans; Male; Myocardial Infarction; Survivors; Ticagrelor | 2023 |
IL-6 helps weave the inflammatory web during acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Humans; Interleukin-6; Mice; Myocardial Infarction; Myocardial Ischemia | 2023 |
Downregulation of ALKBH5 rejuvenates aged human mesenchymal stem cells and enhances their therapeutic efficacy in myocardial infarction.
Topics: Adenosine; Aged; AlkB Homolog 5, RNA Demethylase; Animals; Cellular Senescence; Down-Regulation; Humans; Immunologic Factors; Mesenchymal Stem Cells; Mice; Myocardial Infarction; RNA, Messenger | 2023 |
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve.
Topics: Adenosine; Aged; Blood Flow Velocity; Coronary Artery Disease; Coronary Vessels; Cross-Sectional Studies; Echocardiography, Doppler; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Registries; Risk Factors; Secondary Prevention; Sweden; Vasodilator Agents | 2019 |
Optimizing cardiac ischemic preconditioning and postconditioning via epitranscriptional regulation.
Topics: Adenosine; Gene Expression Regulation; Heme Oxygenase-1; Humans; Ischemic Postconditioning; Ischemic Preconditioning, Myocardial; Methylation; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; RNA; RNA, Messenger; Signal Transduction; Superoxide Dismutase-1; Transcriptome | 2020 |
No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization.
Topics: Adenosine; Coronary Angiography; Coronary Circulation; Coronary Occlusion; Coronary Vessels; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Postoperative Complications; Ultrasonography, Interventional; Vasodilator Agents | 2020 |
Cardiac magnetic resonance for asymptomatic patients with type 2 diabetes and cardiovascular high risk (CATCH): a pilot study.
Topics: Adenosine; Aged; Aged, 80 and over; Asymptomatic Diseases; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Feasibility Studies; Female; Hong Kong; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Pilot Projects; Predictive Value of Tests; Prevalence; Prospective Studies; Reproducibility of Results; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome; Vasodilator Agents | 2020 |
Nitroxide-enhanced MRI of cardiovascular oxidative stress.
Topics: Adenosine; Angiotensin II; Animals; Cardiovascular System; Cyclic N-Oxides; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Magnetic Resonance Imaging; Male; Mice, Inbred C57BL; Myocardial Infarction; Nitrogen Oxides; Obesity; Oxidative Stress; Perfusion; Pyrrolidines | 2020 |
Clinical assessment of adenosine stress and rest cardiac magnetic resonance T1 mapping for detecting ischemic and infarcted myocardium.
Topics: Adenosine; Aged; Contrast Media; Coronary Artery Disease; Coronary Circulation; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Rest; Vasodilator Agents | 2020 |
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk.
Topics: Adenosine; Aged; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Registries; Risk Assessment; Stroke | 2021 |
METTL3 Regulates Angiogenesis by Modulating let-7e-5p and miRNA-18a-5p Expression in Endothelial Cells.
Topics: Adenosine; Animals; Cells, Cultured; Disease Models, Animal; Female; Gene Expression Regulation; Hindlimb; Human Umbilical Vein Endothelial Cells; Humans; Ischemia; Male; Methyltransferases; Mice, Inbred C57BL; MicroRNAs; Myocardial Infarction; Neovascularization, Physiologic; Signal Transduction; Thrombospondin 1 | 2021 |
Loss of m
Topics: Adenosine; Adenoviridae; Animals; Cell Cycle; Heart; Humans; Male; Methylation; Methyltransferases; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Myocardial Infarction; Regeneration; RNA, Messenger; Signal Transduction; Transfection; Up-Regulation | 2021 |
CD73-derived adenosine and tenascin-C control cytokine production by epicardium-derived cells formed after myocardial infarction.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cytokines; Gene Expression Regulation; Male; Myocardial Infarction; Pericardium; Rats; Rats, Wistar; Receptors, Purinergic P2X; Receptors, Purinergic P2Y; Tenascin | 2017 |
Stress Perfusion CMR in Patients With Known and Suspected CAD: Prognostic Value and Optimal Ischemic Threshold for Revascularization.
Topics: Adenosine; Aged; Contrast Media; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Myocardium; Organometallic Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left | 2017 |
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECT-related variables.
Topics: Adenosine; Aged, 80 and over; Coronary Artery Disease; Echocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Male; Myocardial Infarction; Myocardial Perfusion Imaging; Patient Safety; Prognosis; Prospective Studies; Registries; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2019 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Prognostic Value of Coronary CT Angiography With Selective PET Perfusion Imaging in Coronary Artery Disease.
Topics: Adenosine; Aged; Angina, Unstable; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Myocardial Infarction; Myocardial Perfusion Imaging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Vasodilator Agents | 2017 |
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Monitoring platelet reactivity during prasugrel or ticagrelor washout before urgent coronary artery bypass grafting.
Topics: Adenosine; Aged; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Postoperative Hemorrhage; Prasugrel Hydrochloride; Predictive Value of Tests; Preoperative Period; Risk Factors; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
Accurate late gadolinium enhancement prediction by early T1- based quantitative synthetic mapping.
Topics: Adenosine; Aged; Cicatrix; Contrast Media; Female; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Angiography; Male; Middle Aged; Myocardial Infarction; Myocardium; Prospective Studies; Sensitivity and Specificity | 2018 |
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.
Topics: Adenosine; Brain Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polycythemia Vera; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thrombocytosis; Ticagrelor; Ticlopidine | 2017 |
[FFR-Guided Revascularisation - Pros and Cons].
Topics: Adenosine; Angina, Stable; Contraindications; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coronary Stenosis; Cost-Benefit Analysis; Diabetes Complications; Fractional Flow Reserve, Myocardial; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Reference Values; Risk Assessment; Stents; Ultrasonography, Interventional | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Adenosine Production by Biomaterial-Supported Mesenchymal Stromal Cells Reduces the Innate Inflammatory Response in Myocardial Ischemia/Reperfusion Injury.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Enzyme Inhibitors; GPI-Linked Proteins; Humans; Hydrogen Peroxide; Immunity, Innate; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Rats, Sprague-Dawley; Recovery of Function; Stem Cell Niche; Tissue Scaffolds | 2018 |
Impaired Production and Diurnal Regulation of Vascular RvD
Topics: Adenosine; Animals; Blood Platelets; Circadian Rhythm; Fatty Acids, Unsaturated; Humans; Inflammation; Leukocytes; Lipoxygenase; Mice; Myocardial Infarction; Thromboxane B2 | 2018 |
Adenosine Plasma Level and A2A Receptor Expression in Patients With Cardiogenic Shock.
Topics: Adenosine; Aged; Blood Pressure; Female; Heart Failure; Humans; Male; Myocardial Contraction; Myocardial Infarction; Prospective Studies; Receptor, Adenosine A2A; Shock, Cardiogenic; Vasodilation | 2018 |
Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation.
Topics: Adenosine; Animals; Atrial Natriuretic Factor; Cell Line; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Injections, Intravenous; Myocardial Infarction; Myocardium; Nanomedicine; Nanoparticles; Phosphatidylethanolamines; Polyethylene Glycols; Prodrugs; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2018 |
FTO-Dependent N
Topics: Adenosine; Adult; Aged; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Calcium Signaling; Case-Control Studies; Cell Line; Cell Proliferation; Demethylation; Disease Models, Animal; Female; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; Regeneration; RNA Processing, Post-Transcriptional; RNA Stability; RNA, Messenger; Sus scrofa; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervent
Topics: Adenosine; Adult; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Female; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prognosis; Proteoglycans; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
[A Potential Role of Adenosine A 2 b Receptor in Mediating Acupuncture Pretreatment Induced Cardioprotection via Influencing Intracellular Calcium Regulator].
Topics: Acupuncture; Adenosine; Calcium; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Receptor, Adenosine A2B; Receptors, Purinergic P1 | 2018 |
Airway Exposure to Modified Multi-walled Carbon Nanotubes Perturbs Cardiovascular Adenosinergic Signaling in Mice.
Topics: Adenosine; Animals; Aorta, Thoracic; Cyclic AMP; Inhalation Exposure; Lung; Male; Mice, Inbred ICR; Muscle, Smooth, Vascular; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nanotubes, Carbon; Nitric Oxide Synthase; Prostaglandin-Endoperoxide Synthases; Signal Transduction; Vasoconstriction; Vasodilation | 2019 |
Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway.
Topics: Adenosine; Animals; Autonomic Nervous System; Creatine Kinase; Disease Models, Animal; Ganglionic Blockers; Heart; Hexamethonium; Hindlimb; Ischemic Preconditioning; Isolated Heart Preparation; L-Lactate Dehydrogenase; Myocardial Infarction; Myocardial Reperfusion Injury; Rats, Wistar; Regional Blood Flow; Therapeutic Occlusion; Time Factors | 2019 |
Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?
Topics: Adenosine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |
Value of adenosine stress cardiovascular magnetic resonance in the evaluation of vessels supplying previously infarcted territories.
Topics: Adenosine; Aged; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Coronary Vessels; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Reproducibility of Results; Vasodilator Agents | 2019 |
Ticagrelor Does Not Protect Isolated Rat Hearts, Thus Clouding Its Proposed Cardioprotective Role Through ENT 1 in Heart Tissue.
Topics: Adenosine; Animals; Disease Models, Animal; Equilibrative Nucleoside Transporter 1; Ischemic Preconditioning, Myocardial; Isolated Heart Preparation; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Ticagrelor | 2019 |
COA-Cl (2-Cl-C.OXT-A) can promote coronary collateral development following acute myocardial infarction in mice.
Topics: Adenosine; Animals; Collateral Circulation; Coronary Circulation; Mice; Myocardial Infarction; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Vascular Endothelial Growth Factor A | 2019 |
Increased Plasma Adenosine Concentration in the Subacute Phase May Contribute to Attenuation of Left Ventricular Dilation in the Chronic Phase in Patients With Acute Myocardial Infarction.
Topics: Adenosine; Aged; Case-Control Studies; Dilatation; Female; Humans; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Coronary Microcirculation Downstream Non-Infarct-Related Arteries in the Subacute Phase of Myocardial Infarction: Implications for Physiology-Guided Revascularization.
Topics: Adenosine; Aged; Cardiac Catheterization; Case-Control Studies; Clinical Decision-Making; Coronary Artery Disease; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Netherlands; Predictive Value of Tests; Reproducibility of Results; Seoul; Spain; Vascular Resistance; Vasodilator Agents | 2019 |
T1 reactivity as an imaging biomarker in myocardial tissue characterization discriminating normal, ischemic and infarcted myocardium.
Topics: Adenosine; Aged; Contrast Media; Coronary Artery Disease; Coronary Circulation; Diagnosis, Differential; Female; Gadolinium DTPA; Hemodynamics; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Retrospective Studies; Tissue Survival; Vasodilator Agents | 2019 |
Adenosine stress CMR perfusion imaging of the temporal evolution of perfusion defects in a porcine model of progressive obstructive coronary artery occlusion.
Topics: Adenosine; Anesthesia; Animals; Coronary Artery Disease; Disease Models, Animal; Hemodynamics; Ischemia; Magnetic Resonance Imaging; Male; Myocardial Infarction; Perfusion; Swine; Swine, Miniature; Time Factors; Ventricular Remodeling | 2019 |
Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the
Topics: Adenosine; Adult; Ambulances; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Patient Selection; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Research Design; Ticagrelor; Young Adult | 2013 |
The giant leap and small steps to better reperfusion in ST-segment elevation myocardial infarction patients.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Vasodilator Agents | 2013 |
Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Prognosis of normal stress-only gated-SPECT myocardial perfusion imaging: a single center study.
Topics: Adenosine; Aged; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Coronary Artery Disease; Coronary Circulation; Electrocardiography; Exercise Test; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Portugal; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke Volume; Time Factors; Vasodilator Agents | 2013 |
Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Guanidines; Hypothermia, Induced; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Sulfones; Ticagrelor | 2013 |
Adenosine receptor expression in an experimental animal model of myocardial infarction with preserved left ventricular ejection fraction.
Topics: Adenosine; Animals; Disease Models, Animal; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Receptors, Purinergic P1; RNA, Messenger; Stroke Volume; Sus scrofa; Time Factors; Ventricular Function, Left | 2014 |
Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Preoperative Care; Thiophenes | 2013 |
Reply: Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Preoperative Care; Thiophenes | 2013 |
Remote cardioprotection by transfer of coronary effluent from ischemic preconditioned rabbit heart preserves mitochondrial integrity and function via adenosine receptor activation.
Topics: Adenosine; Animals; Disease Models, Animal; Ischemic Preconditioning, Myocardial; Male; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury; Rabbits; Reactive Oxygen Species; Receptors, Purinergic P1; Theophylline | 2014 |
The role of adenosine in preconditioning by brief pressure overload in rats.
Topics: Adenosine; Animals; Disease Models, Animal; Heart Ventricles; Hemodynamics; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Rats; Rats, Sprague-Dawley | 2015 |
Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications.
Topics: Adenosine; Aged; Blood Platelets; Coronary Angiography; Coronary Circulation; Coronary Vessels; Female; Humans; Male; Microcirculation; Middle Aged; Monocytes; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors | 2014 |
Considering the affordability of ticagrelor when used according to NICE guidance.
Topics: Adenosine; Aged; Aged, 80 and over; Angina, Unstable; Cost-Benefit Analysis; Drug Costs; England; Guideline Adherence; Humans; Life Expectancy; Models, Economic; Myocardial Infarction; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Androstadienes; Animals; Apoptosis; Butadienes; Cardiotonic Agents; Caspase 3; Disease Models, Animal; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitriles; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A3; Signal Transduction; Wortmannin | 2014 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Feasibility of dynamic CT-based adenosine stress myocardial perfusion imaging to detect and differentiate ischemic and infarcted myocardium in an large experimental porcine animal model.
Topics: Adenosine; Animals; Blood Flow Velocity; Coronary Angiography; Coronary Circulation; Diagnosis, Differential; Disease Models, Animal; Feasibility Studies; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Predictive Value of Tests; Regional Blood Flow; Reproducibility of Results; Swine; Time Factors; Tomography, X-Ray Computed | 2014 |
[A high-volume single center experience of no-reflow post-percutaneous coronary intervention].
Topics: Adenosine; Aged; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Nitroprusside; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Ventricular Function, Left | 2014 |
Controversies in acute cardiovascular care.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Impact of accuracy of fractional flow reserve to reduction of microvascular resistance after intracoronary adenosine in patients with angina pectoris or non-ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Aged, 80 and over; Angina, Stable; Blood Flow Velocity; Blood Pressure; Coronary Angiography; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Middle Aged; Myocardial Infarction; Vascular Resistance | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Saphenous vein grafts intervention: can adenosine make it better?
Topics: Adenosine; Female; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Regional Blood Flow; Saphenous Vein; Stents | 2014 |
Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment.
Topics: Adenosine; Aged; Angina, Stable; Coronary Artery Disease; Coronary Thrombosis; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticagrelor | 2015 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Physiological assessment of nonculprit stenoses during acute coronary syndromes.
Topics: Adenosine; Angina, Stable; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Myocardial Infarction; Vascular Resistance | 2014 |
Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction.
Topics: Adenosine; Adolescent; Adult; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors | 2015 |
Coronary flow of the infarct artery assessed by transthoracic Doppler after primary percutaneous coronary intervention predicts final infarct size.
Topics: Adenosine; Aged; Biomarkers; Blood Flow Velocity; Coronary Vessels; Creatine Kinase, MB Form; Echocardiography, Doppler; Feasibility Studies; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Microcirculation; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Predictive Value of Tests; Prospective Studies; Serbia; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents | 2014 |
Ischemic and postischemic conditioning of the myocardium in clinical practice: challenges, expectations and obstacles.
Topics: Adenosine; Cyclosporine; Enzyme Activators; Erythropoietin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Ischemic Postconditioning; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Nicorandil; Vasodilator Agents | 2014 |
COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2015 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages.
Topics: Adenosine; Animals; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Macrophages; Male; Microscopy, Confocal; Myocardial Infarction; Neovascularization, Physiologic; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Thrombospondin 1; Up-Regulation | 2015 |
Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts.
Topics: Adenosine; Animals; Heart; Male; Myocardial Infarction; Pyrazines; Rats; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles | 2015 |
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.
Topics: Adenosine; Aged; Blood Platelets; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome | 2015 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[The ATLANTIC study].
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
[Immediate ticagrelor administration useful in STEMI].
Topics: Adenosine; Emergency Medical Services; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists | 2014 |
Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Acute Disease; Adenosine; Age Factors; Aged; Analgesics, Opioid; Drug Interactions; Electrocardiography; Female; Humans; Male; Middle Aged; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2015 |
Editorial: Old dog, new tricks: proangiogenic effect of adenosine via stimulation of thrombospondin-1 in macrophages.
Topics: Adenosine; Animals; Humans; Macrophages; Male; Myocardial Infarction; Neovascularization, Physiologic; Thrombospondin 1 | 2015 |
The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.
Topics: Adenosine; Animals; Disease Models, Animal; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Adenosine A2A; Receptor, Adenosine A3 | 2015 |
Myocardial bridging in a man with non-ST-elevation myocardial infarction.
Topics: Adenosine; Adrenergic beta-Antagonists; Aged; Blood Pressure; Cardiac Catheterization; Coronary Angiography; Coronary Vessels; Hemodynamics; Humans; Male; Metoprolol; Myocardial Bridging; Myocardial Infarction; Nitroglycerin; Respiratory Tract Infections; Systole; Tachycardia | 2015 |
Antiplatelet therapy. Long-term ticagrelor use in patients with history of MI.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
[ATLANTIC trial and feasibility of early administration of ticagrelor in myocardial infarction].
Topics: Adenosine; Coronary Circulation; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticagrelor; Time-to-Treatment; Treatment Outcome | 2014 |
The ATLANTIC trial does not support the safety of prehospital ticagrelor treatment for patients with ST-elevation myocardial infarction.
Topics: Adenosine; Clinical Trials as Topic; Emergency Medical Services; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2015 |
The hazards of approximations and extrapolations: Insights from the ATLANTIC study.
Topics: Adenosine; Clinical Trials as Topic; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2015 |
ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?
Topics: Adenosine; Clinical Trials as Topic; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2015 |
Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge.
Topics: Adenosine; Clinical Trials as Topic; Drug Administration Schedule; Emergency Medical Services; Humans; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2015 |
Ticagrelor-related gout: An underestimated side effect.
Topics: Adenosine; Gout; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor; Uric Acid | 2015 |
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?
Topics: Adenosine; Electrocardiography; Humans; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2015 |
[After myocardial infarct: ticagrelor also has a long-term preventive effect].
Topics: Adenosine; Coronary Disease; Humans; Long-Term Care; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Ticagrelor | 2015 |
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Injections, Intraperitoneal; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Signal Transduction; Ticagrelor; Ticlopidine; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; Hemostatics; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Blood Platelets; Cell Adhesion Molecules; Drug Administration Schedule; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2015 |
Mitral valve disease and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Cardiac Catheterization; Humans; Mitral Valve Insufficiency; Myocardial Infarction; Percutaneous Coronary Intervention; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Extracellular Adenosine Formation by Ecto-5'-Nucleotidase (CD73) Is No Essential Trigger for Early Phase Ischemic Preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Disease Models, Animal; Extracellular Space; Female; Inosine; Ischemic Preconditioning, Myocardial; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Sex Factors; Ventricular Function, Left | 2015 |
Extracellular Hydrolysis of Adenine Nucleotides and Nucleoside Adenosine is Higher in Patients with ST Elevation than Non-ST Elevation in Acute Myocardial Infarction.
Topics: Adenine Nucleotides; Adenosine; Adenosine Deaminase; Biomarkers; Blood Platelets; Cell Membrane; Female; Humans; Hydrolysis; Male; Middle Aged; Myocardial Infarction; Troponin; Up-Regulation | 2015 |
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Treatment Outcome | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction.
Topics: Adenosine; Coronary Angiography; Female; Fractional Flow Reserve, Myocardial; Hemodynamics; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; United Kingdom; Vascular Resistance; Vasodilator Agents | 2016 |
[The PEGASUS-TIMI 54 study].
Topics: Adenosine; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2015 |
Use of ticagrelor in human pregnancy, the first experience.
Topics: Adenosine; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thromboembolism; Ticagrelor | 2015 |
Pneumonitis and pulmonary haemorrhage after acute myocardial infarction.
Topics: Adenosine; Angioplasty; Hemoptysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pneumonia; Purinergic P2Y Receptor Antagonists; Radiography, Thoracic; Thrombosis; Ticagrelor | 2015 |
Adenosine Stress and Rest T1 Mapping Can Differentiate Between Ischemic, Infarcted, Remote, and Normal Myocardium Without the Need for Gadolinium Contrast Agents.
Topics: Adenosine; Adult; Aged; Case-Control Studies; Contrast Media; Coronary Circulation; Diagnosis, Differential; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Meglumine; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Organometallic Compounds; Predictive Value of Tests; Vasodilator Agents; Ventricular Function, Left; Young Adult | 2016 |
Long-term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy.
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2016 |
Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Occlusion; Disease Models, Animal; Drug Administration Schedule; Female; Hemodynamics; Infusions, Parenteral; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; No-Reflow Phenomenon; Swine; Time Factors | 2015 |
Adenosine as Adjunctive Therapy for Acute Myocardial Infarction: Is It Time for Another Clinical Trial?
Topics: Adenosine; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Thrombolytic Therapy | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Remifentanil-induced preconditioning has cross-talk with A1 and A2B adenosine receptors in ischemic-reperfused rat heart.
Topics: Adenosine; Analgesics, Opioid; Animals; Coronary Circulation; Heart; Ischemic Preconditioning; Male; Myocardial Contraction; Myocardial Infarction; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptors, Opioid; Remifentanil; Reperfusion Injury; Time Factors; Ventricular Function, Left | 2016 |
Role of Perfusion at Rest in the Diagnosis of Myocardial Infarction Using Vasodilator Stress Cardiovascular Magnetic Resonance.
Topics: Adenosine; Aged; Chronic Disease; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Purines; Pyrazoles; Rest; Retrospective Studies; Vasodilator Agents | 2016 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Myocardial Infarction; Patient Satisfaction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2015 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.
Topics: Adenosine; Adenylyl Cyclases; Animals; Antiviral Agents; Arterial Pressure; Cardiotonic Agents; Coronary Vessels; Drug Approval; Enzyme Inhibitors; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Sus scrofa; United States; United States Food and Drug Administration; Vidarabine | 2016 |
The Yin and Yang of Long-Term Dual Antiplatelet Therapy.
Topics: Adenosine; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregation; Purinergic P2Y Receptor Antagonists | 2016 |
Escalating Loading Dose Regimens of Ticagrelor in Primary Percutaneous Intervention: A Second Opportunity for IIb/IIIa Inhibitors?
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2016 |
Plasticity of sarcolemmal KATP channel surface expression: relevance during ischemia and ischemic preconditioning.
Topics: Adenosine; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Endocytosis; Endosomes; Hydrazones; Ischemic Preconditioning, Myocardial; Isolated Heart Preparation; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Potassium Channels, Inwardly Rectifying; Protein Kinase C; Protein Kinase Inhibitors; Protein Transport; Sarcolemma; Time Factors | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Assessment; Secondary Prevention; Spain; Ticagrelor; Time Factors | 2016 |
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Propensity Score; Registries; Republic of Korea; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?
Topics: Adenosine; Censorship, Research; Drug Administration Schedule; Hemorrhage; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Ticagrelor | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Electronic Health Records; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2016 |
Pre-Hospital Ticagrelor in ST-Segment Elevation Myocardial Infarction: Should the Hypothesis Be Re-Evaluated?
Topics: Adenosine; Electrocardiography; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Ticagrelor | 2016 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Stress Cardiac MRI in Women With Myocardial Infarction and Nonobstructive Coronary Artery Disease.
Topics: Adenosine; Adult; Aged; Contrast Media; Coronary Artery Disease; Coronary Circulation; Female; Humans; Magnetic Resonance Imaging; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prospective Studies; Ultrasonography, Interventional; Vasodilator Agents | 2016 |
NICE recommends ticagrelor with aspirin for three years post-MI.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Ticagrelor; United Kingdom | 2016 |
Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea.
Topics: Adenosine; Cheyne-Stokes Respiration; Dyspnea; Humans; Hypercapnia; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Respiratory Function Tests; Ticagrelor | 2016 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Italy; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Societies, Medical; Thrombosis; Ticagrelor | 2017 |
Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
Topics: Adenosine; Animals; Blood Platelets; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Myocardial Infarction; Platelet Aggregation Inhibitors; Random Allocation; Swine; Ticagrelor; Ticlopidine | 2016 |
Food and Drug Administration Analysis of Ticagrelor: Using Data From an Enriched Trial to Evaluate Benefit-Risk Difference in an Unstudied Population.
Topics: Adenosine; Clinical Decision-Making; Drug Approval; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy.
Topics: Adenosine; Aged; Canada; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Topics: Adenosine; Adenosine Monophosphate; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Effect of a 180 mg ticagrelor loading dose on myocardial necrosis in patients undergoing elective percutaneous coronary intervention: A preliminary study.
Topics: Adenosine; Coronary Angiography; Dose-Response Relationship, Drug; Elective Surgical Procedures; Electrocardiography; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2017 |
The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study.
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gelatin; Gene Expression Regulation, Enzymologic; Humans; Macrophage Activation; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Receptor, Adenosine A3; RNA Interference; RNA, Messenger; RNA, Small Interfering; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Toll-Like Receptor 4; Up-Regulation | 2008 |
Intravenous adenosine reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel.
Topics: Adenosine; Animals; Coronary Circulation; Disease Models, Animal; Echocardiography; Endothelin-1; Injections, Intravenous; KATP Channels; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Radioimmunoassay; Random Allocation; Swine; Swine, Miniature; Treatment Outcome; Vasodilator Agents | 2008 |
Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Bone Marrow Transplantation; Cardiovascular Agents; Cell Degranulation; Cells, Cultured; Cyclohexanecarboxylic Acids; Disease Models, Animal; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Phenethylamines; Purines; Receptor, Adenosine A2A; Time Factors; Tryptases; Whole-Body Irradiation | 2008 |
Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Contrast Media; Coronary Circulation; Exercise Test; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Prospective Studies; Severity of Illness Index | 2008 |
High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine.
Topics: Adenosine; Aged; Caffeine; Central Nervous System Stimulants; Coffee; Coronary Artery Disease; Coronary Vessels; Drug Interactions; Female; Humans; Hyperemia; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Prospective Studies; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Vasodilation; Vasodilator Agents | 2008 |
Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats.
Topics: Adenosine; Animals; Blood Pressure; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Carriers; Fluorescence; Infusions, Intravenous; Liposomes; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Polyethylene Glycols; Rats; Rats, Wistar; Vasodilator Agents | 2009 |
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
Topics: Adenosine; Animals; Biological Transport; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Theophylline; Thioinosine | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Animals; Cardiotonic Agents; Creatine Kinase, MB Form; Female; Glutathione; Heart; Heart Ventricles; Hyperhomocysteinemia; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Lactate Dehydrogenases; Male; Methionine; Myocardial Infarction; Myocardial Reperfusion Injury; Oxidative Stress; Rats; Rats, Wistar; Severity of Illness Index; Thiobarbituric Acid Reactive Substances | 2009 |
Magnetic resonance adenosine perfusion imaging in patients after coronary artery bypass graft surgery.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Angina Pectoris; Contrast Media; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Feasibility Studies; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prospective Studies; Recurrence; Sensitivity and Specificity; Time Factors; Treatment Outcome; Vascular Patency; Vasodilator Agents | 2009 |
Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning.
Topics: Adenosine; Animals; Animals, Newborn; Cells, Cultured; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Lysophospholipids; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Perfusion; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Receptors, Purinergic P1; Recovery of Function; Signal Transduction; Sphingosine; Theophylline; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2009 |
Pathology, imaging and treatment of cardiac microvascular obstruction.
Topics: Adenosine; Coronary Vessels; Humans; Magnetic Resonance Angiography; Myocardial Infarction; Nicorandil; Nitroprusside; Vasodilator Agents; Verapamil | 2010 |
Prognostic value of adenosine stress cardiovascular magnetic resonance in patients with low-risk chest pain.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Angina Pectoris; Chest Pain; Coronary Stenosis; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Discharge; Patient Readmission; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Time Factors | 2009 |
[Low-dose adenosine echocardiography for detection of myocardial viability in patients with acute myocardial infarction.].
Topics: Adenosine; Dobutamine; Echocardiography; Humans; Myocardial Infarction; Myocardium | 2009 |
Comparison of adenosine stress and dobutamine stress by real-time myocardial contrast echocardiography in detecting myocardium ischemia in dogs.
Topics: Adenosine; Animals; Coronary Circulation; Dobutamine; Dogs; Echocardiography; Female; Hemodynamics; Male; Myocardial Infarction | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Letter by Venetucci et al regarding article "Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial".
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Circulation; Humans; Injections; Microcirculation; Myocardial Infarction; Randomized Controlled Trials as Topic; Treatment Outcome; Vasodilator Agents | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Blood Pressure; Bone Marrow Cells; Bone Marrow Transplantation; Cell Movement; Histamine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Neutrophils; Receptor, Adenosine A3 | 2010 |
Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit.
Topics: Adenosine; Aminoimidazole Carboxamide; Analysis of Variance; Animals; Deoxyribonucleosides; Disease Models, Animal; Hemodynamics; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Rabbits; Random Allocation | 2010 |
ST segment elevation during adenosine pharmacological stress testing in a patient with coronary artery disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Myocardial Infarction; Myocardial Perfusion Imaging; Receptor, Adenosine A2A; Tomography, Emission-Computed, Single-Photon; Vasodilation; Vasodilator Agents | 2009 |
Adenosine postconditioning protects against myocardial ischemia-reperfusion injury though modulate production of TNF-α and prevents activation of transcription factor NF-kappaB.
Topics: Adenosine; Animals; Blood Pressure; Diastole; Heart Rate; Interleukin-10; Ischemic Postconditioning; Male; Malondialdehyde; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NF-kappa B; Protein Binding; Rats; Rats, Sprague-Dawley; Systole; Tumor Necrosis Factor-alpha | 2011 |
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Laser-Doppler Flowmetry; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Tissue Plasminogen Activator | 2010 |
Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts.
Topics: 5'-Nucleotidase; Acetamides; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Aminopyridines; Animals; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Phenethylamines; Purines; Receptor, Adenosine A2A; Receptor, Adenosine A2B | 2010 |
Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine.
Topics: Adenosine; Animals; Enzyme Inhibitors; Femoral Nerve; Hindlimb; Injections, Intra-Arterial; Ischemia; Ischemic Preconditioning; Male; Models, Animal; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Rabbits; S-Nitroso-N-Acetylpenicillamine; Signal Transduction | 2010 |
Mast cells contribute to altered vascular reactivity and ischemia-reperfusion injury following cerium oxide nanoparticle instillation.
Topics: Adenosine; Analysis of Variance; Animals; Aorta, Thoracic; Bronchoalveolar Lavage Fluid; Cerium; Chemokine CCL3; Gene Expression Regulation; Histocytochemistry; Interleukin-10; Interleukin-13; Interleukin-6; Lung; Male; Mast Cells; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Osteopontin; Particle Size; Pneumonia; Prostaglandin D2; Reperfusion Injury; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2011 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?
Topics: Adenosine; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2011 |
Two-dimensional strain combined with adenosine stress echocardiography assessment of viable myocardium.
Topics: Adenosine; Analysis of Variance; Animals; Coronary Occlusion; Disease Models, Animal; Dogs; Echocardiography, Doppler, Color; Echocardiography, Stress; Myocardial Contraction; Myocardial Infarction; Myocardium; Predictive Value of Tests; ROC Curve; Tissue Survival; Ventricular Function, Left | 2011 |
Improved outcome prediction by SPECT myocardial perfusion imaging after CT attenuation correction.
Topics: Adenosine; Aged; Death, Sudden, Cardiac; Disease-Free Survival; Electrocardiography; Endpoint Determination; Female; Follow-Up Studies; Heart; Heart Diseases; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Organophosphorus Compounds; Organotechnetium Compounds; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Risk Factors; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Performance of adenosine "stress-only" perfusion MRI in patients without a history of myocardial infarction: a clinical outcome study.
Topics: Adenosine; Chest Pain; Coronary Angiography; Coronary Circulation; Disease-Free Survival; Exercise Test; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over preimaging information for the prediction of adverse events.
Topics: Adenosine; Aged; Coronary Stenosis; Exercise Test; Female; Follow-Up Studies; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Ventricular Function, Left | 2011 |
Adenosine modifies the balance between membrane and soluble forms of Flt-1.
Topics: Adenosine; Cell Membrane; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Gene Expression; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Macrophages; Myocardial Infarction; Neovascularization, Physiologic; Reverse Transcriptase Polymerase Chain Reaction; Solubility; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Experimental pig model of old myocardial infarction with long survival leading to chronic left ventricular dysfunction and remodeling as evaluated by PET.
Topics: Adenosine; Animals; Chronic Disease; Coronary Vessels; Disease Models, Animal; Male; Myocardial Infarction; Positron-Emission Tomography; Survival Rate; Swine; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adult; Aged; Case-Control Studies; Cell Membrane; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Female; Heparitin Sulfate; Humans; Hyaluronic Acid; Inflammation; Ligands; Lipopolysaccharides; Luxembourg; Macrophages; Male; Middle Aged; Myocardial Infarction; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Registries; RNA, Messenger; Time Factors; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2011 |
Prognostic value of adenosine stress cardiovascular magnetic resonance and dobutamine stress echocardiography in patients with low-risk chest pain.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Chi-Square Distribution; Coronary Artery Disease; Dobutamine; Echocardiography, Stress; Emergency Service, Hospital; Exercise Test; Female; Georgia; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prognosis; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2012 |
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Hydroxy Acids; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Potassium Channel Blockers; Purinergic P1 Receptor Antagonists; Rabbits; Reperfusion Injury; Superoxides; Tetrazoles; Theophylline | 2011 |
Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Humans; Myocardial Infarction; Nitric Oxide; Potassium Channel Blockers; Reperfusion Injury; Tetrazoles | 2011 |
Adenosine and opioid receptors do not trigger the cardioprotective effect of mild hypothermia.
Topics: Adenosine; Analgesics, Opioid; Animals; Fluorocarbons; Hypothermia, Induced; Morphine; Myocardial Infarction; Naloxone; Narcotic Antagonists; Purinergic P1 Receptor Antagonists; Rabbits; Receptors, Opioid; Receptors, Purinergic P1; Theophylline; Time Factors | 2012 |
Gender-based prognostic value of pharmacological cardiac magnetic resonance stress testing: head-to-head comparison of adenosine perfusion and dobutamine wall motion imaging.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Coronary Artery Disease; Coronary Circulation; Disease Progression; Disease-Free Survival; Dobutamine; Female; Germany; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Multivariate Analysis; Myocardial Contraction; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Sex Factors; Time Factors | 2012 |
Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Receptor Cross-Talk; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2011 |
Pressure-wire based assessment of microvascular resistance using calibrated upstream balloon obstruction: a predictor of myocardial viability.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Calibration; Cardiac Catheterization; Cardiac Catheters; Chi-Square Distribution; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Linear Models; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardium; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Stents; Tissue Survival; Transducers, Pressure; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2012 |
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Characterization of microvascular and myocardial damage within perfusion defect area at myocardial contrast echocardiography in the subacute phase of myocardial infarction.
Topics: Adenosine; Aged; Algorithms; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Media; Coronary Circulation; Echocardiography; Electrocardiography; Female; Gadolinium; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Predictive Value of Tests; Risk Assessment; Sensitivity and Specificity; Troponin T; Vasodilator Agents | 2012 |
Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Odds Ratio; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Severity of Illness Index; South Australia; Time Factors; Treatment Outcome; Vasodilator Agents | 2011 |
CMR imaging: creating contrast without cosmetics...
Topics: Adenosine; Animals; Coronary Circulation; Edema, Cardiac; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardial Reperfusion Injury; Spin Labels; Vasodilation; Vasodilator Agents | 2011 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measuremen
Topics: Adenosine; Aged; Chi-Square Distribution; Contrast Media; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Humans; Linear Models; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Predictive Value of Tests; Prospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left | 2012 |
PET and MRI for the evaluation of regional myocardial perfusion and wall thickening after myocardial infarction.
Topics: Adenosine; Coronary Circulation; Coronary Vessels; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Positron-Emission Tomography; Regional Blood Flow; Retrospective Studies; Stress, Physiological; Treatment Outcome | 2012 |
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Role of A2B adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells.
Topics: Adenosine; Adenosine Deaminase; Agammaglobulinemia; Animals; Antigens, Ly; Cells, Cultured; Chemokine CXCL1; Female; Interleukin-6; Male; Membrane Proteins; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myocardial Infarction; Myocardium; Paracrine Communication; Platelet Endothelial Cell Adhesion Molecule-1; Receptor, Adenosine A2B; RNA, Messenger; Severe Combined Immunodeficiency; Stem Cells; Up-Regulation; Vascular Endothelial Growth Factor A | 2012 |
Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; B-Lymphocytes; Cells, Cultured; Erythrocytes; Female; Flow Cytometry; Granulocytes; Leukocytes; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; T-Lymphocytes | 2012 |
Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles.
Topics: Adenosine; Animals; Blood Pressure; Cardiotonic Agents; Drug Carriers; Drug Delivery Systems; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nanomedicine; Nanoparticles; Rats; Rats, Wistar; Silicon Dioxide; Tissue Distribution | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.
Topics: Acetylcholine; Adenosine; Adult; Blood Flow Velocity; Coronary Angiography; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Hospitalization; Humans; Laser-Doppler Flowmetry; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitroglycerin; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Stroke; United States; Vasodilator Agents | 2012 |
Effectiveness of myocardial contrast echocardiography quantitative analysis during adenosine stress versus visual analysis before percutaneous therapy in acute coronary pain: a coronary artery TIMI grading comparing study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Analysis of Variance; Coronary Angiography; Echocardiography; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Pain; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index | 2012 |
The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation.
Topics: Adenosine; Animals; Ethanolamines; Extracellular Signal-Regulated MAP Kinases; Formoterol Fumarate; Ischemic Preconditioning, Myocardial; Isoproterenol; Myocardial Infarction; Phosphatidylinositol 3-Kinases; Potassium Channels; Protein Kinase C; Proto-Oncogene Proteins c-akt; Rats; Reactive Oxygen Species; Receptors, Adrenergic, beta; Receptors, Purinergic P1; Triazines; Triazoles | 2012 |
The predictive value of chronic kidney disease for assessing cardiovascular events under consideration of pretest probability for coronary artery disease in patients who underwent stress myocardial perfusion imaging.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angina, Unstable; Chi-Square Distribution; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticlopidine | 2012 |
Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Cause of Death; Chi-Square Distribution; Female; Heart Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Predictive Value of Tests; Prognosis; Propensity Score; Proportional Hazards Models; Purines; Pyrazoles; Reference Values; Risk Factors; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left | 2012 |
Cardioprotection with adenosine in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Humans; Myocardial Infarction | 2012 |
What's new in the UA/NSTEMI guidelines?
Topics: Adenosine; Angina, Unstable; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Thrombosis; Ticagrelor | 2012 |
[The incidence of postoperative myocardial infarction and the left ventricular function in patients with type 2 diabetes mellitus after recanalization of chronic coronary occlusions].
Topics: Adenosine; Chronic Disease; Comorbidity; Coronary Occlusion; Diabetes Mellitus, Type 2; Humans; Incidence; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Placebos; Postoperative Complications; Vasodilator Agents; Ventricular Function, Left | 2012 |
High coronary artery calcium score affects clinical outcome despite normal stress myocardial perfusion imaging and normal left ventricular ejection fraction.
Topics: Adenosine; Aged; Coronary Circulation; Coronary Vessels; Diabetes Mellitus; Dipyridamole; Exercise Test; Female; Humans; Male; Middle Aged; Multimodal Imaging; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Positron-Emission Tomography; Regression Analysis; Stroke Volume; Tomography, X-Ray Computed; Vascular Calcification; Vasodilator Agents | 2013 |
Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
Topics: Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticagrelor; Treatment Outcome | 2013 |
Adenosine stimulates the migration of human endothelial progenitor cells. Role of CXCR4 and microRNA-150.
Topics: Adenosine; Cell Movement; Cell- and Tissue-Based Therapy; Endothelial Cells; HEK293 Cells; Humans; Leukocytes, Mononuclear; MicroRNAs; Myocardial Infarction; Receptors, CXCR4; Regeneration; Stem Cells; Up-Regulation | 2013 |
Intermediate-term prognostic value of reversible perfusion deficit diagnosed by adenosine CMR: a prospective follow-up study in a consecutive patient population.
Topics: Adenosine; Aged; Angina, Stable; Chi-Square Distribution; Contrast Media; Coronary Circulation; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Time Factors; Vasodilator Agents | 2013 |
Adenosine myocardial perfusion single photon emission computed tomographic stress testing 24-72 h after uncomplicated myocardial infarction.
Topics: Adenosine; Aged; Exercise Test; Female; Humans; Male; Myocardial Infarction; Retrospective Studies; Safety; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2002 |
Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.
Topics: Adenosine; Animals; Cardiotonic Agents; Echocardiography; Gene Dosage; Mice; Mice, Transgenic; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Receptor, Adenosine A3; Receptors, Purinergic P1; RNA, Messenger | 2002 |
Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene.
Topics: Adenosine; Analysis of Variance; Animals; Decanoic Acids; Diazoxide; Hydroxy Acids; Ischemic Preconditioning, Myocardial; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardium; Perfusion; Potassium Channel Blockers; Potassium Channels; Recombinant Proteins; Tumor Necrosis Factor-alpha | 2002 |
Pharmacological preconditioning in rabbit myocardium is blocked by chloride channel inhibition.
Topics: Adenosine; Animals; Cells, Cultured; Chloride Channels; Dose-Response Relationship, Drug; Enzyme Activators; Glycolates; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Perfusion; Protein Kinase C; Rabbits; Receptors, Purinergic P1; Tetradecanoylphorbol Acetate | 2002 |
Reperfusion duration paradox with late myocardial preconditioning in rabbits.
Topics: Adenosine; Animals; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Nitric Oxide Donors; Purinergic P1 Receptor Agonists; Rabbits; S-Nitroso-N-Acetylpenicillamine; Time Factors | 2002 |
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.
Topics: Adenosine; Age Factors; Animals; Apoptosis; Cardiotonic Agents; Cell Survival; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Muscle Fibers, Skeletal; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Necrosis; Oxygen; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2002 |
Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase.
Topics: Acetylcholine; Adenosine; Animals; Female; Hemodynamics; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardium; Phosphatidylinositol 3-Kinases; Pyrimidines; Rabbits; src-Family Kinases; Vasodilator Agents | 2003 |
Quantitative assessment of harmonic power Doppler myocardial perfusion imaging with intravenous Levovist in patients with myocardial infarction: comparison with myocardial viability evaluated by thallium-201 single-photon emission computed tomography and
Topics: Adenosine; Aged; Blood Flow Velocity; Contrast Media; Coronary Angiography; Coronary Circulation; Echocardiography, Doppler; Exercise Test; Female; Humans; Injections, Intravenous; Linear Models; Male; Microcirculation; Middle Aged; Myocardial Infarction; Polysaccharides; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 2002 |
Life support treatment.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Humans; Life Support Care; Myocardial Infarction; Practice Guidelines as Topic; Tachycardia, Ventricular | 2002 |
Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Animals; Autoradiography; Contrast Media; Coronary Angiography; Coronary Thrombosis; Disease Models, Animal; Dogs; Echocardiography, Doppler, Color; Male; Models, Cardiovascular; Myocardial Infarction; Myocardial Reperfusion; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Severity of Illness Index; Technetium; Treatment Outcome; Vasodilator Agents | 2003 |
Combined first-pass perfusion and viability study at MR imaging in patients with non-ST segment-elevation acute coronary syndromes: feasibility study.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Contrast Media; Coronary Angiography; Electrocardiography; Feasibility Studies; Female; Gadolinium DTPA; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Troponin T | 2003 |
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors.
Topics: Adenosine; Analgesics, Opioid; Animals; ATP-Binding Cassette Transporters; Benzylidene Compounds; Free Radicals; Heart Diseases; In Vitro Techniques; KATP Channels; Mitochondria, Heart; Morphine; Myocardial Infarction; Myocardial Reperfusion Injury; Naltrexone; Potassium Channels; Potassium Channels, Inwardly Rectifying; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor Cross-Talk; Receptors, Opioid, delta; Receptors, Purinergic P1 | 2003 |
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.
Topics: Adenosine; Anesthesia; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, Animal; Dogs; Iodine Radioisotopes; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2003 |
Protein kinase C-delta mediates adenosine A3 receptor-induced delayed cardioprotection in mouse.
Topics: Adenosine; Alkaloids; Animals; Benzophenanthridines; Blotting, Western; Cell Nucleus; Cytosol; Dihydropyridines; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Heart Diseases; Heart Function Tests; In Vitro Techniques; Isoenzymes; Male; Mice; Myocardial Contraction; Myocardial Infarction; NF-kappa B; Phenanthridines; Protein Kinase C; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2003 |
Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects.
Topics: Adenosine; Adenosine Diphosphate; Alkaloids; Animals; Benzophenanthridines; Calcium Channel Blockers; Decanoic Acids; Diazoxide; Enzyme Inhibitors; Hydroxy Acids; Hypoxanthine; Inosine; Ischemic Preconditioning, Myocardial; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Myocardial Contraction; Myocardial Infarction; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Perfusion; Phenanthridines; Phenethylamines; Potassium Channels; Protein Kinase C; Receptors, Purinergic P2; Signal Transduction; Xanthine | 2003 |
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts.
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Animals; Cytosol; GTP-Binding Proteins; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Protein Kinase C; Protein Kinase C-epsilon; Protein Transport; Rabbits; Receptors, Purinergic P1; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2003 |
Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; CHO Cells; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Furans; Humans; Iodine Radioisotopes; Isoxazoles; Myocardial Infarction; Myocardial Reperfusion Injury; Purines; Rabbits; Radioligand Assay; Receptor, Adenosine A3; Sertraline; Transfection | 2003 |
[Treatment of myocardial infarct].
Topics: Adenosine; Humans; Myocardial Infarction; Nikethamide; Theophylline | 1954 |
Reduction of infarct size and preservation of endothelial function by multidose intravenous adenosine during extended reperfusion.
Topics: Adenosine; Animals; Arteries; Cell Adhesion; Coronary Circulation; Coronary Vessels; Creatine Kinase; Dogs; Drug Administration Schedule; Endothelium, Vascular; Female; Hemodynamics; Injections, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Time Factors; Vasodilation | 2004 |
[Limb ischemic preconditioning reduces infarct size following myocardial ischemia-reperfusion in rats].
Topics: Adenosine; Animals; Extremities; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley | 2004 |
Impact of flow level on coronary flow velocity pattern. A doppler flow study in patients with first acute myocardial infarction.
Topics: Acute Disease; Adenosine; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Chi-Square Distribution; Cohort Studies; Contrast Media; Coronary Circulation; Echocardiography, Doppler; Female; Fluorocarbons; Follow-Up Studies; Humans; Hyperemia; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Stents; Vasodilator Agents; Ventricular Function, Left | 2004 |
Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Blood Pressure; Caspase 3; Caspases; Chromones; Enzyme Inhibitors; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Phenethylamines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rabbits; Receptor, Adenosine A2A; Signal Transduction | 2004 |
Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts.
Topics: 2-Aminoadipic Acid; Adenosine; Animals; Cardiotonic Agents; Dogs; Methotrexate; Myocardial Infarction; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Theophylline | 2004 |
Adenosine and a nitric oxide donor enhances cardioprotection by preconditioning with isoflurane through mitochondrial adenosine triphosphate-sensitive K+ channel-dependent and -independent mechanisms.
Topics: Adenosine; Anesthetics, Inhalation; Animals; Cardiovascular Agents; Diazoxide; Dose-Response Relationship, Drug; Flavoproteins; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Isoflurane; Male; Membrane Proteins; Mitochondria, Heart; Myocardial Infarction; Nitric Oxide Donors; Oxidation-Reduction; Potassium Channels; Rats; Rats, Sprague-Dawley; S-Nitroso-N-Acetylpenicillamine | 2004 |
Gated (99m)Tc-tetrofosmin SPECT for discriminating infarct from artifact in fixed myocardial perfusion defects.
Topics: Adenosine; Artifacts; Echocardiography; Electrocardiography; Exercise Test; Female; Gated Blood-Pool Imaging; Heart; Humans; Male; Myocardial Contraction; Myocardial Infarction; Organophosphorus Compounds; Organotechnetium Compounds; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2004 |
Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts.
Topics: 5'-Nucleotidase; Adenosine; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cells, Cultured; Coronary Circulation; Dogs; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium; Oxidative Stress; Propanolamines; Propranolol | 2004 |
Treatment of saphenous vein graft thrombosis with distal protection, thrombectomy, and adenosine prior to reperfusion: a complete approach to preserving microvascular integrity.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Female; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Saphenous Vein; Stents; Thrombectomy; Thrombosis; Vasodilator Agents | 2004 |
Coronary microembolization does not induce acute preconditioning against infarction in pigs-the role of adenosine.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Stenosis; Female; Ischemic Preconditioning, Myocardial; Male; Models, Animal; Myocardial Infarction; Myocardium; Swine; Swine, Miniature; Tumor Necrosis Factor-alpha | 2004 |
Coronary flow velocity reserve does not correlate with TIMI frame count in patients undergoing non-emergency percutaneous coronary intervention.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Collateral Circulation; Coronary Circulation; Coronary Vessels; Female; Humans; Male; Middle Aged; Myocardial Infarction; Ultrasonography | 2004 |
Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat.
Topics: Adenosine; Animals; Anti-Arrhythmia Agents; Drug Combinations; Hemodynamics; Lidocaine; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Ventricular Fibrillation | 2004 |
Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Nicorandil; Treatment Outcome | 2004 |
Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways.
Topics: Adaptation, Physiological; Adenosine; Animals; Blood Pressure; Disease Models, Animal; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Signal Transduction; Vasodilator Agents | 2005 |
Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Hemodynamics; Humans; Hyperemia; Life Tables; Male; Middle Aged; Myocardial Infarction; Pressure; Single-Blind Method; Transducers, Pressure; Ultrasonography, Interventional | 2004 |
Contribution of KATP+ channels to coronary vasomotor tone regulation is enhanced in exercising swine with a recent myocardial infarction.
Topics: Adenosine; Adenosine Triphosphate; Animals; Blood Pressure; Coronary Circulation; Female; Heart Rate; Male; Myocardial Infarction; Oxygen; Physical Conditioning, Animal; Physical Exertion; Potassium Channels; Sus scrofa; Ventricular Remodeling | 2005 |
Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging.
Topics: Adenosine; Adult; Aged; Cineangiography; Coronary Angiography; Coronary Disease; Coronary Stenosis; Female; Humans; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Sensitivity and Specificity; Syndrome; Vasodilator Agents | 2004 |
Symbols within words: have we neglected the AdeNOsine A2 receptor?
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Cardiotonic Agents; Humans; Myocardial Infarction; Receptors, Adenosine A2 | 2005 |
A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy.
Topics: Adenosine; Aged; Aged, 80 and over; Cause of Death; Coronary Circulation; Coronary Disease; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Predictive Value of Tests; Prognosis; Risk Assessment; Tomography, Emission-Computed, Single-Photon | 2005 |
Quantitative instruments for predicting risk ... and benefit.
Topics: Adenosine; Coronary Circulation; Coronary Disease; Electrocardiography; Exercise Test; Humans; Myocardial Infarction; Predictive Value of Tests; Prognosis; Reproducibility of Results; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Alpha1-receptor or adenosine A1-receptor dependent pathway alone is not sufficient but summation of these pathways is required to achieve an ischaemic preconditioning effect in rabbits.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Enzyme Inhibitors; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Protein Kinase C; Quinazolines; Rabbits; Receptor, Adenosine A1; Receptors, Adrenergic, alpha-1; Staurosporine; Theophylline; Tyramine; Vasodilator Agents | 2005 |
Sustained cardioprotection afforded by A2A adenosine receptor stimulation after 72 hours of myocardial reperfusion.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Blotting, Western; Cardiotonic Agents; Cyclic AMP Response Element-Binding Protein; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Phenethylamines; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Time Factors | 2005 |
Delayed adenosine A1 receptor preconditioning in rat myocardium is MAPK dependent but iNOS independent.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Animals; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Heart Ventricles; Hydrogen Peroxide; Ischemic Preconditioning, Myocardial; Male; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocytes, Cardiac; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidants; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Time Factors | 2005 |
New insights into adenosine-mediated myocardial protection.
Topics: Adenosine; Animals; Cardiotonic Agents; Myocardial Infarction; Nitric Oxide; Nitric Oxide Synthase; Rats; Receptors, Purinergic P1 | 2005 |
Cardioprotection with adenosine: 'a riddle wrapped in a mystery'.
Topics: Adenosine; Animals; Cardiotonic Agents; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase; Rats | 2005 |
Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway.
Topics: Adenosine; Animals; Cardiotonic Agents; Ganglionic Blockers; Hexamethonium; Infusions, Intravenous; Ischemic Preconditioning; Male; Microdialysis; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Rats; Rats, Wistar | 2005 |
Role of nitric oxide during coronary endothelial dysfunction after myocardial infarction.
Topics: Adenosine; Amidines; Animals; Benzylamines; Bradykinin; Coronary Circulation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Heart; Immunohistochemistry; In Vitro Techniques; Male; Myocardial Infarction; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Proadifen; Rats; Rats, Wistar; RNA, Messenger; Superoxides | 2005 |
[Beneficial effects of adenosine on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion].
Topics: Adenosine; Animals; Cardiac Output; Coronary Circulation; Disease Models, Animal; Female; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Pulmonary Wedge Pressure; Swine; Swine, Miniature | 2005 |
Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine.
Topics: Adenosine; Animals; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Perfusion; Purinergic P1 Receptor Antagonists; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Theophylline; Triazines; Triazoles; Xanthines | 2005 |
Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Amidines; Animals; Benzylamines; Blood Pressure; Body Temperature; Enzyme Inhibitors; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide Donors; Receptors, Opioid, delta | 2005 |
[Study of no-reflow phenomenon after reperfusion for acute myocardial infarction].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Coronary Circulation; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Thrombolytic Therapy; Vasodilator Agents | 2005 |
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Adenosine A3 Receptor Agonists; Animals; Cardiotonic Agents; CHO Cells; Cricetinae; Drug Design; Humans; Mice; Myocardial Infarction; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A3; Reperfusion Injury; Ventricular Function, Left | 2005 |
Value of adenosine infusion for infarct size determination using real-time myocardial contrast echocardiography.
Topics: Adenosine; Animals; Computer Systems; Dogs; Echocardiography; Image Enhancement; Infusions, Intravenous; Myocardial Infarction; Myocardium; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Vasodilator Agents | 2006 |
Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.
Topics: Acetamides; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Alkaloids; Androstadienes; Animals; Aorta; Benzophenanthridines; Constriction; Enzyme Activators; Female; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Phenanthridines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Purines; Rabbits; Receptor, Adenosine A2B; Signal Transduction; Tetradecanoylphorbol Acetate; Wortmannin; Xanthines | 2006 |
Role of adenosine in acute myocardial infarction.
Topics: Adenosine; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion; Vasodilator Agents | 2006 |
AMISTAD trials: possible reasons for lack of success.
Topics: Adenosine; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion; Vasodilator Agents | 2006 |
The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Humans; Microcirculation; Myocardial Infarction; Myocardial Reperfusion; Vasodilator Agents; Verapamil | 2006 |
Cardioprotective role of endogenous hydrogen peroxide during ischemia-reperfusion injury in canine coronary microcirculation in vivo.
Topics: Acetylcholine; Adenosine; Animals; Coronary Vessels; Dogs; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Hemodynamics; Hydrogen Peroxide; Male; Microcirculation; Myocardial Infarction; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Reperfusion Injury; Vasodilation; Vasodilator Agents | 2006 |
Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146).
Topics: Adenosine; Alkynes; Animals; Biomarkers; Blood Pressure; Cardiotonic Agents; Coronary Circulation; Creatine Kinase; Dogs; Female; Heart Rate; Hemodynamics; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardium; Necrosis; Receptors, Adenosine A2; Reperfusion Injury | 2006 |
[Effect of adenosine on endothelin-1 in the infarcted reflow and no-reflow myocardium of mini-swine].
Topics: Adenosine; Animals; Disease Models, Animal; Endothelin-1; Female; Male; Myocardial Infarction; Myocardial Reperfusion; Swine; Swine, Miniature | 2006 |
Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Adenosine; Animals; Antigens, CD; beta Catenin; Cadherins; Calcium Channel Blockers; Coronary Circulation; gamma Catenin; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; RNA, Messenger; Swine; Swine, Miniature | 2006 |
Moving preconditioning from bench to bedside.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Coronary Artery Bypass; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Ribonucleosides; Survival Rate | 2006 |
Reduction of apoptosis in the amygdala by an A2A adenosine receptor agonist following myocardial infarction.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Amygdala; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Body Weight; Caspase 3; Caspases; In Situ Nick-End Labeling; Myocardial Infarction; Myocardium; Organ Size; Phenethylamines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2006 |
The added value of ECG-gating for the diagnosis of myocardial infarction using myocardial perfusion scintigraphy and artificial neural networks.
Topics: Adenosine; Automation; Diagnosis, Computer-Assisted; Electrocardiography; Humans; Myocardial Infarction; Myocardium; Neural Networks, Computer; Organophosphorus Compounds; Organotechnetium Compounds; Perfusion; Radiographic Image Interpretation, Computer-Assisted; Radionuclide Angiography; Radiopharmaceuticals; Sensitivity and Specificity | 2006 |
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Histamine; In Vitro Techniques; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; p-Methoxy-N-methylphenethylamine; Pyridines; Radioligand Assay; Receptor, Adenosine A3; Triazines; Triazoles | 2006 |
Adenosine as an adjunct to reperfusion in myocardial infarction.
Topics: Adenosine; Humans; Myocardial Infarction; Myocardial Reperfusion; Vasodilator Agents | 2006 |
The functional reserve of collaterals supplying long-term chronic total coronary occlusions in patients without prior myocardial infarction.
Topics: Adenosine; Aged; Blood Flow Velocity; Blood Pressure; Chronic Disease; Collateral Circulation; Coronary Angiography; Coronary Disease; Echocardiography, Doppler; Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Stress, Physiological; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Peri-infarct ischemia determined by cardiovascular magnetic resonance evaluation of myocardial viability and stress perfusion predicts future cardiovascular events in patients with severe ischemic cardiomyopathy.
Topics: Adenosine; Adult; Aged; Cardiomyopathies; Contrast Media; Coronary Circulation; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Prognosis; Prospective Studies; Vasodilator Agents | 2006 |
Preserved hyperaemic response in supraclavicular ultrasonography demonstrates function on demand of the LIMA to LAD string sign graft after CABG.
Topics: Adenosine; Blood Flow Velocity; Clavicle; Coronary Angiography; Coronary Circulation; Coronary Vessels; Electrocardiography; Female; Follow-Up Studies; Humans; Hyperemia; Internal Mammary-Coronary Artery Anastomosis; Male; Middle Aged; Myocardial Infarction; Postoperative Care; Preoperative Care; Prospective Studies; Treatment Outcome; Ultrasonography, Doppler, Pulsed; Vascular Patency; Vasodilator Agents | 2007 |
Safety and diagnostic accuracy of stress cardiac magnetic resonance imaging vs exercise tolerance testing early after acute ST elevation myocardial infarction.
Topics: Adenosine; Aged; Coronary Angiography; Coronary Stenosis; Cross-Sectional Studies; Electrocardiography; Exercise Test; Exercise Tolerance; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Selection | 2007 |
Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors.
Topics: 5'-Nucleotidase; Adenosine; Aminopyridines; Animals; Cardiotonic Agents; Cell Hypoxia; Drug Evaluation, Preclinical; Extracellular Fluid; Female; Ischemic Preconditioning, Myocardial; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Receptor, Adenosine A2B; Up-Regulation; Xanthines | 2007 |
Value of electrocardiographically gated single-photon emission computed tomographic myocardial perfusion scintigraphy in a cohort of symptomatic postmenopausal women.
Topics: Adenosine; Aged; Angina Pectoris; Cohort Studies; Coronary Angiography; Coronary Circulation; Coronary Disease; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Hospitalization; Humans; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Prospective Studies; Radiopharmaceuticals; Risk Factors; Sensitivity and Specificity; Survival Rate; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2007 |
Novel cardiovascular MRI and CT methods for evaluation of ischemic heart disease.
Topics: Adenosine; Animals; Cell Survival; Decision Making; Dobutamine; Gadolinium; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Myocardial Infarction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Prognosis; Risk Assessment; Sympathomimetics; Tomography, X-Ray Computed | 2007 |
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Kinetic analysis of 99mTc-sestamibi evaluates the protective effects by ischaemic preconditioning on ischaemic myocardium in an isolated rabbit heart.
Topics: Adenosine; Animals; Blood Pressure; Cardiovascular Agents; Heart; Heart Rate; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Reperfusion Injury; Technetium Tc 99m Sestamibi | 2007 |
Adenosine conditioning and pacing in conjunction with early intra-aortic balloon pump use and glycoprotein IIb/IIIa inhibition to accomplish complete multivessel revascularization in an octogenarian with profound cardiogenic shock.
Topics: Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Vessels; Female; Humans; Intra-Aortic Balloon Pumping; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Pacemaker, Artificial; Platelet Glycoprotein GPIIb-IIIa Complex; Severity of Illness Index; Shock, Cardiogenic; Stents | 2007 |
CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury.
Topics: Adenosine; Adenosine Monophosphate; Animals; Antigens, CD; Apyrase; Disease Models, Animal; Enzyme Induction; Ischemic Preconditioning, Myocardial; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium | 2007 |
Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine.
Topics: Adenosine; Animals; Cardiology; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Perfusion; Predictive Value of Tests; Treatment Outcome | 2007 |
Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha.
Topics: Adenosine; Animals; Apoptosis; Hypoxia-Inducible Factor 1, alpha Subunit; Ischemic Preconditioning, Myocardial; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reactive Oxygen Species | 2008 |
Intermittent ST-segment depressions during adenosine stress test.
Topics: Adenosine; Aged; Angina Pectoris; Coronary Artery Disease; Coronary Occlusion; Coronary Stenosis; Coronary Vessels; Diagnosis, Differential; Electrocardiography; Exercise Test; Gated Blood-Pool Imaging; Humans; Male; Myocardial Infarction; Spasm; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2007 |
Myocardial reperfusion injury.
Topics: Adenosine; Humans; Muscle Cells; Myocardial Infarction; Myocardial Reperfusion Injury; Vasodilator Agents | 2007 |
The reversal of no reflow and its effect on clinical outcome.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Vessels; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Infusions, Intralesional; Male; Myocardial Infarction; Neovascularization, Physiologic; Survival Rate; Treatment Outcome | 2008 |
AMP deaminase, 5'-nucleotidase and adenosine deaminase in rat myocardial tissue in myocardial infarction and hypothermia.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; AMP Deaminase; Animals; Hypothermia; Muscles; Myocardial Infarction; Myocardium; Nucleoside Deaminases; Nucleotidases; Nucleotide Deaminases; Rats | 1982 |
Management of acute myocardial infarction with natural physiological agents.
Topics: Acute Disease; Adenosine; Animals; Carnitine; Collateral Circulation; Dipyridamole; Dogs; Epoprostenol; Glucose; Humans; Insulin; Isoproterenol; Magnesium; Methoxamine; Myocardial Infarction; Nitroglycerin; Potassium; Vasodilator Agents | 1983 |
[Effect of myocardial ischemia on adenine nucleotide metabolism].
Topics: Adenine Nucleotides; Adenosine; Angina Pectoris; Cardiac Catheterization; Coronary Disease; Electric Stimulation; Humans; Hypoxanthines; Inosine; Middle Aged; Myocardial Infarction; Neurocirculatory Asthenia; Time Factors | 1984 |
Pharmacological profile of razinodil as a possible new drug for ischemic myocardial diseases.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Guinea Pigs; Hemodynamics; Male; Morpholines; Myocardial Infarction; Swine; Triazines; Vasodilator Agents | 1981 |
Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size.
Topics: Adenosine; Animals; Extracellular Space; Female; Injections, Intravenous; Male; Microdialysis; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rabbits | 1995 |
Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A3 receptor involvement.
Topics: Adenosine; Animals; Antihypertensive Agents; Cells, Cultured; Glucose; Myocardial Infarction; Myocardial Ischemia; Myocardium; Naphthalenes; Phenethylamines; Phenylisopropyladenosine; Polycyclic Compounds; Protein Kinase C; Purinergic Antagonists; Pyruvates; Pyruvic Acid; Rabbits; Receptors, Purinergic P1; Theophylline; Time Factors; Trypan Blue; Xanthines | 1994 |
Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery.
Topics: Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Female; Heart; Heart Failure; Humans; Intraoperative Complications; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Peripheral Vascular Diseases; Postoperative Complications; Predictive Value of Tests; Preoperative Care; Pulmonary Edema; Radionuclide Imaging; Regression Analysis; Risk Factors; Sensitivity and Specificity; Vasodilator Agents | 1995 |
Adenosine deaminase inhibition augments interstitial adenosine but does not attenuate myocardial infarction.
Topics: Adenosine; Adenosine Deaminase Inhibitors; Animals; Coronary Circulation; Dogs; Extracellular Space; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Pentostatin; Regional Blood Flow | 1995 |
Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Disease Models, Animal; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Rabbits; Ribonucleosides; Time Factors; Ventricular Fibrillation | 1995 |
Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
Topics: Adenosine; Adenosine Triphosphate; Animals; Benzopyrans; Chromatography, High Pressure Liquid; Collateral Circulation; Coronary Circulation; Dihydropyridines; Dogs; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Neutrophils; Peroxidase; Potassium Channels; Time Factors; Vasodilator Agents | 1995 |
Theophylline for the treatment of atrioventricular block after myocardial infarction.
Topics: Adenosine; Adult; Aged; Electrocardiography; Heart Block; Humans; Male; Middle Aged; Monitoring, Physiologic; Myocardial Infarction; Theophylline | 1995 |
Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Death, Sudden, Cardiac; Disease-Free Survival; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Stroke Volume; Thallium Radioisotopes; Tomography, Emission-Computed | 1995 |
Continuous monitoring of energy metabolites using microdialysis during myocardial ischaemia in the pig.
Topics: Adenosine; Animals; Energy Metabolism; Female; Guanosine; Hemodynamics; Hypoxanthine; Hypoxanthines; Inosine; Lactates; Lactic Acid; Male; Microdialysis; Monitoring, Physiologic; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyruvates; Pyruvic Acid; Swine | 1995 |
Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog.
Topics: Adenosine; Animals; Cell Movement; Coronary Circulation; Dogs; Female; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Neutrophils; Niacinamide; Nicorandil; Nitroglycerin; Peroxidase; Regional Blood Flow; Vasodilator Agents | 1995 |
Acadesine reduces myocardial infarct size by an adenosine mediated mechanism.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Coronary Circulation; Extracellular Space; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rabbits; Receptors, Purinergic P1; Regional Blood Flow; Ribonucleosides; Theophylline | 1995 |
[Use of pharmacological-stress echocardiography].
Topics: Adenosine; Adenosine Triphosphate; Aged; Algorithms; Coronary Disease; Dipyridamole; Dobutamine; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Preoperative Care; Prognosis; Vascular Surgical Procedures | 1994 |
Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism.
Topics: Adenosine; Animals; Arginine; Lactates; Lactic Acid; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Rabbits; Theophylline; Time Factors | 1995 |
The ATP-dependent potassium channel: an endogenous cardioprotective mechanism.
Topics: Acetylcholine; Adenosine; Animals; Anti-Arrhythmia Agents; Coronary Disease; Decanoic Acids; Disease Models, Animal; Dogs; Female; Glyburide; Hydroxy Acids; Infusions, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Potassium Channel Blockers; Potassium Channels | 1994 |
Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.
Topics: Adenosine; Animals; Antihypertensive Agents; Female; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Ischemia; Perfusion; Purinergic Antagonists; Rabbits; Receptors, Purinergic P1; Theophylline; Xanthines | 1994 |
[An increase in adenosine release contributes to the infarct size limiting effect of ischemic preconditioning].
Topics: Adenosine; Animals; Coronary Circulation; Dogs; Myocardial Infarction; Myocardial Ischemia; Myocardium; Oxygen | 1993 |
Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.
Topics: Adenosine; Animals; Heart; Hemodynamics; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Rabbits; Receptors, Purinergic P1; Theophylline; Time Factors | 1994 |
The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart.
Topics: Acetylcholine; Adenosine; Animals; Bradycardia; Drug Tolerance; Female; Hemodynamics; Hypotension; Infusions, Intravenous; Male; Muscle Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Purinergic P1 Receptor Antagonists; Rabbits; Receptors, Muscarinic; Receptors, Purinergic P1 | 1994 |
Cellular mechanisms in ischemic preconditioning: the role of adenosine and protein kinase C.
Topics: Adenosine; Animals; Blood Pressure; GTP-Binding Proteins; Myocardial Infarction; Myocardial Ischemia; Protein Kinase C; Rabbits; Receptors, Purinergic P1; Tyramine; Virulence Factors, Bordetella | 1994 |
Transesophageal electrocardiography and adenosine in the diagnosis of wide complex tachycardia.
Topics: Adenosine; Coronary Artery Bypass; Electrocardiography; Humans; Intubation, Gastrointestinal; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Tachycardia, Supraventricular; Tachycardia, Ventricular | 1994 |
Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction.
Topics: Adenosine; Adenosine Triphosphate; Animals; Coronary Circulation; Dogs; Heart Failure; Hypertrophy, Left Ventricular; Magnetic Resonance Spectroscopy; Myocardial Infarction; Myocardium; Phosphocreatine; Time Factors; Ventricular Function, Left | 1994 |
A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels.
Topics: Adenosine; Adenosine Triphosphate; Animals; Decanoic Acids; Dogs; Female; Glyburide; Hydroxy Acids; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Potassium Channels; Time Factors | 1994 |
Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Animals; Dogs; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Time Factors | 1994 |
Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel.
Topics: Adenosine; Adenosine Triphosphate; Animals; Blood Pressure; Cardiotonic Agents; Coronary Vessels; Heart Rate; Lidocaine; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Phenylisopropyladenosine; Potassium Channel Blockers; Potassium Channels; Receptors, Purinergic P1; Reference Values; Swine; Time Factors | 1994 |
A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia.
Topics: Adenosine; Adrenergic alpha-1 Receptor Antagonists; Animals; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Phenylisopropyladenosine; Rabbits; Random Allocation; Receptors, Adrenergic, alpha-1; Theophylline; Xanthines | 1994 |
Myocardial infarction and purine transport inhibition in anaesthetised ferrets.
Topics: Adenosine; Animals; Atenolol; Blood Gas Analysis; Blood Pressure; Coronary Circulation; Ferrets; Heart Rate; Hemodynamics; Injections, Intravenous; Leukocyte Count; Male; Microspheres; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Peroxidase; Thioinosine | 1994 |
Exercise and pharmacologic stress testing for prognosis after acute myocardial infarction.
Topics: Adenosine; Exercise Test; Heart; Humans; Myocardial Infarction; Prognosis; Radionuclide Imaging; Thallium Radioisotopes | 1994 |
Acadesine extends the window of protection afforded by ischaemic preconditioning.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Rabbits; Ribonucleosides; Theophylline; Time Factors | 1994 |
Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity.
Topics: 5'-Nucleotidase; Adaptation, Biological; Adenosine; Animals; Blood Pressure; Dogs; Endocardium; Esophagus; Hemodynamics; Methoxamine; Myocardial Infarction; Myocardial Ischemia; Perfusion; Prazosin; Receptors, Adrenergic, alpha-1; Risk Factors | 1994 |
Study of myocardial infarct remodeling by single-photon emission computed tomographic imaging.
Topics: Adenosine; Aged; Feasibility Studies; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 1993 |
Attenuation of postischaemic dysfunction by ischaemic preconditioning is not mediated by adenosine in the isolated rat heart.
Topics: Adenosine; Animals; Blood Pressure; Heart Rate; Lactates; Lactic Acid; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Phenylisopropyladenosine; Purinergic Antagonists; Rats; Rats, Sprague-Dawley; Xanthines | 1993 |
Quantitative demonstration of dipyridamole-induced coronary steal and alteration by angioplasty in man: analysis by simultaneous, continuous dual Doppler spectral flow velocity.
Topics: Adenosine; Aminophylline; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Dipyridamole; Echocardiography, Doppler; Humans; Hyperemia; Male; Middle Aged; Myocardial Infarction | 1993 |
Detection of viable myocardium in segments with fixed defects on thallium-201 scintigraphy: usefulness of magnetic resonance imaging early after acute myocardial infarction.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Female; Heart; Humans; Magnetic Resonance Imaging; Male; Myocardial Infarction; Myocardium; Thallium Radioisotopes; Thrombolytic Therapy; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
Simulated ischemia does not protect against efferent sympathetic denervation following acute myocardial infarction in canine hearts.
Topics: Adenosine; Analysis of Variance; Animals; Denervation; Dogs; Female; Heart; Hemodynamics; Hydrogen-Ion Concentration; Hypoxia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Neurons, Efferent; Sympathetic Nervous System; Time Factors | 1993 |
Ischaemic preconditioning and myocardial adaptation to ischaemia.
Topics: Adaptation, Physiological; Adenosine; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium | 1993 |
Ischaemic preconditioning.
Topics: Adenosine; Adenosine Triphosphate; Angioplasty, Balloon, Coronary; Heart; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium | 1994 |
An adenosine A1 receptor agonist, R(-)-N-(2-phenylisopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits.
Topics: Adenosine; Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Phenylisopropyladenosine; Rabbits; Receptors, Purinergic P1 | 1993 |
Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein.
Topics: Acetylcholine; Adenosine; Animals; Arrhythmias, Cardiac; GTP-Binding Proteins; Heart Rate; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Pertussis Toxin; Rats; Rats, Sprague-Dawley; Virulence Factors, Bordetella | 1993 |
Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels.
Topics: Adenosine; Adenosine Triphosphate; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Glyburide; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Potassium Channels; Rabbits | 1993 |
Pretreatment with the adenosine A1 selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits.
Topics: Adenosine; Animals; Disease Models, Animal; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rabbits; Receptors, Purinergic | 1993 |
Adenosine slows ischaemic metabolism in canine myocardium in vitro: relationship to ischaemic preconditioning.
Topics: Adenosine; Animals; Dogs; In Vitro Techniques; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Perfusion | 1993 |
Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Heart; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rabbits; Receptors, Purinergic | 1993 |
Use of translesional coronary flow velocity for interventional decisions in a patient with multiple intermediately severe coronary stenoses.
Topics: Adenosine; Adult; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Cineangiography; Coronary Angiography; Coronary Circulation; Coronary Disease; Echocardiography, Doppler; Humans; Male; Myocardial Infarction | 1993 |
Effectiveness of thrombolysis is associated with a time-dependent increase of malondialdehyde in peripheral blood of patients with acute myocardial infarction.
Topics: Adenosine; Chromatography, High Pressure Liquid; Female; Free Radicals; Humans; Hypoxanthine; Hypoxanthines; Male; Malondialdehyde; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Thrombolytic Therapy; Time Factors; Uric Acid; Xanthine; Xanthines | 1993 |
Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning.
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rabbits; Receptors, Purinergic; Ribonucleosides; Time Factors | 1993 |
Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischaemia and reperfusion.
Topics: Adenosine; Animals; Coronary Vessels; Depression, Chemical; Dogs; Endothelins; Female; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Regional Blood Flow; Time Factors | 1993 |
Quantitative adenosine 201Tl single-photon emission computed tomography for the early assessment of patients surviving acute myocardial infarction.
Topics: Adenosine; Coronary Disease; Female; Heart; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Thallium Radioisotopes; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
Variability of coronary blood flow reserve assessed by Doppler catheter after successful thrombolysis in patients with acute myocardial infarction.
Topics: Adenosine; Adult; Aged; Blood Flow Velocity; Cardiac Catheterization; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Humans; Middle Aged; Myocardial Infarction; Thrombolytic Therapy; Tissue Plasminogen Activator | 1993 |
Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs.
Topics: Adenosine; Adenosine Triphosphate; Animals; Blood Glucose; Coronary Circulation; Coronary Disease; Dogs; Female; Glyburide; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Potassium Channels; Purines; Receptors, Purinergic; Sulfonamides; Xanthines | 1993 |
Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release.
Topics: Adenosine; Adrenergic alpha-Antagonists; Animals; Catecholamines; Heart; Hemodynamics; Hypoxia; In Vitro Techniques; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Phenoxybenzamine; Rabbits; Theophylline; Time Factors | 1995 |
Adenosine technetium-99m sestamibi (SPECT) for the early assessment of jeopardized myocardium after acute myocardial infarction.
Topics: Adenosine; Aged; Cardiovascular Agents; Coronary Vessels; Evaluation Studies as Topic; Female; Heart; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardium; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1995 |
Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine.
Topics: Adenosine; Animals; Blood Pressure; Dogs; Drug Evaluation, Preclinical; Female; Gadolinium; Heart Rate; Injections; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Rats; Rats, Sprague-Dawley; Sodium Chloride; Tachycardia, Ventricular | 1996 |
Cost-effectiveness of myocardial perfusion imaging with SPECT in the emergency department evaluation of patients with unexplained chest pain.
Topics: Adenosine; Adult; Aged; Chest Pain; Colorado; Cost-Benefit Analysis; Emergency Service, Hospital; Evaluation Studies as Topic; Female; Heart; Hospital Costs; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Patient Admission; Prospective Studies; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1996 |
Ischaemic preconditioning.
Topics: Adenosine; Angina, Unstable; Humans; Myocardial Infarction; Myocardial Ischemia; Recombinant Proteins; Thrombolytic Therapy; Tissue Plasminogen Activator | 1996 |
Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs.
Topics: Adenosine; Animals; Dogs; Female; Lidocaine; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium | 1996 |
Factors influencing regional myocardial contractile response to inotropic stimulation. Analysis in humans with stable ischemic heart disease.
Topics: Adenosine; Adrenergic beta-Agonists; Aged; Ammonia; Carbon Isotopes; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Deoxyglucose; Dobutamine; Echocardiography; False Negative Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Sensitivity and Specificity; Tomography, Emission-Computed | 1996 |
Coronary reserve abnormalities in the infarcted myocardium. Assessment of myocardial viability immediately versus late after reflow by contrast echocardiography.
Topics: Adenosine; Animals; Coronary Circulation; Dipyridamole; Dogs; Echocardiography; Heart; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Regression Analysis; Time Factors; Vasodilation | 1996 |
Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs.
Topics: Adenosine; Animals; Dogs; Female; Glyburide; Ion Channel Gating; Male; Methylene Blue; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Niacinamide; Nicorandil; Nitric Oxide; Nitroglycerin; Potassium Channels; Vasodilator Agents | 1996 |
Pre-conditioning with adenosine leads to concentration-dependent infarct size reduction in the isolated rabbit heart.
Topics: Adenosine; Animals; Dose-Response Relationship, Drug; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Perfusion; Rabbits | 1996 |
Cardioprotection with ischemic preconditioning and MLA: role of adenosine-regulating enzymes?
Topics: 5'-Nucleotidase; Adenosine; Adenosine Kinase; Adenosine Triphosphate; Adjuvants, Immunologic; Animals; Coronary Circulation; Dogs; Energy Metabolism; Enzymes; Hemodynamics; Ischemic Preconditioning, Myocardial; Lipid A; Myocardial Infarction; Myocardium; Phosphates; Regional Blood Flow | 1996 |
Adrenergic activation confers cardioprotection mediated by adenosine, but is not required for ischemic preconditioning.
Topics: Adenosine; Adrenergic alpha-Agonists; Animals; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Norepinephrine; Phentolamine; Prazosin; Rabbits; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Theophylline; Tyramine | 1996 |
Sensitivity to ischemia of chronically infarcted rat hearts; effects of long-term captopril treatment.
Topics: Adenosine; Animals; Blood Flow Velocity; Captopril; Ischemia; Male; Myocardial Infarction; Perfusion; Rats; Rats, Wistar; Sensitivity and Specificity | 1996 |
Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence.
Topics: Adenosine; Animals; Cardiovascular Agents; Drug Evaluation, Preclinical; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Necrosis; Neutrophil Activation; Platelet Activation; Poly A; Rabbits; Time Factors | 1996 |
Effect of temperature on myocardial infarction in swine.
Topics: Adenosine; Adenosine Deaminase; Animals; Body Temperature; Coronary Circulation; Female; Heart; Hemodynamics; Male; Myocardial Infarction; Theophylline | 1996 |
Myocardial contrast echocardiography in acute myocardial infarction using aortic root injections of microbubbles in conjunction with harmonic imaging: potential application in the cardiac catheterization laboratory.
Topics: Adenosine; Albumins; Animals; Cardiac Catheterization; Contrast Media; Dogs; Echocardiography; Heart; Myocardial Infarction; Purinergic P1 Receptor Agonists; Radionuclide Imaging; Technetium Tc 99m Aggregated Albumin; Vasodilator Agents | 1997 |
KATP channels and memory of ischemic preconditioning in dogs: synergism between adenosine and KATP channels.
Topics: Adenosine; Adenosine Triphosphate; Animals; Benzopyrans; Coronary Circulation; Dihydropyridines; Dogs; Drug Combinations; Female; Gases; Glyburide; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Potassium Channels | 1997 |
Stress echocardiography using adenosine combined with nitroglycerin-dobutamine in the detection of viable myocardium in patients with previous myocardial infarction.
Topics: Adenosine; Cardiotonic Agents; Cell Survival; Dobutamine; Drug Combinations; Echocardiography; Electrocardiography; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Nitroglycerin; Sensitivity and Specificity; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 1997 |
Adenosine therapy at reperfusion on myocardial infarct size.
Topics: Adenosine; Animals; Dogs; Myocardial Infarction; Myocardial Reperfusion; Myocardium | 1997 |
Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cardiotonic Agents; Dogs; Drug Approval; Enzyme Activation; Heart Failure; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Neutropenia; Protein Kinase C; Pyrazines; Quinolines; Second Messenger Systems | 1997 |
Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Animals; Cardiotonic Agents; Dipyridamole; Dogs; Enzyme Activation; Enzyme Inhibitors; Infusions, Intra-Arterial; Ion Channel Gating; Myocardial Infarction; Myocardial Reperfusion Injury; Potassium Channels; Pyrazines; Quinolines; Receptors, Purinergic P1; Theophylline | 1997 |
Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine.
Topics: Adenosine; Animals; Blood Pressure; Cardiotonic Agents; Coronary Circulation; Female; Heart Rate; Hemodynamics; Inosine; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Piperazines; Swine; Time Factors; Ventricular Function, Left | 1997 |
Hemodynamic changes do not mediate the cardioprotection induced by the A1, adenosine receptor agonist CCPA in the rabbit.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Analysis of Variance; Animals; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Felodipine; Hemodynamics; Male; Myocardial Infarction; Purinergic P1 Receptor Agonists; Rabbits; Vasodilator Agents | 1997 |
Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits.
Topics: Adenosine; Animals; Heart; Hemodynamics; Histamine; Male; Myocardial Infarction; Myocardial Stunning; Rabbits; Rats; Receptors, Purinergic P1 | 1997 |
Time course of delayed myocardial protection after transient adenosine A1-receptor activation in the rabbit.
Topics: Adenosine; Animals; Blood Pressure; Heart Rate; HSP70 Heat-Shock Proteins; Hydrogen-Ion Concentration; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Purinergic P1 Receptor Agonists; Rabbits; Time Factors | 1997 |
Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse hemodynamic effects.
Topics: Adenosine; Adrenergic alpha-Agonists; Animals; Blood Pressure; Cardiovascular Agents; Feasibility Studies; Female; Heart; Heart Rate; Hemodynamics; Infusions, Intravenous; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Norepinephrine; Rabbits | 1997 |
Adenosine technetium-99m sestamibi single-photon emission tomography for the assessment of jeopardized myocardium early after acute myocardial infarction. Paradoxical scintigraphic underestimation of jeopardized myocardium in patients with a severe infarc
Topics: Adenosine; Case-Control Studies; Coronary Angiography; Coronary Disease; Dobutamine; Echocardiography; Female; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 1997 |
Myocardial infarction related atrial fibrillation: role of endogenous adenosine.
Topics: Adenosine; Aged; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Purinergic P1 Receptor Antagonists; Theophylline | 1997 |
Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size.
Topics: Adenosine; Adenosine Deaminase Inhibitors; Animals; Blood Flow Velocity; Disease Models, Animal; Enzyme Inhibitors; Extracellular Space; Female; Ischemic Preconditioning, Myocardial; Male; Microdialysis; Myocardial Infarction; Myocardial Ischemia; Pentostatin; Swine; Swine, Miniature | 1997 |
Adenosine inhibition of neutrophil damage during reperfusion does not involve K(ATP)-channel activation.
Topics: Adenosine; Adenosine Triphosphate; Animals; Cardiovascular Agents; Cell Adhesion; Creatine Kinase; Female; Glyburide; Hemodynamics; Male; Myocardial Infarction; Myocardium; Neutrophils; Peroxidase; Phenethylamines; Potassium Channels; Rabbits; Reperfusion Injury; Superoxides | 1997 |
[Experimental study on adenosine hypothesis of bradyarrhythmias occurring in myocardial hypoxia and its clinical significance].
Topics: Adenosine; Aminophylline; Animals; Bradycardia; Cardiotonic Agents; Guinea Pigs; Myocardial Infarction; Rabbits | 1996 |
Utility of stress single-photon emission computed tomography (SPECT) perfusion imaging in predicting outcome after coronary artery bypass grafting.
Topics: Adenosine; Aged; Angina Pectoris; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Dipyridamole; Exercise Test; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Recurrence; Reoperation; Risk Factors; Survival Analysis; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 1997 |
Failure of preconditioning to improve postcardioplegia stunning of minimally infarcted hearts.
Topics: Adenosine; Animals; Coronary Circulation; Creatine Kinase; Heart Arrest, Induced; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Stunning; Rabbits; Ventricular Function, Left | 1997 |
Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection.
Topics: Adenosine; Animals; Dipyridamole; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Purines; Rabbits; Vasodilator Agents | 1998 |
Diastolic indexes during dobutamine stress echocardiography in patients early after myocardial infarction.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiac Catheterization; Diastole; Dobutamine; Echocardiography, Doppler; Female; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Radionuclide Imaging; Technetium Tc 99m Sestamibi; Time Factors | 1998 |
Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction.
Topics: Adenosine; Aged; Analysis of Variance; Death, Sudden, Cardiac; Exercise Test; Follow-Up Studies; Health Care Costs; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Tomography, Emission-Computed, Single-Photon | 1998 |
Tachycardia preconditions infarct size in dogs: role of adenosine and protein kinase C.
Topics: Adenosine; Animals; Blood Flow Velocity; Blood Pressure; Coronary Vessels; Diastole; Dogs; Female; Heart Rate; Heart Ventricles; Hemodynamics; Ischemia; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Protein Kinase C; Purinergic P1 Receptor Antagonists; Systole; Tachycardia; Time Factors; Ventricular Dysfunction, Left; Ventricular Fibrillation | 1998 |
Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors.
Topics: 2-Chloroadenosine; Adenosine; Animals; Cardiovascular Agents; Cell Culture Techniques; Cell Division; Collagen; Fibroblasts; Fibrosis; Heart Ventricles; Male; Myocardial Infarction; Protein Biosynthesis; Proteins; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2B; Receptors, Purinergic P1 | 1998 |
Protection afforded by preconditioning to the diabetic heart against ischaemic injury.
Topics: Adenosine; Animals; Cardiovascular Agents; Coronary Vessels; Diabetes Mellitus, Experimental; Endothelium, Vascular; Ischemic Preconditioning, Myocardial; Male; Myocardial Contraction; Myocardial Infarction; Nitroprusside; Perfusion; Random Allocation; Rats; Rats, Sprague-Dawley; Serotonin; Time Factors; Vasodilator Agents | 1998 |
Myocardial perfusion scintigraphy (SPECT) during adenosine stress can be performed safely early on after thrombolytic therapy in acute myocardial infarction.
Topics: Adenosine; Aged; Dyspnea; Electrocardiography; Exercise Test; Female; Heart Block; Heart Rate; Humans; Hyperemia; Male; Middle Aged; Myocardial Infarction; Technetium Tc 99m Sestamibi; Thrombolytic Therapy; Tomography, Emission-Computed, Single-Photon | 1998 |
Adenosine-enhanced ischemic preconditioning provides enhanced postischemic recovery and limitation of infarct size in the rabbit heart.
Topics: Adenosine; Animals; Cardioplegic Solutions; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Heart Arrest, Induced; Infusions, Intra-Arterial; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Ischemia; Organ Size; Rabbits; Vasodilator Agents; Ventricular Function, Left | 1998 |
Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart.
Topics: Acetylcholine; Adenosine; Adenosine Diphosphate Ribose; Animals; Dogs; GTP-Binding Proteins; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; NAD; Pertussis Toxin; Rabbits; Rats; Rats, Wistar; Virulence Factors, Bordetella | 1998 |
Myocardial preconditioning produced by ischemia, hypoxia, and a KATP channel opener: effects on interstitial adenosine in dogs.
Topics: Adenine Nucleotides; Adenosine; Animals; Benzopyrans; Dihydropyridines; Dogs; Extracellular Space; Hemodynamics; Hypoxanthine; Hypoxia; Inosine; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Ischemia; Potassium Channels; Uric Acid; Xanthine | 1998 |
Intravenous adenosine and lidocaine in patients with acute myocardial infarction.
Topics: Adenosine; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Hemodynamics; Humans; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Pilot Projects; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents | 1998 |
Alterations in small arterioles precede changes in limb skeletal muscle after myocardial infarction.
Topics: Acetylcholine; Adenosine; Animals; Arterioles; Female; Heart Failure; Hemodynamics; Muscle, Skeletal; Myocardial Infarction; Norepinephrine; Rats; Rats, Wistar; Vasoconstriction; Vasodilation; Ventricular Function, Left | 1998 |
Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart.
Topics: Adenosine; Animals; Blood Pressure; Heart Rate; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardium; Sheep | 1998 |
Interstitial ATP level and degradation in control and postmyocardial infarcted rats.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Heart; Hypoxanthine; In Vitro Techniques; Inosine; Intracellular Fluid; Male; Microdialysis; Myocardial Contraction; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Time Factors; Xanthine | 1998 |
Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin.
Topics: Adenosine; Adenosine Deaminase; Analysis of Variance; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Chromatography, High Pressure Liquid; Coronary Circulation; Coronary Vessels; Hemodynamics; Ischemic Preconditioning, Myocardial; Microdialysis; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Receptor, Bradykinin B2; Swine; Swine, Miniature | 1998 |
Loss of myocardial protection from ischemic preconditioning following chronic exposure to R(-)-N6-(2-phenylisopropyl)adenosine is related to defect at the adenosine A1 receptor.
Topics: Adenosine; Animals; Carbachol; Down-Regulation; Female; GTP-Binding Proteins; Hemodynamics; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Protein Kinase C; Rabbits; Receptors, Purinergic P1 | 1998 |
Influence of an early adrenergic blockade on thrombotic infarct size and myocardial metabolism.
Topics: Adenosine; Adrenergic beta-Antagonists; Animals; Blood Glucose; Dogs; Fatty Acids, Nonesterified; Female; Lactic Acid; Male; Metoprolol; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Oxygen; Oxygen Consumption; Regional Blood Flow | 1998 |
The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig.
Topics: Adenosine; Anesthesia; Animals; Blood Pressure; Coronary Disease; Female; Heart Rate; Male; Molecular Structure; Myocardial Infarction; Purinergic P1 Receptor Agonists; Reperfusion Injury; Swine; Time Factors; Ventricular Dysfunction; Xanthines | 1999 |
Adenosine-enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia.
Topics: Adenosine; Animals; Blood; Blood Pressure; Cold Temperature; Heart; Heart Arrest, Induced; Heart Rate; Injections; Ischemic Preconditioning, Myocardial; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Sheep; Ventricular Function, Left | 1999 |
Myocardial bridging.
Topics: Adenosine; Adrenergic beta-Agonists; Dobutamine; Exercise Test; Heart Rate; Humans; Myocardial Infarction; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 1999 |
Delayed preconditioning with adenosine is mediated by opening of ATP-sensitive K(+) channels in rabbit heart.
Topics: Action Potentials; Adenosine; Adenosine Triphosphate; Animals; Cardiovascular Agents; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Potassium Channels; Rabbits; Time Factors | 1999 |
A Na+-H+ exchange inhibitor (SM-20550) protects from microvascular deterioration and myocardial injury after reperfusion.
Topics: Acetylcholine; Adenosine; Amidines; Animals; Coronary Vessels; Dogs; Female; Indoles; Male; Microcirculation; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Peroxidase; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Sodium-Hydrogen Exchangers; Vascular Resistance; Vasodilator Agents | 1999 |
The effect of body temperature on myocardial protection conferred by ischaemic preconditioning or the selective adenosine A1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion.
Topics: Adenosine; Anesthesia; Animals; Blood Pressure; Body Temperature; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Purinergic P1 Receptor Agonists; Rabbits; Xanthines | 1999 |
Rabbit heart can be "preconditioned" via transfer of coronary effluent.
Topics: Adenosine; Animals; Blood Transfusion; Coronary Circulation; Coronary Vessels; In Vitro Techniques; Ischemic Preconditioning; Models, Cardiovascular; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Norepinephrine; Perfusion; Rabbits; Time Factors; Ventricular Function, Left | 1999 |
The hemodynamic effects of adenosine infusion after experimental right heart infarct in young swine.
Topics: Adenosine; Animals; Blood Gas Analysis; Body Temperature; Cardiac Output; Female; Heart Rate; Hemodynamics; Infusions, Intravenous; Male; Myocardial Contraction; Myocardial Infarction; Pulmonary Circulation; Stroke Volume; Swine; Vascular Resistance; Vasodilator Agents | 2000 |
Spontaneous and diffuse coronary artery spasm unresponsive to conventional intracoronary pharmacological therapy: a case report.
Topics: Adenosine; Adult; Coronary Angiography; Coronary Vasospasm; Coronary Vessels; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Female; Humans; Injections, Intra-Arterial; Myocardial Infarction; Nitroglycerin; Vasodilator Agents; Verapamil | 2000 |
Adenosine induced atrial fibrillation precipitating polymorphic ventricular tachycardia.
Topics: Adenosine; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart Rate; Humans; Infusions, Intravenous; Myocardial Infarction; Procainamide; Tachycardia, Supraventricular | 2000 |
Downregulation of adenosine and P2X receptor-mediated cardiovascular responses in heart failure rats.
Topics: Adenosine; Adenosine Triphosphate; Animals; Blood Pressure; Cardiovascular System; Decerebrate State; Down-Regulation; Electric Stimulation; Ganglia; Heart Failure; Heart Rate; Male; Myocardial Infarction; Purinergic P2 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2 | 2000 |
Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase.
Topics: Adenosine; Animals; Arteries; Coronary Circulation; Coronary Vessels; Hemodynamics; Ischemic Preconditioning, Myocardial; Ligation; Male; Myocardial Infarction; Myocardium; Oligonucleotides, Antisense; Purinergic P1 Receptor Agonists; Rats; Rats, Wistar; Receptors, Purinergic P1; Risk Factors; Superoxide Dismutase; Time Factors | 2000 |
Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism.
Topics: Adenosine; Animals; Blood Pressure; Coronary Circulation; Coronary Thrombosis; Dogs; Fibrinolytic Agents; Heart Rate; Myocardial Infarction; Myocardial Ischemia; Recombinant Proteins; Thrombolytic Therapy; Tissue Plasminogen Activator | 2000 |
Does resveratrol induce pharmacological preconditioning?
Topics: Adenosine; Animals; Antioxidants; Cardiovascular Physiological Phenomena; Heart; Ischemic Preconditioning, Myocardial; Male; Muscle Contraction; Myocardial Infarction; Myocardial Ischemia; Myocardium; Phosphates; Phosphorylation; Rats; Rats, Sprague-Dawley; Recovery of Function; Regional Blood Flow; Reperfusion Injury; Resveratrol; Stilbenes | 2000 |
Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice.
Topics: Adenosine; Animals; Enzyme Inhibitors; Female; Heart; Ischemic Preconditioning, Myocardial; Isothiuronium; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Purinergic P1 Receptor Agonists; Receptors, Purinergic P1; Ventricular Function, Left | 2000 |
Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon.
Topics: Adenosine; Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Vessels; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Treatment Outcome; Vascular Patency | 2000 |
Hibernating myocardium, stunning, ischemic preconditioning: clinical relevance.
Topics: Adenosine; Angina, Unstable; Angioplasty, Balloon, Coronary; Chronic Disease; Female; Humans; Ischemic Preconditioning, Myocardial; Male; Middle Aged; Myocardial Infarction; Myocardial Stunning; Vasodilator Agents | 2000 |
Anti-stunning and anti-infarct effects of adenosine-enhanced ischemic preconditioning.
Topics: Adenosine; Animals; Disease Models, Animal; Female; Heart Function Tests; Hemodynamics; Ischemic Preconditioning, Myocardial; Linear Models; Male; Myocardial Infarction; Myocardial Stunning; Organ Size; Recovery of Function; Sheep; Time Factors | 2000 |
Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins.
Topics: Adenosine; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; CD18 Antigens; Coronary Circulation; DNA Fragmentation; Dogs; Drug Evaluation, Preclinical; Female; Gene Expression Regulation; Genes, bcl-2; Hemodynamics; Injections, Intra-Arterial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Necrosis; Neutrophils; Phenethylamines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Purinergic P1 | 2001 |
Adenosine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion.
Topics: Adenosine; Animals; Dihydropyridines; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rabbits; Receptors, Purinergic P1; Ventricular Pressure; Xanthines | 2001 |
Adenosine-induced late preconditioning in mouse hearts: role of p38 MAP kinase and mitochondrial K(ATP) channels.
Topics: Adenosine; Adenosine Triphosphate; Animals; Blotting, Western; Ischemic Preconditioning, Myocardial; Male; Mice; Mice, Inbred ICR; Mitochondria; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocardial Ischemia; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Potassium Channels; Signal Transduction; Vasodilator Agents; Ventricular Function, Left | 2001 |
Mitochondrial ATP dependent potassium channels mediate non-ischemic preconditioning by tachycardia in dogs.
Topics: Adenosine; Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Blood Flow Velocity; Decanoic Acids; Dogs; Female; Glyburide; Heart; Heart Rate; Hemodynamics; Hydroxy Acids; Hypoglycemic Agents; Male; Mitochondria; Myocardial Infarction; Myocardium; Necrosis; Potassium Channels; Tachycardia; Time Factors | 2001 |
A(2b) receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts.
Topics: 2-Chloroadenosine; Adenosine; Animals; Becaplermin; Cell Division; Cells, Cultured; Collagen; Cyclic AMP; DNA; Enzyme Activation; Fibroblasts; Hypertension; Male; Mitogen-Activated Protein Kinases; Mitogens; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Oligonucleotides, Antisense; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2B; Receptors, Purinergic P1; Signal Transduction | 2001 |
Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium.
Topics: Adenosine; Animals; Blood Pressure; Coronary Circulation; Coronary Vessels; Heart; Heart Rate; Hemodynamics; Myocardial Infarction; Myocardial Reperfusion; Myocardial Stunning; Phenethylamines; Purinergic P1 Receptor Agonists; Receptor, Adenosine A2A; Swine | 2001 |
A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.
Topics: Adenine; Adenosine; Animals; Binding, Competitive; Cell Line; Consciousness; Decanoic Acids; Humans; Hydroxy Acids; Iodine Radioisotopes; Ischemic Preconditioning, Myocardial; Membranes; Myocardial Infarction; Nitroarginine; Norbornanes; Phenethylamines; Rabbits; Radioligand Assay; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2001 |
Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study.
Topics: Adenosine; Anesthesia; Animals; Blood Pressure; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Purinergic P1 Receptor Agonists; Rabbits | 2000 |
Energy-related metabolites during and after induced myocardial infarction with special emphasis on the reperfusion injury after extracorporeal circulation.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Dialysis Solutions; Disease Models, Animal; Energy Metabolism; Extracorporeal Circulation; Guanine; Heart Arrest, Induced; Hypoxanthine; Inosine; Lactic Acid; Microdialysis; Myocardial Infarction; Myocardium; Pyruvic Acid; Reperfusion Injury; Swine; Taurine | 2001 |
Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction.
Topics: Adenosine; Aged; Coronary Circulation; Death, Sudden, Cardiac; Exercise Test; Female; Gated Blood-Pool Imaging; Humans; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Risk Assessment; Stroke Volume; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 2001 |
Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels.
Topics: Acetylcholine; Adenosine; Animals; Bradykinin; Decanoic Acids; Free Radical Scavengers; Free Radicals; Hemodynamics; Hydroxy Acids; In Vitro Techniques; Ion Channel Gating; Ischemic Preconditioning, Myocardial; Mitochondria, Heart; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Narcotics; Phenylephrine; Potassium Channel Blockers; Potassium Channels; Rabbits; Signal Transduction; Tiopronin | 2001 |
Role of adenosine in ischemic preconditioning in rats depends critically on the duration of the stimulus and involves both A(1) and A(3) receptors.
Topics: Acetamides; Adenosine; Analysis of Variance; Animals; Cryoprotective Agents; Dihydropyridines; Histamine H1 Antagonists; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Purinergic Antagonists; Purinergic P1 Receptor Antagonists; Pyrilamine; Rats; Rats, Wistar; Receptors, Purinergic; Receptors, Purinergic P1; Theophylline; Time Factors | 2001 |
Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury.
Topics: Adenosine; Aging; Animals; Diazoxide; Diglycerides; Heart; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Time Factors; Vasodilator Agents | 2001 |
Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium.
Topics: Adaptation, Physiological; Adenosine; Animals; Heart; In Vitro Techniques; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Receptor, Adenosine A3; Receptors, Purinergic P1; Xanthines | 2001 |
Pharmacological delayed preconditioning against ischaemia-induced ventricular arrhythmias: effect of an adenosine A(1)-receptor agonist.
Topics: Adenosine; Animals; Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Heart Ventricles; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Purinergic P1 Receptor Agonists; Rabbits | 2001 |
Myocardial infarction during adenosine stress test.
Topics: Adenosine; Aged; Echocardiography, Stress; Electrocardiography; Female; Humans; Myocardial Infarction; Vasodilator Agents | 2002 |
Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Analysis of Variance; Animals; Calcium; Drug Synergism; Enzyme Inhibitors; Magnesium; Male; Models, Animal; Myocardial Infarction; Myocardium; Purinergic P1 Receptor Antagonists; Rabbits; Theophylline | 2002 |
Recanalization of an occluded major side branch after stenting with intracoronary adenosine.
Topics: Adenosine; Aged; Collateral Circulation; Coronary Circulation; Coronary Thrombosis; Coronary Vasospasm; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Stents; Vasodilator Agents | 2002 |
Sites of action of adenosine in interorgan preconditioning of the heart.
Topics: Adenosine; Animals; Blood Pressure; Coronary Vessels; Ganglionic Blockers; Heart Rate; Hexamethonium; Injections, Intra-Arterial; Injections, Intravenous; Intestine, Small; Ischemia; Ischemic Preconditioning, Myocardial; Male; Mesenteric Arteries; Mesentery; Myocardial Infarction; Myocardial Ischemia; Myocardium; Portal Vein; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P1; Theophylline | 2002 |
Adenosine A(1)-receptor induced late preconditioning and myocardial infarction: reperfusion duration is critical.
Topics: Adenosine; Animals; Cardiac Catheterization; Coronary Vessels; Disease Models, Animal; Disease Progression; Heart Ventricles; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Purinergic P1 Receptor Agonists; Rabbits; Receptors, Purinergic P1; Time Factors; Treatment Outcome; Wakefulness | 2002 |
[Adenosine metabolism in the myocardium in experimental myocardial infarct].
Topics: Adenosine; Adenosine Deaminase; Adenosine Monophosphate; AMP Deaminase; Animals; Dogs; Myocardial Infarction; Myocardium; Nucleotidases | 1979 |
[Possible metabolic mechanisms of coronary circulatory disorder in an intact area of the left ventricle in experimental myocardial infarct].
Topics: Adenosine; Adenosine Monophosphate; Aminohydrolases; Animals; Coronary Circulation; Coronary Disease; Dogs; Enzyme Activation; Heart Ventricles; Myocardial Infarction; Myocardium; Nucleotidases; Time Factors | 1979 |
Effects of acute cellular injury on coronary vascular reactivity in awake dogs.
Topics: Adenosine; Animals; Blood Pressure; Coronary Vessels; Dogs; Heart Injuries; Heart Rate; Hemodynamics; Myocardial Infarction; Regional Blood Flow | 1978 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Disease; Dipyridamole; Heparin; Hirudins; Humans; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Platelet Aggregation; Prostaglandins E | 1976 |
Coronary steal: its role in detrimental effect of isoproterenol after acute coronary occlusion in dogs.
Topics: Adenosine; Animals; Blood Pressure; Collateral Circulation; Coronary Circulation; Disease Models, Animal; Dogs; Isoproterenol; Myocardial Infarction | 1976 |
Effect of ischemia and infarction on regional content of adenine nucleotides and derivatives in canine left ventricle.
Topics: Adenine Nucleotides; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Coronary Disease; Dogs; Female; Heart Ventricles; Hypoxanthines; Inosine; Male; Myocardial Infarction; Myocardium | 1976 |
[Pathophysiology and clinic of coronary insufficiency (author's transl)].
Topics: Adenosine; Angina Pectoris; Coronary Angiography; Coronary Circulation; Coronary Disease; Heart Rate; Humans; Myocardial Contraction; Myocardial Infarction; Myocardium; Vascular Resistance | 1976 |
Ischemic preconditioning protects against infarction in rat heart.
Topics: Adaptation, Physiological; Adenosine; Animals; Coronary Disease; Glyburide; Heart; In Vitro Techniques; Male; Myocardial Infarction; Purinergic Antagonists; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Ventricular Fibrillation | 1992 |
Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress.
Topics: Adenosine; Aged; Coronary Angiography; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Radionuclide Imaging; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Thallium Radioisotopes | 1992 |
Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Heart; Hemodynamics; Male; Methods; Myocardial Infarction; Myocardium; Rabbits; Receptors, Purinergic; Theophylline | 1992 |
[Atrioventricular block in acute inferior myocardial infarction].
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aminophylline; Atropine; Female; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Time Factors | 1992 |
Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction.
Topics: Adenosine; Animals; Coronary Disease; Female; Heart; Hemodynamics; Injections, Intravenous; Male; Myocardial Infarction; Phenethylamines; Phenylisopropyladenosine; Rabbits | 1992 |
[Effects of adenosine on blood prostaglandin level and platelet aggregation in experimental myocardial infarct].
Topics: Adenosine; Animals; Dinoprostone; Male; Myocardial Infarction; Platelet Aggregation; Prostaglandins; Rabbits; Thromboxane B2; Time Factors | 1991 |
Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species.
Topics: Adenosine; Animals; Blood Pressure; Collateral Circulation; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rabbits | 1991 |
[Cardioprotective effect of combined use of coenzyme Q9 and cyclohexyladenosine in ischemia, reperfusion and acute myocardial infarction].
Topics: Adenosine; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Arrest, Induced; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Inbred Strains; Ubiquinone | 1991 |
Adenosine infusion to patients with ischaemic heart disease may provoke left ventricular dysfunction detected by echocardiography.
Topics: Adenosine; Adult; Aged; Coronary Circulation; Coronary Disease; Diastole; Echocardiography, Doppler; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Mitral Valve; Myocardial Infarction; Stress, Physiological; Vasodilator Agents; Ventricular Function, Left | 1991 |
Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Drug Evaluation, Preclinical; Female; Infusions, Intra-Arterial; Male; Microscopy, Electron; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Necrosis; Time Factors; Ventricular Function, Left | 1991 |
Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period.
Topics: Adenosine; Animals; Coronary Circulation; Dogs; Female; Infusions, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Time Factors | 1991 |
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.
Topics: Adenosine; Animals; Female; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Purines; Rabbits; Receptors, Purinergic; Sulfonamides; Theophylline | 1991 |
Adenosine exacerbates ischemic myocardial injury during regional coronary hypoxemia in the dog.
Topics: Adenosine; Analysis of Variance; Animals; Coronary Vessels; Dogs; Electrocardiography; Female; Heart; Hypoxia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Oxygen Consumption; Perfusion | 1990 |
Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow.
Topics: Adenosine; Animals; Coronary Circulation; Dogs; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Time Factors; Ventricular Function | 1990 |
Evidence for decreased coronary flow reserve in viable postischemic myocardium.
Topics: Adenosine; Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Vessels; Dogs; Female; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium | 1990 |
[Microdialysis study of release of adenine nucleotide breakdown products into the intercellular space of the myocardium in ischemia and reperfusion].
Topics: Adenine Nucleotides; Adenosine; Animals; Dialysis; Extracellular Space; Hypoxanthine; Hypoxanthines; Inosine; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rats; Rats, Inbred Strains | 1990 |
Combined adenosine and lidocaine administration limits myocardial reperfusion injury.
Topics: Adenosine; Animals; Coronary Circulation; Dogs; Drug Combinations; Hemodynamics; Lidocaine; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Osmolar Concentration | 1990 |
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Topics: Adenosine; Animals; Aspirin; Coronary Circulation; Dogs; Female; Male; Myocardial Infarction; Receptors, Prostaglandin; Receptors, Thromboxane; Reperfusion Injury; Thromboxane A2 | 1989 |
Cardiac work and capillary density in normal and vascularly compromised hearts.
Topics: Adenosine; Animals; Blood Pressure; Capillaries; Cardiomegaly; Endocardium; Female; Heart; Heart Rate; Male; Myocardial Infarction; Necrosis; Norepinephrine; Organ Size; Rabbits; Xanthines | 1989 |
[Hemodynamic and metabolic effects of adenosine in experimental myocardial infarction].
Topics: Adenosine; Adenosine Triphosphate; Animals; Drug Evaluation, Preclinical; Hemodynamics; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardium; Rabbits; Succinate Dehydrogenase | 1988 |
[Effect of adenosine on the size of experimental myocardial infarction and "no re-flow" areas].
Topics: Adenosine; Animals; Coronary Circulation; Coronary Vessels; Ligation; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Rabbits | 1988 |
Effect of adenosine and inosine on experimental myocardial infarction in rats.
Topics: Adenosine; Animals; Female; Inosine; Isoproterenol; Male; Myocardial Infarction; Myocardium; Rats | 1988 |
Effect of diltiazem on infarct size, reperfusion flow and flow reserve: the effect of timing of treatment.
Topics: Adenosine; Animals; Coronary Circulation; Diltiazem; Dogs; Female; Hemodynamics; Male; Myocardial Infarction; Perfusion; Time Factors | 1988 |
[Anti-arrhythmic effect of adenosine in experimental myocardial infarction].
Topics: Adenosine; Animals; Dose-Response Relationship, Drug; Male; Myocardial Infarction; Rats; Tachycardia, Supraventricular | 1987 |
Mechanism of atropine-resistant atrioventricular block during inferior myocardial infarction: possible role of adenosine.
Topics: Adenosine; Aminophylline; Atropine; Bradycardia; Drug Resistance; Female; Heart Block; Humans; Middle Aged; Myocardial Infarction | 1986 |
Editorial: Accomplices in crime.
Topics: Acute Disease; Adenosine; Animals; Collateral Circulation; Coronary Circulation; Dogs; Drug Synergism; Electrocardiography; Heart; Humans; Isoproterenol; Lactates; Myocardial Infarction; Stimulation, Chemical; Subclavian Steal Syndrome; Vasodilator Agents | 1974 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrine; Glomerulonephritis; Heart Valve Prosthesis; Humans; Hypertension, Malignant; Ischemia; Myocardial Infarction; Platelet Adhesiveness; Postoperative Complications; Prostaglandins; Pyrimidines; Thromboembolism; Thrombophlebitis; Thrombosis; Xanthines | 1974 |